









Innovative nanosystems for diagnosis and 




NanoFar, Erasmus Mundus Joint Doctorate in Nanomedicine and Pharmaceutical 
Innovation 
University of Santiago de Compostela 

















Nanosistemas innovadores para el diagnóstico 




Programa de doctorado en Nanomedicina e Innovación Farmacéutica 
Universidad de Santiago de Compostela 














AUTHORIZATION OF THE THESIS SUPERVISORS 
Innovative nanosystems for diagnosis and treatment of colorectal cancer 
 
Dr. María de la Fuente Freire, Full time Researcher (Miguel Servet program). Head of the Nano-
Oncology Unit, Health Research Institute of Santiago de Compostela (IDIS), Servizo Galego de 
Saúde (SERGAS). Santiago de Compostela, Spain. 
Prof. Rafael López López, Associate Professor, Department of Medicine, University of Santiago 
de Compostela, Spain. 
Prof. André Luxen, Full Professor, Laboratory of Radiochemistry, Cyclotron Research Center 
(CRC), University of Liége, Belgium 
REPORT: 
That the present thesis, corresponds to the work carried out by Miss Surasa Nagachinta, under our 
supervision, and that we authorize its presentation considering it gathers the necessary 
requirements of article 34 of the USC Doctoral Studies regulation, and that as supervisors of this 
thesis, it does not incur in the abstention causes established by the law 40/2015.  
At Santiago de Compostela on __________________ 2018 
 
 









AUTORIZACIÓN DEL DIRECTOR / TUTOR DE LA TESIS 
Nanosistemas innovadores para el diagnóstico y tratamiento del cáncer de colon 
 
Dra María de la Fuente Freire, Investigadora (programa Miguel Servet). Directora de la Unidad de 
Nano-Oncología del Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), 
SERGAS, Santiago de Compostela, España. 
Prof. Rafael López López, profesor asociado, departamento de Medicina, Universidad de Santiago 
de Compostela, España. 
Prof. André Luxen, Full Professor, Laboratory of Radiochemistry, Cyclotron Research Center 
(CRC), Universidad de Liége, Belgium 
INFORMA/N: 
Que la presente tesis, se corresponde con el trabajo realizado por Dña. Surasa Nagachinta, bajo mi 
dirección, y autorizo su presentación, considerando que reúne los requisitos exigidos en la 
Regulación de Estudios de Doctorado de la USC, y que como director de esta no incurre en las 
causas de abstención establecidas en la Ley 40/2015.  
En Santiago de Compostela a __________________ de 2018 
 
 









PhD CANDIDATE STATEMENT 
Innovative nanosystems for diagnosis and treatment of colorectal cancer 
 
Miss Surasa Nagachinta  
I submit my Doctoral thesis, following the procedure according to the Regulation, stating that: 
1) This thesis gathers the results corresponding to my work. 
2) When necessary, explicit mention is given to the collaborations the work may have had. 
3) The present document is the final version submitted for its defense and coincide with the 
document sent in electronic format. 
4) I confirm that this thesis does not incur in any plagiarism of any other authors or documents 
submitted by me for obtaining other degrees.  
 
At Santiago de Compostela, ______________________ 2018  
 










DECLARACIÓN DEL AUTOR/A DE LA TESIS  
Nanosistemas innovadores para el diagnóstico y tratamiento del cáncer de colon 
 
Dña. Surasa Nagachinta  
Presento mi tesis, siguiendo el procedimiento adecuado a la Regulación, y declaro que:  
1) La tesis abarca los resultados de la elaboración de mi trabajo. 
2) De ser el caso, en la tesis se hace referencia a las colaboraciones que tuvo este trabajo. 
3) La tesis es la versión definitiva presentada para su defensa y coincide con la versión enviada 
en formato electrónico. 
4) Confirmo que la tesis no incurre en ningún tipo de plagio de otros autores ni de trabajos 



















Dedicated to my beloved family  



































First and foremost, I extend my gratitude to the European Commission (EACEA) for the 
Erasmus Mundus grant under the Nanofar Joint Doctoral Program. I would like to thank deeply 
Prof. Frank Boury and related NanoFar members for their dedication to this European doctorate 
program. This also includes my NanoFar friends with whom I had incredible times during NanoFar 
classes and meetings. I was very happy to be part of this great PhD programme. I wish to all of my 
friends the best for their future and hopefully to stay in touch for the upcoming years. 
I would like to gratefully thank Dr. María de la Fuente Freire, Prof. Rafael López López, 
and Prof. André Luxen for giving me this opportunity to undertake this PhD in their groups during 
the past three years. I cordially appreciate their continued guidance, enthusiasm and help 
throughout my thesis. Dr. María de la Fuente Freire gave me a lot of her time as well as invaluable 
advice for my research. She made a lot of efforts on the revision of my thesis, letting me learn 
many excellent skills in academic writing. I really appreciate all of her inspiration and contribution. 
I would also like to thank Prof. Rafael López López for his prompt support, especially when I had 
a health problem. I express my sincere appreciation to my supervisor, Prof. André Luxen. He 
strongly supported me with the best resource for my scientific adventure in Belgium. Despite his 
busy schedule, he took the time needed and went out of his way to discuss my experimental works. 
I really appreciate all of his supportive contributions.   
Also, I would like to thank my colleagues in Lab18 and Lab13 at IDIS for the fruitful 
collaboration during my work. In special, thanks to Belen, Abi, Marta, Sai, Sandra10, Sandra, 
Raneem for your constant support, inside and outside of the lab. Thanks to the members of our 
neighbor lab, Sabella, Alba, Pablo, Mariajo, Miguel, Eloi, Maria, and Ana for always helping me 
with all the lab equipment and cell experiments. My gratitude also goes to all the researchers in the 
hospital for their continued welcome and support. I learned and grew a lot from their experience 
and guidance. Their friendship made these years so much fun and brought about some of the most 
unforgettable times of my life.  
 
 
Many thanks to all the people who have collaborated with me in CIMUS, CACTUS, and 
the hospital, Balby, Belen, Lucia, Estaban, and Marta for your scientific guidance and support. 
Marta devoted a lot of time and effort to take good pictures from confocal. Balby supported me 
every time for the freeze-dry cycle. To people in CIMUS, Lena, Nataliya, Sonia, Adriana, Jose, 
Tamara, Irene, Carla, Sofia, Sara, Andrea, and German: thank you so much for sharing your 
knowledge and ideas with me. To Puri thank you so much for your help with all administrative 
works. All the time you have been very kind, helpful and resourceful.  
I would like to thank my Asian friends, Howl, Paul, Maruthi, Ulung, and Muhammad for 
having such a big heart and for letting me be a part of the Asian family. You are enormous. In 
special, thanks to Maruthi for walking alongside me since we started this “camino” in PhD. I would 
like to thank also Mehtap, Yuki and Carla for all the friendship and support wherever we are! Thank 
you so much for being with me during the hard times. 
To all the cyclotron members, you are an amazing team. I would like to thank Sylvestre for 
all your help. You greatly improved my knowledge in chemistry and taught me several 
radiolabeling techniques. Thank you for being patient, especially at the beginning of my labelling 
experiment. I would also like to thank Christian for his support during the labelling experiment. I 
am grateful to my PET-MRI team, Guillaume, Mohamed, and Alain for your advice in the 
biodistribution study. Of course, Melisa and Natacha, for all the experiments we performed 
together and for sharing your mice-working experience. I owe a huge thanks to Agostinho, Jerome 
and Nicolas. Thank you for all the fun moments, you are awesome!   
I would like to thank Brigitte and Annick for helping me with all the paper works in 
Belgium and for ordering our chemicals. Christine, for her help and many practical things in the 
lab. Charlotte, for her technical support for DLS. Besides, I would like to thank all the people of 
both the cyclotron center and the chemistry building with whom I had to chance to work during 
my PhD. In special, thanks to Jeremie, Paul, and Shabnam for the time that we studied together 
during animal lectures and for being great colleagues. Yes! we passed the exam.  
 
Certainly, I warmly thank my NanoFar friends in Liège. Bathabile for the first introduction 
to the city and the information about the accommodation. Rahmet and Zeynep for all the time we 
spent in both scientific study and leisure activities. And all my international lunchmates at the 
cafeteria, John, Ruben, and Nikola for sharing great talks and interesting topics during lunch time.  
Of course, my deepest gratitude goes to my parents and my big family. Even though we are 
far away from each other by distance, I always feel their presence and support. Their eternal 
guidance is beyond words. Finally, I thank all my proofreaders, Air, Rob, and Martin, who have 
been very kind during the tight schedule I had to submit my thesis. 
This PhD programme is now hopefully coming to an end. I am grateful for this great 
opportunity to build up my academic experience and for all the people it has enabled me to meet 
and cooperate with. As much as I enjoy reaching its destination, I want to thank each and every 














CONFLICT OF INTEREST  
 
























Table of contents 
 
Abstract /Resumen........................................................................................................................27 
Resumen in extenso ......................................................................................................................33  
Chapter 1 – Introduction ............................................................................................................... 55 
Background, hypothesis and objectives ....................................................................................116 
Chapter 2 – Sphingomyelin nanoemulsions for miRNA replacement therapies to interfere cancer 
progression ...................................................................................................................................126 
Chapter 3 – A radiolabelling strategy with Fluorine-18 for in vivo imaging of lipid-based 
nanosystems by PET ……............................................................................................................156 
Chapter 4 – Overall discussion and Conclusion 
Overall discussion.........................................................................................................................186 






































The main goal of this thesis has been the engineering of innovative nanosystems of 
application in the treatment and molecular diagnosis of colorectal cancer. Sphingomyelin 
nanoemulsions (SNs) were selected for this purpose, and their composition adapted to and efficient 
association of oncosuppressor miRNAs for development of anticancer gene therapies able to stop 
tumor growth and proliferation. Additionally, a procedure for developing 18F-radiolabelled SNs for 
imaging and diagnosis purposes was optimized, and validated by PET. 
SNs, formulated by the ethanol injection method, provide ideal conditions for the 
incorporation of sensitive biomolecules such as nucleic acids. For miRNA association two 
approaches were followed. First, it was incorporated a cationic lipid, stearylamine, to allow further 
miRNA association to the surface of nanoemulsions via electrostatic interactions. Second method 
involved the preformation of lipid complexes (miRNA and DOTAP) and subsequent encapsulation 
into SNs. Both approaches demonstrated to mediate an efficient association and delivery of 
oncosuppressor miRNA145 to colorectal cancer cells. The second strategy rendered an improved 
uptake and subsequent increase in the intracellular levels of miRNA145. Functional assays 
confirmed that this formulation was able to exert an anti-tumor activity, through the inhibition of 
cell proliferation, colony-forming, and cell migration capacities, highlighting the potential of this 
approach for the development of miRNAs gene replacement therapies.  
Secondly, it was attempted the radiolabelling of SNs with 18F, following an indirect method 
that uses 4-[18F]fluorobenzamido-N-ethylmaleimide ([18F]FBEM) as a 18F-prosthetic group. The 
chemical reaction was performed between the maleimide group of [18F]FBEM and the thiol 
functional groups located at the surface of either SNs bearing PEG-SH, or SNs decorated with the 
RPM peptide. Biodistribution studies and PET images allowed us to conclude that it is possible to 
track the radiolabelled SNs after intravenous injection to mice. 
In conclusion, it has been proved that SNs are versatile nanosystems that can be adapted to 
different medical needs. SNs are efficient nanosystems for the delivery of innovative-targeted gene 
therapies, and can be successfully radiolabeled allowing whole-body read-outs by PET. Altogether, 
SNs are a promising platform for therapy and diagnosis of colorectal cancer, and have potential for 





El objetivo principal de esta tesis ha sido el desarrollo de nanosistemas innovadores de 
aplicación en el tratamiento y diagnóstico molecular del cáncer colorrectal. En este trabajo se 
exploró el potencial de nanoemulsiones de esfingomielina (SNs) para la asociación de miRNAs 
oncosupresores como estrategia para detener el crecimiento y la proliferación tumoral. Por otro 
lado, se optimizó un procedimiento para desarrollar SNs radiomarcadas con 18F con fines 
diagnósticos mediante imagen molecular por Tomografía de Emisión de Positrones (PET).  
Para la asociación del miRNA se propusieron dos enfoques. En primer lugar, la 
incorporación de un lípido catiónico, la estearilamina, de modo que se vea favorecida la asociación 
del miRNA mediante el establecimiento de interacciones electrostáticas. En segundo lugar, la 
formación previa de complejos lipídicos (miRNA-DOTAP) para su posterior encapsulación en SNs. 
Ambos enfoques demostraron ser adecuados para la asociación y la administración del miRNA 
oncosupresor (miR145) a células de cáncer colorrectal. La segunda estrategia produjo un mayor 
aumento en los niveles intracelulares de miR145. Ensayos funcionales confirmaron a su vez que 
esta formulación presenta un gran potencial para el desarrollo de terapias antitumorales, dado es 
capaz de mediar una inhibición de la proliferación celular, capacidad de formación de colonias, y 
migración.  
Se procedió además a marcar las SNs con 18F, para su uso en imagen diagnóstica (PET), 
empleando un método indirecto que utiliza 4-[18F]fluorobenzamido-N-etilmaleimida ([18F]FBEM) 
como grupo protésico 18F. La conjugación química se realizó mediante la reacción del grupo 
maleimida del [18F]FBEM, con grupos funcionales tiol, introducidos en SNs en forma de lípido 
C18-PEG12-SH, o tras ser decoradas con el péptido RMP. Los estudios de biodistribución y las 
imágenes permitieron rastrear las SNs tras ser inyectadas por vía intravenosa en ratones.  
En conclusión, ha sido demostrado que las SNs son nanosistemas versátiles que pueden 
adaptarse a diferentes necesidades médicas. Las SNs han demostrado ser eficientes para la 
administración de terapias antitumorales basadas en la miRNAs, y pueden ser radiomarcadas para 
aplicación en imagen molecular. En conjunto, SNs son una plataforma prometedora para la terapia 




























Resumen in extenso 
 El cáncer colorrectal es la tercera causa principal de fallecimiento asociado al cáncer. La 
tasa de supervivencia disminuye drásticamente cuando se produce la diseminación tumoral y 
formación de metástasis. Aunque diversas estrategias han sido desarrolladas para el tratamiento del 
cáncer de colon, existe una considerable diferencia en lo que respecta a la supervivencia del 
paciente cuando es tratado desde la etapa temprana de la enfermedad, o cuando el cáncer se 
encuentra en estadio avanzado1-3. Asimismo, debido a la administración no específica de los 
fármacos quimioterapéuticos convencionales, casi la totalidad de los pacientes sufren amplios 
efectos secundarios4,5. Para mejorar el pronóstico y supervivencia de los pacientes, es necesario 
desarrollar nuevos métodos de diagnóstico y monitorización de la enfermedad, que detecten la 
formación de metástasis de manera temprana, así como nuevas terapias más efectivas y dirigidas, 
para abordar la aparición de resistencias a medicamentos, y disminuir la toxicidad de los 
tratamientos.  
En las últimas décadas, la nanotecnología ha desempeñado un papel significativo en la 
administración de fármacos antitumorales dada la alta versatilidad y potencial de los nanosistemas 
para el transporte de fármacos clásicos y de nuevos biofármacos6-8. Además de moléculas 
terapéuticas, los nanosistemas pueden asociar agentes de diagnóstico para ser monitorizados 
mediante el uso de modalidades avanzadas de imagen, como Resonancia Magnética Nuclear 
(RMN), Tomografía Computarizada (TC), Tomografía por Emisión de Positrones (PET), 
Tomografía Computarizada por Emisión de Fotones Individuales (SPECT) y ultrasonidos (US)9,10.  
Esta tesis doctoral se ha centrado esencialmente en el desarrollo de nanoemulsiones 
lipídicas para el diseño de nuevas estrategias terapéuticas y de diagnóstico del cáncer de colon. 
Partiendo de una composición sencilla, nanoemulsiones compuestas a base de vitamina E y 
esfigomielina (nanoemulsiones de esfingomielina, SNs), se ha procedido a i) adaptar la 
formulación para favorecer la asociación de miRNAs oncosupresores, con el objeto de determinar 
la eficacia de esta estrategia para interferir la progresión tumoral, y ii) proceder a su radiomarcaje 
con 18F para su aplicación en imagen molecular (PET). 
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SNs para la liberación de miRNAs oncosupresores capaces de interrumpir la progresión 
tumoral en cáncer colorrectal.   
La irrupción de nanofármacos en el mercado, junto con los éxitos obtenidos en ensayos 
clínicos, conjuntamente con la aparición de varias terapias novedosas basadas en polinucleótidos, 
están impulsando una creciente demanda de nanovehículos de transporte de fármacos más 
eficientes y seguros11,12. A pesar de que la administración de material genético basada en partículas 
virales ha sido extensamente evaluada, a día de hoy todavía presenta inconvenientes como la 
seguridad a largo plazo y limitaciones en su capacidad de carga13. Por ello, el desarrollo de sistemas 
no virales de administración de polinucleótidos se presenta como una opción alternativa para el 
transporte de material genético como el ADN plasmídico (pDNA), ARN interferente (siRNA) y 
micro-ARN (miRNA). Entre ellos, los nanosistemas lipídicos poseen varias ventajas en 
comparación con los vectores virales, en términos de seguridad, metodología de preparación, 
producción a gran escala y posible modificación química14. Las formulaciones compuestas por 
núcleos oleosos poseen dificultades para inmovilizar a los polinucleótidos ya que estas moléculas 
exhiben una tendencia natural a migrar a las interfaces agua-aceite y difundir en el medio externo. 
El empleo de nanoemulsiones catiónicas se ha estudiado en este trabajo para abordar este problema. 
De esta forma el grupo amino del lípido cargado positivamente puede interaccionar con la carga 
negativa del grupo fosfato de los polinucleótidos, lo que resulta en una eficiente asociación del 
material genético15. Este trabajo se centra en dos estrategias principales. Por un lado, la inclusión 
de un lípido catiónico (estearilamina (ST)) como un componente adicional de SNs, para favorecer 
la asociación del miRNA mediante el establecimiento de interacciones electrostáticas (SNs-ST-
miRNA). Por otro lado, la preparación previa de complejos DOTAP-miRNA para su posterior 
inclusión en el núcleo oleoso de la nanoemulsión (SNs-DOTAP-miRNA) (Figura 1). Estas dos 
nanoemulsiones basadas en miRNA han sido sintetizadas con una sencilla técnica, ampliamente 
caracterizadas, y su potencial terapéutico evaluado en células de cáncer colorrectal (SW480). 
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Figura 1. Ilustración esquemática de los componentes de las nanoemulsiones con estearilamina, (SNs-ST-miRNA) y 
DOTAP (SNs-DOTAP-miRNA). 
SNs son formulaciones sencillas, biocompatibles y biodegradables, producidas mediante el 
método de inyección de etanol. Se componen principalmente de un aceite, vitamina E (VitE), y un 
surfactante de naturaleza esfingoide, esfingomielina (SM). Se han incluido además derivados 
lipídicos de polietilengliol (PEG) (SH-PEG12-C18) en una menor proporción, con el objetivo de 
mejorar la estabilidad de la formulación, y para permitir una posterior funcionalización con 
ligandos o radioisótipos16,17. Además, como se ha descrito anteriormente, también se han 
incorporado pequeñas cantidades de lípidos catiónicos, ST y DOTAP, para aumentar la eficacia de 
asociación de miRNAs. 
Para la preparación de SNs, en primer lugar se disuelven los componentes lipídicos en 
etanol, VitE:SM:PEG en una proporción 10:1:0,1 p/p. Posteriormente un volumen de 110µl se 
inyecta sobre 1ml de agua ultrapura, y de forma espontánea se obtienen las nanoemulsiones, que 
presentan un tamaño promedio de 131 + 8 nm, un índice de polidispersión (PDI) de 0.2 y una carga 
superficial ligeramente negativa de -13 ± 7mV. El análisis fisicoquímico complementario realizado 
mediante la técnica de Nanoparticle Tracking Analysis (NTA) muestra correlación con los 
parámetros determinados previamente, confirmando así el tamaño y la distribución relativamente 
monodispersa de las SNs desarrolladas, y aportando a mayores un dato de concentración de 
4.2x1012 ± 2.1x1010 partículas/ml. 
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La formulación denominada SNs-ST-miRNA se desarrolló tras incorporar ST en la 
composición de SNs. La interacción entre los lípidos catiónicos y los ácidos nucleicos está 
intensamente influenciada por su interacción carga-carga. Por lo tanto la selección de ST se realizó 
en base a la presencia en su estructura de un grupo amino primario con carga positiva en un amplio 
rango de pH18,19. Se prepararon y caracterizaron nanoemulsiones con relaciones VitE:SM:PEG:ST 
de 10:1:0.1:0.1 a 10:1:0.1:2 (p/p). En base a sus propiedades fisicoquímicas (tamaño y carga 
superficial), la formulación con ratio VitE:SM:PEG:ST 10:1:0.1:1 (SNs-ST) fue seleccionada para 
estudios posteriores. 
A continuación se evaluaron en detalle las condiciones de asociación de miRNA. Para ello 
se agregaron cantidades crecientes de SNs-ST sobre una solución de miRNA (10 µg) (relaciones 
miRNA: ST de 1: 1 a 1:10) y se incubaron bajo agitación magnética. Se observó que el aumento 
de la proporción de SNs-ST (y por lo tanto de grupos catiónicos) afecta principalmente a las 
propiedades superficiales de los nanosistemas. Todos los tamaños obtenidos se mantuvieron 
alrededor de 150-170 nm, con bajos índices de polidispersión en todos los casos, excepto en las 
relaciones miRNA:ST 1:5 y 1:7 para las cuales se observó una agregación masiva. Esto puede ser 
debido a la neutralización de la carga superficial, como se ha observado para otros nanosistemas 
catiónicos lipídicos20-22. La asociación eficaz del miRNA a la superficie de SNs-ST se confirmó 
mediante un ensayo de electroforesis en gel. Tras los experimentos de asociación, las 
nanoemulsiones SNs-ST-miRNA con una relación de masa miRNA:ST 1:10 se seleccionaron para 
los siguientes experimentos de transfección (Tabla 1).  
Por otro lado se prepararon las nanoemulsiones denominadas SNs-DOTAP-miRNA a partir 
de complejos lipídicos preformados. Estos complejos se sintetizaron haciendo interaccionar 
miRNA con dos lípidos catiónicos previamente seleccionados (ST y DOTAP) a distintos ratios. 
Tras una evaluación en cuanto a características fisicoquímicas se consideró a los complejos de 
miRNA:DOTAP en una proporción de 1:15 (p/p) como candidatos ideales para su incorporación 
adicional en las SNs. Los nanosistemas SNs-DOTAP-miRNA fueron a su vez caracterizados 
exhibiendo un tamaño de partícula promedio de 124 ± 9 nm, un PDI de 0.2 y una carga superficial 
de +37 ± 3 mV (Tabla 1). Adicionalmente se realizó un análisis de electroforesis en gel para 
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demostrar que el miRNA es complejado de manera eficiente con el lípido catiónico DOTAP, y que 
la asociación a SNs efectivamente proporciona una protección adicional.  
Tabla 1. Tamaño (nm), PDI (ídice de polidispersión) y carga superficial (mV) de las nanoemulsiones SNs-ST-miRNA y 
SNs-DOTAP-miRNA. 
Formulación Tamaño (nm) PDI Carga Superficial (mV) 
SNs-ST-miRNA 
SNs-DOTAP-miRNA 
148 ± 8 
124 ± 9 
0.2 
0.2 
+26 ± 3 
+37 ± 3 
 Se realizaron estudios de internalización celular mediante microscopía confocal (se 
muestran los núcleos celulares de células SW480 teñidos en azul) con los dos prototipos 
desarrollados (SNs-ST-miRNA y SNs-DOTAP-miRNA), empleando un doble marcaje 
fluorescente (miRNA marcado con Cy5, Cy5-miRNA, y esfigomielina (SM) con TopFluor®, 
TopFluor®-SM). Ambas formulaciones fueron internalizadas eficientemente por las células (señal 
verde) siendo el Cy5-miRNA conjuntamente transportado a los citoplasmas celulares (señal roja) 
(Figura 2). Es destacable que las imágenes combinadas de ambos canales (rojo y verde) ilustran 
que tanto las SNs-ST-miRNA como las SNs-DOTAP-miRNA se incorporan en forma de 
nanoemulsiones estables, ya que se puede observar una co-localización de las señales en ambos 
casos. Posteriormente, se llevaron a cabo estudios cuantitativos mediante análisis por citometría de 
flujo (FACS). Las formulaciones SNs-DOTAP-miRNA mostraron una mayor co-localización de 
Cy5-miRNA y TopFluor®-SM en comparación con las SNs-ST-miRNA. Esto puso de manifiesto 
que la formación de complejos con miRNA y posterior asociación a SNs favorece una mayor 
protección y median de esta forma su administración intracelular mejorada respecto a cuando este 






Figura 2. Internalización de nanoemulsiones SNs-ST-miRNA y SNs-DOTAP-miRNA en células SW480. Proyección 
máxima de las imágenes de microscopía confocal de nanoemulsiones marcadas con TopFluor® esfingomielina 
(TopFluor®-SM, verde), y miR145 marcado con Cy5 (Cy5-miR145, rojo) (4 h a 37ºC). Núcleo celular teñido con Hoechst 
(azul). 
 
Figura 3. Expresión de miR145 después de la transfección con SNs-ST-miRNA145, complejos lipídicos 145 (LP145) y 
SNs-DOTAP-miRNA145 (así como con nanosistemas preparados con la secuencia truncada, SNs-ST-miRNAscr, LPscr, y 
SNs-DOTAP-miRNAscr) (A). Expresión relativa de miR145 después de la transfección con LP145, mezcla física de LP145 
y SNs, y SNs-DOTAP-miRNA145 en células SW480 (B). (2 µg miRNA/pocillo en placas de 6 pocillos, 4 h incubación, 72 
horas post-transfección, datos normalizados frente al control interno RNU6) (**** p<0.0001, *** p<0.001, and ** p<0.01). 
SNs-ST-miRNA 
SNs-DOTAP-miRNA 
Hoechst                       TopFluor®-SM                              Cy5-miR145                  Merge  
B A 
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Los datos de transfección muestran, de manera coherente, una mayor eficacia para SNs-
DOTAP-miRNA145 (64 veces más que las SNs-ST-miRNA). Además, comparando la eficiencia 
de transfección de los complejos lipídicos (LP145), una mezcla física de complejos y 
nanoemulsiones (LP145 + SNs) y SNs-DOTAP-miRNA, los resultados destacan los beneficios de 
integrar dichos complejos con SNs (Figura 3A y 3B). 
Finalmente, se evaluó la capacidad de las SNs-DOTAP-miRNA145 para suprimir el 
crecimiento tumoral en células de cáncer colorrectal SW480. Se realizaron para ello tanto ensayos 
de proliferación como de migración. En los estudios de proliferación se observó que tanto el 
número de células como el de colonias celulares transfectadas con SNs-DOTAP-miRNA145 se 
redujo significativamente con respecto a las células control no tratadas y las células tratadas con la 
secuencia control (Figura 4A y 4B). Los estudios de cicatrización o “wound healing” también 
confirmaron sus efectos en términos de migración. La herida creada artificialmente en la placa de 
células SW480 tratadas con SNs-DOTAP-miRNA145 permaneció con una mayor abertura al final 
del estudio que la herida control y la tratada con las SNs-DOTAP-miRNAscr (Figura 4C). Estos 
resultados indican claramente que los SNs-DOTAP-miRNA145 inhiben el crecimiento y la 
migración en células de cáncer colorrectal (SW480), en línea con estudios previos24,25. 
 40 
 
Figura. 4. Actividad citostática de las nanoemulsiones SNs-DOTAP-miRNA145 en células transfectadas SW480. 
Proliferación de células SW480 72 h post-transfección (**** p<0.0001) (A). Análisis cuantitativo de recuento de 
número de columnas, 2 semanas después de la transfección (*** p<0.001 y ** p<0.01) (B). Imágenes representativas 
mostrando la migración celular observada en el estudio de wound healing para las células control, células tratadas 
con SNs-DOTAP-miRNA145 y la misma formulación con la secuencia truncada (SNs-DOTAP-miRNAscr). Las imágenes 
se obtuvieron a tiempos 0, 24, 48, 72 y 96 horas tras el tratamiento. Las líneas negras delimitan los márgenes 
establecidos (C).  
 En conclusión, en este trabajo se han desarrollado con éxito SNs que asocian y encapsulan 
eficientemente miRNA145, SNs-ST-miRNA y SNs-DOTAP-miRNA. Ambas formulaciones 
poseen un tamaño comprendido entre 120-150 nm y presentan poblaciones monodispersas. 
Estudios in vitro confirman su capacidad para acceder al citoplasma celular, liberar eficientemente 
su carga (miRNA145), y posteriormente restaurar su expresión de manera eficaz. La restitución de 
los niveles de miRNA145 posterior a la administración de SNs-DOTAP-miRNA demostró ser 
efectiva, suprimiendo la proliferación de las células tumorales, la formación de colonias y la 
migración. Estudios adicionales de este estas nanoemulsiones SNs-DOTAP-miRNA en un modelo 
animal de cáncer de colon podrán confirmar el potencial de esta plataforma para el diseño de 





Radiomarcaje de SNs con 18F para PET 
Actualmente las técnicas de imagen guiada están desempeñando un papel muy importante 
para el estudio de la biodistribución y la farmacocinética de fármacos. Además de las modalidades 
de imagen anatómica, como la Tomografía Computarizada (TC) y la Imagen por Resonancia 
Magnética (IRM), las estrategias de imagen molecular pueden a su vez facilitar la localización y 
cuantificación de las sondas radiomarcadas. Las imágenes de Tomografía por Emisión de 
Positrones (PET), técnica de imagen molecular no invasiva, se utilizan ampliamente en la práctica 
clínica diaria para el diagnóstico debido a su accesibilidad, alta sensibilidad y exactitud 
cuantitativa26,27. La 18F-fluorodeoxiglucosa (18F-FDG), análogo fluorado de la glucosa, es usada 
clínicamente para la obtención de imágenes en oncología en base a su amplia incorporación a 
tejidos tumorales que presentan un aumento del metabolismo de la glucosa. Este agente de 
diagnóstico clínico, aprobado por la agencia americana de alimentos y medicamentos (FDA), es el 
radiofármaco que ha permitido la entrada de la técnica de PET a nivel hospitalario y por lo tanto 
ha ayudado a mejorar el diagnóstico y el tratamiento del cáncer28,29. No obstante, en ciertos casos, 
las imágenes obtenidas con 18F-FDG pueden incurrir en falsos positivos, ya que este radiofármaco 
no es un marcador específico de proliferación de células neoplásicas, sino cuantificador del elevado 
metabolismo glucídico existente en tejidos. Por este motivo, puede ser difícil alcanzar cantidades 
suficientes de 18F-FDG en el área diana. En consecuencia, esto ha llevado al desarrollo de sistemas 
de administración más específicos para la obtención de imágenes tumorales30,31. 
Es posible desarrollar nanosistemas radiomarcados capaces de aumentar la señal, la 
sensibilidad y la resolución de la imagen adquirida en comparación con los radiofármacos 
estándares actuales como por ejemplo la 18F-FDG32. Además, es posible adaptar su composición 
para lograr incrementar su estabilidad en plasma y su vida media en circulación, por lo que tienen 
un gran potencial para aplicaciones clínicas33-35. Entre los radioisótopos, el 18F puede considerarse 
como un prometedor emisor de positrones para imagen por PET debido varios factores como una 
vida media de 110 min que permite tomar imágenes durante varias horas, su baja energía de 
positrones que genera imágenes de alta resolución, y su producción a gran escala con una elevada 
eficiencia36-38. Por lo tanto la utilización del 18F para el radiomarcaje de nanosistemas se presenta 
como una alternativa interesante. 
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En esta tesis hemos desarrollo un método para el marcaje de nanoemulsiones lipídicas con 
18F. En primer lugar se comenzó con la síntesis de un grupo protésico marcado con 18F, [18F]FBEM, 
que posteriormente se conjugó con grupos tiol (-SH) mediante la reacción de adición de Michael, 
localizados bien en la superficie de las nanoemulsiones de esfingomielina que incorporan SH-
PEG12-C18 en su composición (SNs), o bien con el residuo cisteína en SNs decoradas con el péptido 
RPM (SNs-RPM), Posteriormente, ambas nanoemulsiones radiomarcadas (SNs-[18F]FBEM y 
SNs-RPM-[18F]FBEM) fueron purificadas, caracterizadas, e inyectadas en ratones sanos, para 
determinar su potencial para futuros estudios de imagen molecular por PET. 
Las nanoemulsiones evaluadas en este estudio fueron preparadas mediante un método de 
baja energía utilizando el procedimiento de inyección de etanol39. Tanto las SNs como las SN-
RPM se formaron espontáneamente después de la inyección de la fase lipídica sobre la fase acuosa 
bajo agitación magnética. La síntesis de [18F]FBEM se realizó a partir de una metodología 
publicada anteriormente40. [18F]FBEM fue sintetizado y se llevó a completa evaporación formando 
una fina película. Después de reducir el enlace disulfuro para reactivar la función tiol libre en SNs 
y SNs-RPM, estas fueron añadidas sobre la película de [18F]FBEM para su marcaje, seguido de un 
paso de purificación para eliminar el agente reductor. 
El radiomarcaje se llevó a cabo mediante la reacción química entre el grupo maleimida de 
[18F]FBEM y los grupos tiol libres en la superficie de las SNs y las SNs-RPM. Las nanoemulsiones 
radiomarcadas fueron de nuevo purificadas obteniéndose los dos prototipos de nanoemulsión SNs-
[18F]FBEM y SNs-RPM-[18F]FBEM. El rendimiento radioquímico (RRQ) obtenido (corrigiendo 
la desintegración) fue de un 35.1 + 5.7% (n=4) y 39.4 + 5.5% (n=4) para SNs-[18F]FBEM and SNs-
RPM-[18F]FBEM respectivamente. Ambas nanoemulsiones marcadas con [18F]FBEM exhiben 
tamaños hidrodinámicos entre 130-150 nm con bajo PDI y carga superficial positiva. No se 
observan cambios significativos con respecto a las nanoemulsiones no marcadas, lo que nos 
permite concluir que el proceso de radiomarcaje es respetuoso y no compromete la estructura ni la 
estabilidad de los nanosistemas. Ambas formulaciones poseen un pH entre 7-8 y una osmolaridad 
de entre 280-290 mOsm/kg, características que los hacen adecuados para inyección parenteral 
(Tabla 2). La confirmación de la posición del radiomarcaje, bien en el lípido o el péptido asociado 
a las nanoemulsiones, se analizó mediante un detector gamma y UV en UPLC con respecto a sus 
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estándares predeterminados (Ref); Ref-[18F]FBEM, Ref-SH-PEG12-C18 (Ref-lipid), y Ref-
RPMpeptide-PEG8-C18 (Ref-peptide) (Figura 5). Este experimento confirmó que la posición de 
radiomarcaje se produjo en los grupos funcionales tiol tanto de lípidos como péptidos. Por otro 
lado, no se observó marcaje inespecífico en ninguna de las formulaciones. Finalmente, el proceso 
de purificación fue realizado con éxito obteniéndose nanoemulsiones marcadas y purificadas. 
Tabla 2. Rendimiento radioquímico (RRQ), tamaño en nm, índice de polidispersión (PDI), carga superficial (mV), pH, 











SNs-[18F]FBEM 35.1 ± 5.7 136 ± 9 0.2 +38 ± 6 7.6 ± 0.2 287 ± 5 




Figura 5. Representación esquemática de cromatogramas de UPLC mostrando señales de los detectores UV y gamma 
de los compuestos Ref-[19F]FBEM) (A), [18F]FBEM (B), Ref-lipid(C), [18F]FBEM-lipid (D), Ref-peptide (E) y [18F]FBEM-
peptide (F). 
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Este estudio es un ejemplo del correcto marcaje de nanoemulsiones de esfingomielina con 
[18F]FBEM usando un método de marcaje indirecto y en ausencia de solventes orgánicos. La unión 
se basa en la reacción de adición de Michael entre grupos tiol-maleimida. Este radiomarcaje de 
nanoemulsiones puede realizarse tanto antes como después de la formulación de estas. Ejemplos 
de marcaje con diferentes grupos protésicos 18F antes y después de la formación de nanosistemas 
pueden encontrarse en la literatura41-44. Debido a la corta vida media del 18F, el método de 
radiomarcaje a posteriori muestra una ventaja al permitir obtener altos rendimientos radioquímicos 
con respecto al radiomarcaje previo. El proceso de radiomarcaje de estas nanoemulsiones se realizó 
controlando los valores de osmolaridad y pH para alcanzar las características apropiadas de las para 
su inyección en animales45. 
Para determinar el comportamiento in vivo de las nanoemulsiones radiomarcadas estas 
fueron administradas mediante inyección en cola a ratones sanos. Por un lado, se midió la 
radioactividad en los órganos diseccionados para determinar la biodistribución ex vivo. Por otro 
lado, se realizaron estudios PET-MRI tanto para realizar estudios farmacocinéticos como para 
demostrar el potencial de las nanoemulsiones desarrolladas como agentes de contraste para la 
obtención de imágenes in vivo.  
El patrón ex vivo indicó que ambas nanoemulsiones parecen ser capturadas por el sistema 
retículo-endotelial (SRE). Patrones de biodistribución similares han sido descritos para otras 
nanopartículas lipídicas46-48. Una posible estrategia para modular la biodistribución y la interacción 
con las células del SRE podría ser la modificación de su superficie, por ejemplo con polietilenglicol 
(PEG) o otras moléculas hidrofilicas49-51. De hecho, las SNs decoradas con el péptido RPM (SNs-
RPM-[18F]FBEM) dieron lugar a una menor acumulación tanto en bazo como en hígado. Se 
observó además la acumulación de las nanoemulsiones en intestino, riñón y pulmón. La captación 
en los pulmones podría estar relacionada con su tamaño un fenómeno de agregación que haga que 
se acumulen en los capilares pulmonares. La presencia de radiactividad en el intestino podría 
deberse a su excreción hepática a través de la vesícula biliar en las heces. La baja cantidad de 
radioactividad detectada en hueso indica la ausencia de defluoración, ya que el 18F libre tiene 
direccionalidad hacia tejido óseo, lo que sugiere que la mayor parte del radiomarcaje 18F permanece 
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en las formulaciones y que las nanoemulsiones radiomarcadas son estables tras la inyección 




Figure 6. Perfil de biodistribución ex vivo de SNs-[18F]FBEM and SNs-RPM-[18F]FBEM en órganos de ratones BALB/c 3 
horas post-inyección. 
Se realizaron estudios de biodistribución (Figura 7) y farmacocinética in vivo empleando 
PET-MRI. La región de interés dibujada en los ventrículos del corazón confirmó el éxito de la 
inyección en la vena de la cola, ya que la radioactividad disminuyó después de la administración. 
Por otro lado, las curvas de actividad-tiempo revelaron una rápida captación en el hígado y el bazo. 
Se pudieron observar dos rutas de eliminación (hígado y riñón), primando la excrección hepática. 
La biodistribución y la farmacocinética de las formulaciones desarrolladas en este trabajo indican 
que esta metodología puede sentar las bases para el radiomarcaje de nanosistemas lipídicos para 












































Figura 7. Biodistribución in vivo de SNs-[18F]FBEM (izquierda) y SNs-RPM-[18F]FBEM (derecha) en ratones macho 
BALB/c 2 horas post-inyección usando la técnica de imagen PET-IRM: dos diferentes secciones del plano coronal 
muestran respectivamente los riñones (A,C) y el hígado y la vejiga (B,D).  
En conclusión, el radiomarcaje de nanosistemas lipídicos se desarrolló con éxito tanto para 
nanoemulsiones de esfingomielina (SNs-[18F]FBEM) como para nanoemulsiones decoradas con 
péptidos (SNs-RPM-[18F]FBEM) usando un método sencillo y condiciones suaves, sin alterar sus 
propiedades fisicoquímicas. Las nanoemulsiones radiomarcadas pueden ser monitorizadas por 
PET-MRI abriendo la puerta al desarrollo de nanosistemas lipídicos para su uso en diagnóstico por 
imagen molecular. Asimismo, esta estrategia puede ser aplicada a otro tipo de nanoestructuras, 
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1. Colorectal cancer 
 Cancer is a major public-health disease worldwide. Despite progress in cancer treatment in 
terms of surgery and chemotherapy, cancer is a leading cause of death1. Estimated data from 
GLOBOCAN 2018 showed that colorectal cancer (CRC) is on the third place for incidence and 
second place for mortality among 36 human malignancies in 185 Countries (Figure 1)2. 
 
Figure 1. Distribution of Cases and Deaths for the 10 Most Common Cancers in 2018. [Reproduced from Bray, F., et 
al. (2018). GLOBOCAN 20182 with permission.]  
 
It is well known that there are two major pathways of genetic alterations in colorectal 
carcinogenesis. One is the chromosomal instability (CIN) and the other is microsatellite instability 
(MSI). CIN is characterized by allelic losses on chromosome which stimulates clonal diversity. 
MSI refers to replication errors in primary sequences of chromosomes, either by aberrant 
methylation or by somatic mutation. Owing to recent progress in molecular biology, other routes, 
including the transforming growth factor-β/SMAD, the serrated, and the epigenetic pathway have 
been reported3. In the invasion and metastasis steps of colorectal cancers, various genes have now 
been identified as being involved in proteolysis, adhesion, angiogenesis, and cell growth4.  
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Generally, development of colorectal cancer initiates when the normal epithelium 
transforms to a small adenoma by the activation of the Wnt/β-catenin pathway. Further K-RAS 
mutation leads to the formation of a large adenoma. The final step involves p53 inactivation and 
transforming growth factor beta (TGF-β) signaling pathway mutation (Figure 2)5.  
Apart from genetics, age is one of the major factors in the development of CRC especially 
in elderly people. Other causes are obesity, diabetes, dietary, smoking, and consuming of alcohol. 
To screen colon cancer, several tests can be performed such as colonoscopy, sigmoidoscopy, fecal 
occult blood test, fecal immunochemical test, DNA testing, and CT colonography (Figure 3)6,7. 
 
Figure 2. Steps involved in CRC progression. 
The American Joint Committee on Cancer (AJCC)/ TNM system clarifies the stage of CRC 
by the letters T, N, and M, describing the areas of cancer growth. The T score means the growth of 
the primary tumor. The N score refers to nearby cancer growth within the colon or lymph nodes. 
Lastly, the M score states if the cancer has spread to distant sites. These scores are combined to 
give the stage of cancer (Table 1). Stage 0, the carcinoma has not grown beyond the first layer of 
its wall. This is a noninvasive cancer. If all the cancer was removed during an endoscopic 
polypectomy, it may not need more treatment. During stage I, the carcinoma has developed into 
either the second or third layer of the colon wall. Stage II represents the cancer that reaches the 
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fourth layer of or outside the colon wall. However, there is no cancer in nearby or distant sites. For 
Stage III, the cancer has spread from the colon to nearby lymph nodes or there are tumor deposits 
(small secondary tumors within the colon). Stage IV demonstrates the colon cancer that has spread 
to distant organs. Common distant sites are liver and lungs. Generally, it is rated twice. The first 
rate before treatment is called the clinical stage. It defines how far the cancer has spread and how 
many lymph nodes have cancer. Nevertheless, some cancers could be found after surgery. Thus, a 
second rate is performed, named the pathologic stage8.  
Figure 3. Overview of colorectal cancer. [Adapted from Benerjee, A., et al. (2017). Drug Discov. Today6 with 
permission.] 
 
2. Therapeutic approaches for colorectal cancer 
 Generally, the therapeutic methods for CRC are surgery, cryosurgery, radiation therapy, 
and chemotherapy. Surgery and radiotherapy are the most effective treatments for local and non-
metastatic cancers, while chemotherapy, hormone, and biological therapies are commonly used 
with metastatic tumors. 
2.1. Surgery and radiotherapy 
When tumor is still at a local site, surgery is the standard procedure for Stage I-III CRC. 
Usually, the surgeon removes not only the tumor but also colon sections including fat and lymph 
nodes. The healthy parts of colon are generally reconnected at the end. However, if they are not 
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able to be re-joined, a rerouted colon surgery will be carried out. This procedure is called colostomy 
which results in an opening in the abdomen. It is often a temporary method while the bowel is 
healing. Radiation therapy eradicates the tumor via high-energy rays. This treatment could be 
utilized alone or combined with other therapies either to reduce tumor volume before surgery or to 
abolish the remaining cancer cells after chemotherapy. In some cases, it may also be used to relieve 
the pain by diminishing cancer size when tumor removal is not possible9,10. 
Table 1. TNM classification and AJCC 8th edition Staging of Colon Cancer. [Reproduced from Vogel, JD., et al. (2017). 
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the guidelines set forth by the College of American Pa-
thologists.57–59 When suspected to be involved, the most 
apical central lymph nodes should be marked on the 
specimen because their metastatic involvement is a nega-
tive prognostic indicator.60,61
Colotomy and local excision of a colon cancer is an 
inadequate surgical technique for curative resection. It is 
associated with a risk of tumor spillage into the peritoneal 
cavity, and the lack of a lymphadenectomy increases the 
risk of tumor progression.
3. Routine performance of extended lymphadenectomy 
is not recommended. Grade of Recommendation: 
Strong recommendation based on moderate-quality 
evidence, 1B.
Lymph node metastasis outside the standard field of resection 
(ie, proximal to primary feeding vessel and associated central 
(D2) nodes) occurs in 3% to 11% of colon cancers and is 
more likely with advanced T-stage cancers.61–64 Central lymph 
node involvement in the absence of pericolic or intermediate 
lymph node involvement (“skip metastases”) occurs in ≤2% 
TABLE 2.   TNM classification and AJCC 8th edition Staging of Colon Cancer
Definition of primary tumor (T)
 T Category T Criteria
 TX Primary tumor cannot be assessed
 T0 No evidence of primary tumor
 Tis Carcinoma in situ, intramucosal adenocarcinoma (involvement of lamina propria, no extension through the 
muscularis mucosae)
 T1 Tumor invades submucosa
 T2 Tumor invades muscularis propria
 T3 Tumor invades through the muscularis propria into the pericolonic tissue
 T4a Tumor penetrates to the surface of the visceral peritoneum (serosa)
 T4b Tumor invades and/or is adherent to other organs or structures
Regional lymph node staging (N)
 NX Regional lymph nodes cannot be assessed
 N0 No regional lymph node metastasis
 N1 1 to 3 regional lymph nodes are positive (tumor in lymph nodes measuring ≥0.2mm), or any number of 
tumor deposits are present and all identifiable lymph nodes are negative
 N1a 1 regional lymph node is positive
 N1b 2–3 regional lymph nodes are positive
 N1c No regional lymph nodes are positive, but there are tumor deposits in subserosa, mesentery, or 
nonperitonealized pericolic or perirectal tissues without regional nodal metastases
 N2a 4 or more regional lymph nodes are positive
 N2b 7 or more regional lymph nodes are positive
Distant metastasis staging (M)
 M0 No distant metastasis
 M1a Metastasis confined to 1 organ or site is identified without peritoneal metastasis
 M1b Metastasis confined to 2 or more organs or sites is identified without peritoneal metastasis
 M1c Metastasis to the peritoneal surface is identified alone or with other site or organ metastases
Stage T N M
0 Tis N0 M0
I 1–2 N0 M0
IIA T3 N0 M0
IIB T4a N0 M0
IIC T4b N0 M0
IIIA T1-T2 N1-N1c M0
 T1 N2a M0
IIIB T3-T4a N1-N1c M0
 T2-T3 N2a M0
 T1-2 N2b M0
IIIC T4a N2a M0
 T3-T4a N2b M0
 T4b N1-N2 M0
IVA Any T Any N M1a
IVB Any T Any N M1b
IVC Any T Any N M1C
AJCC = American Joint Committee on Cancer.
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2.2. Chemotherapy  
To lessen cancer cell division, different drugs or drug combinations are utilized as a 
principal therapeutic strategy. Chemotherapeutic drugs disrupt the life cycle of cancer cells in 
different ways such as damaging their DNA or interfering with the process of DNA synthesis. Most 
of them are administrated through vein, whereas the others are taken orally. Typically, 
chemotherapeutic drugs are given in combination to reduce the chance of drug resistance compared 
with using a single drug. Chemotherapy is used in cycles of treatment days followed by days of 
rest. Depending on which drugs are used, the cycles are varied; for example, 14 or 21 days long 
offering a chance for the body to recover. Nonetheless, this conventional chemotherapy still has 
pitfalls related to the delivery of drugs to the non-target site, and unwanted side effects. For instance, 
neutropenia, anemia, mucositis, gastrointestinal toxicity, diarrhea, nausea, vomiting, fatigue, hand-
foot syndrome, hematologic disorders, and liver toxicity are major drawbacks suffered by a number 
of patients11,12. Chemotherapy regimens used for colon cancer are shown in Table 2.   
Table 2. Chemotherapy regimens used for colon cancer13,14.  
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2.3. Targeted therapies  
 Targeted cancer therapies are molecules that impede the spreading of tumor by targeting or 
interfering with specific molecules that play an essential role in tumor progression and growth. 
Targeted therapy is considered less harmful to normal cells than conventional chemotherapy drugs. 
Many of the substances are considered biologic therapies because they are derived from antibodies, 
Y-shaped proteins. Targeted therapy for colon cancer basically targets the VEGF (vascular 
endothelial growth factor) and EGFR (epidermal growth factor receptor) pathways (Figure 4).  
Normally, cancer cells receive food and oxygen from blood for growing. VEGF is one of 
the substances created by cancer cells which attaches to surface receptors of endothelial cells to 
stimulate the growth of blood vessels. Thus, VEGF pathway works as anti-angiogenic therapies to 
stop the growth of abnormal blood vessels that feed tumors. Currently, there are three kinds of 
drugs in the line for treating metastatic colorectal cancer cancer including antibody, fusion protein, 
and tyrosine kinase inhibitor. Bevacizumab (Avastin®) is an antibody, which binds to VEGF 
before reaching its receptors at endothelial cells. As a result, VEGF cannot attach to its endothelial 
surface receptors and no growth signals being produced. Ramucirumab (Cyramza®) binds to 
VEGF receptors on the outside of endothelial cells blocking VEGF from attaching its receptors. 
Regorafenib (Stivarga®) is a tyrosine kinase inhibitor (TKI), in oral dosage form. TKI attaches to 
VEGF receptors on the inside of endothelial cells or surface receptors within cancer cells and stops 
growth signals. Ziv-aflibercept (Zaltrap®) is a fusion protein designed to target multiple growth 
factors involved in cancer and angiogenesis. It acts as a decoy and traps VEGF. As a consequence, 
it is unable to bind to the real receptor. 
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Figure 4. Targeted therapy. vascular endothelial growth factor (VEGF) (A) and epidermal growth factor receptor 
(EGFR) (B) pathways. 
The epidermal growth factor receptor (EGFR) is one of the surface receptors on cancer cells 
that can trigger tumor development. When EGF (epidermal growth factor) binds to EGFR, the 
chemical pathway of growth signals is turned on. EGFR signaling plays an important role in the 
development of the disease especially with an abnormality of gene. Anti-EGFR treatment targets 
this receptor to interrupt its signal and hamper tumor growth15. Cetuximab (Erbitux®) and 
Panitumumab (Vectibix®) bind to the ends of EGFRs that are outside of the cell; hence, EGF is 
blocked from attaching and triggering growth signals. Moreover, it also attracts immune cells 
triggering the killing system for cancer.  
To date, the therapeutic results have not yet reached satisfactory outcomes due to drug 
resistance. As primary treatment, surgery has shown a good effectiveness; however, patients still 
confront recurrence, which is a main shortcoming and frequently leads to death. The attempts to 
achieve early diagnosis and efficient treatment are ultimate goals to improve patient survival16. The 
severe adverse effects of cancer drugs to the non-cancer cells greatly limit the maximal allowable 
systemic dose, resulting in insufficient drug concentrations reaching the carcinoma.  Therefore, 
improvements of anticancer delivery are necessary to target specifically tumor cells and 
differentiate normal cells in order to overcome the side effects and systemic toxicity.  An overview 
regarding the potential of nanotechnology to improve delivery of anticancer drugs is provided in 
section 4. 
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3. Gene therapies 
 Nowadays, nucleic acid-based therapies are being proposed for the treatment of prevalent 
and rare diseases17,18. There are numerous kinds of nucleic acid drugs that affect at a specific step 
of the gene expression process such as protein-expressing plasmid DNA (pDNA) and messenger 
RNA (mRNA), antisense oligonucleotides (ASOs), microRNA (miRNA), small interfering RNA 
(siRNA), and genome editing systems (the CRISPR-Cas9 system). Each of them plays a role at a 
different level, e.g., genomic, transcriptional, and post-transcriptional step contributing to 
upregulation of gene expression or disruption of gene expression19. Therefore, the main advantage 
of gene therapy is that it can be precisely designed to achieve the desired therapeutic effect. Gene 
therapy has also been suggested for the development of improved and specific treatments against 
CRC. Various gene therapy methods include gene correction, immunogenetic manipulation and 
virotherapy20. Common mutations in CRC, such as those of the tumor suppressor, p53 or the proto-
oncogene, K-RAS have also been assessed as therapeutic targets21,22. A closer description of the 
main gene therapy approaches is provided in the next epigraph, with some specific examples of 
different approaches specifically designed to treat CRC:  
3.1. Upregulation of gene expression with plasmid DNA (pDNA) 
A plasmid DNA is a small, circular, double-stranded DNA molecule between 5 and 20 kbp. 
It naturally exists in bacterial cells and some eukaryotes. Generally, the genes carried in plasmids 
provide bacteria with genetic benefits, thus pDNA are introduced into cells to restore the deficiency 
or insufficient production of a specific protein. Until now, there are more than 100 plasmid-based 
therapies being tested in clinical trials. A recent study of targeted lipoplex loading recombinant 
interleukin-15 plasmid (pIL15) demonstrated in vivo antitumor effect, suppression tumor growth 
in CT26 colon cancer mouse model23.  
3.2. Messenger RNA (mRNA) 
 mRNA is a natural biomolecule that carries a portion of the DNA code to other parts of the 
cell for processing. It is a single-stranded nucleotides known as ribonucleic acid. During the 
transcription step, a single strand of DNA is decoded by RNA polymerase, and mRNA is produced. 
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The feasibility of using mRNA for therapeutic protein expression in vivo has been studied as an 
alternative to DNA-based gene therapy. Though mRNA is less stable than DNA, it offers several 
merits such as higher transfection efficiency in non-dividing cells (no nuclear localization required), 
no potential for mutagenesis in the genome, predictable kinetics, rapid expression, decreased 
immunogenicity, and increased safety profile (lack of CpG motifs)24.  Commonly, mRNAs are 
employed in vaccination strategies targeting dendritic cells (DCs) resulting in the development of 
a tumor vaccine25. An example related to the use of mRNA for CRC treatment refers to 
immunizations mediated by mRNA-loaded DCs in patients with resected hepatic metastases of 
colon cancer26. 
3.3 Disruption of gene expression  
The concept of RNA interference (RNAi) is to disrupt disease-related gene and protein 
expression. Such a method is straightforward and evolutionary regulates gene expression. From 
Watson-Crick base-pair hybridization, a sequence that is complementary to a specific mRNA 
inhibits the expression of that mRNA and blocks the translation of genetic information from DNA 
to protein27. RNAi is based on a post-transcriptional regulation activated by a double-stranded RNA 
(dsRNA), which pave the way for sequence-specific silencing of a mRNA. It was discovered in 
Caenorhabditis elegans by Fire and Mello in 1998 including endogenous (miRNA) or exogenous 
(siRNA and shRNA) RNAs28.  When the double-stranded RNA molecules incorporate into the 
RNA-induced silencing complex (RISC), gene silencing begins. While miRNAs bind partially to 
their target mRNAs causing degradation or translational inhibition, siRNAs and shRNAs bind 
completely to and cleave the complementary strand29. Though toxicity related with siRNA and 
shRNA overexpression is being debated, miRNA could be a safer choice because it does not 
compromise the gene knockdown efficacy. 
3.4 microRNA (miRNA) 
 MicroRNAs (miRNAs) are small non-coding RNAs. They can regulate post-transcriptional 
gene expression and silence a broad set of target genes via diverse mechanisms, either restoring or 
repressing miRNA expression and activity30. They are often 18–25 nucleotides in length, which 
endogenously synthesized and promote mRNA degradation and/or translational inhibition. 
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Because of significant changes of their expression in cancer, miRNAs are supposed to be key 
factors in cancer genetics and to have potential as anticancer drugs. Their functions include cell 
survival, proliferation, apoptosis, tumor growth, and metastasis.  
 
Figure 5. microRNA generation and silencing mechanisms. [Reproduced from Chen, Y., et al. (2015). Adv. Drug Deliv. 
Rev.29 with permission]  
In mammalian cells, primary miRNA precursors (pri-miRNAs) are initially produced as 
short hairpin structures in the nucleus by RNA polymerase II. They are further cleaved by Drosha 
in the nucleus, transported into the cytoplasm by exportin-5, and finally converted into double-
stranded duplexes by the RNAse Dicer31. Mature miRNAs are recognized by Argonaute 2 (AGO2) 
and incorporated into the RISC complex. They are unwounded and annealed to the target mRNAs 
carrying complementary sequences causing an inhibition of translation and degradation of mRNA32. 
miRNAs are capable of regulating tens to hundreds of mRNAs through the imperfect base pairing 
between miRNAs and the 3′ or 5′ untranslated region of the target mRNAs (Figure 5). 
In cancer, the roles of miRNAs include manipulating gene expressions, regulating 
downstream signaling pathways, and thus controlling cancer formation and progression. Therefore, 
they have been utilized in cancer therapy as therapeutic agents or biomarkers to regulate multiple 
cancer-related genes in terms of cell cycle progression, metabolism, cell death, angiogenesis, 
3.1. Cell proliferation and cell death
Five groups of miRNAs, including the miR-15a/16 cluster, the miR-
17/20 cluster, the miR-221/222 cluster, and the let-7 and miR-34
families, can target cell cycle regulators to control cell cycle checkpoints
and progression [30]. Dysfunction of the cell cycle-related miRNAs
increases cell proliferation, leading to tumor growth promotion. In
contrast, recent study has highlighted miRNAs as anti-apoptotic or
pro-apoptotic regulators by targeting various mRNAs associated with
key apoptotic pathways in cancer. For instance, miRNA-221/222 cluster
targeting p27, PTEN, and PUMA, miRNA-128 targeting BAX andmiRNA-
17/19 cluster targeting BIM act as anti-apoptotic miRNAs to maintain
survival of cancer cells and contribute to drug resistance [31–33]. On
the other hand, pro-apoptotic miRNAs 15a/b and 16 targeting BCL2
family serve as anti-cancer guardians [34].
3.2. Metabolism
The miRNA expression profiles associated with metabolism are
distinct fromnormal cells. miRNAs play as key regulators ofmetabolism
in cancer cells to increase nutrient uptake and the accumulation of
materials for controlling metabolic flux [35]. For example, miRNAs
such as miR-133, miR-138 and miR-150 targeting glucose transporter,
miR-33a/b targeting metabolic enzymes to regulate fatty acid metabo-
lism and AMPK pathway and miR-29b targeting amino acid catabolism
are involved in modulating cancer cell metabolism and biogenesis to
support tumor growth and proliferation [36–39].
3.3. Metastasis and angiogenesis
miRNAs have impact on bo h intrinsic signaling pathways of cancer
cells and interactions between cancer cells and tumor stroma to
regulate invasion and metastasis. For instance, miR-200 family and
miR-205 are downregulated in various tumors to promote epithelial–
mesenchymal transition (EMT) progression and facilitate cancer cell
invasion [40]. miR-29b upregulated in breast cancer cells suppresses
the expression of MMP2 and MMP9 and consequently triggers
extracellular matrix (ECM) remodeling to facilitate cancer cell
migration and local invasion [40]. Besides, angiogenesis is required
for supporting the formation of both primary and metastatic lesions.
miR-424 triggered by hypoxia stabilizes hypoxia-inducible factor-α
(HIF-α) and enhances angiogenesis in tumor microenvironment [41].
miR-503 suppresses the expression of angiogenic factors like fibroblast
growth factor (FGF) 2 and VEGF-A. miR-503 is downregulated in
hepatocellular carcinoma (HCC), resulting in increased angiogenesis
and tumorigenesis [42].
3.4. miRNAs in cancer diagnosis and cancer therapy
As we summarized above, the aberrant expressions of miRNAs
are associated with tumor formation, progression and metastasis.
Moreover, the abnormal expressions of miRNAs are also correlated
with the resistant mechanisms to chemotherapy. Thus, miRNAs can
serve as both diagnostic and prognostic biomarkers in cancer [43]. For
example, miR-155 overexpression and let-7a downregulation are
associated with poor disease outcome in lung cancer [44]. For prognos-
tic applications, overexpression of miR-221 and miR-222 are associated
with poor therapeutic outcome of anti-estrogenic therapies such
as Tamoxifen and Fulvestran, while tumor suppressor miR-205 is
responsible for enhanced therapeutic effect of tyrosine kinase inhibitors
[45–47]. Many reports have demonstrated the significance of micro-
RNAs as diagnostic and prognostic biomarkers. Besides, miRNAs can
also serve as either therapeutic agents or therapeutic targets in cancer.
In the following sections, we will further focus on the therapeutic
applications of miRNAs.
4. miRNAs: therapeutic agents or therapeutic targets?
According to the functions of miRNAs, cancer types and stages,
both antagonists and mimics are developed as miRNA-based
therapeutic strategies to achieve tumor regression [48]. miRNA antago-
nists – single-stranded oligonucleotides with miRNA complementary
sequences – are designed to interrupt the miRNA processing as well as
RISC assembly, and result in increased expression of the tumor
Fig. 1. Schematic representation of themicroRNA generation and silencingmechanisms. Hairpin-forming pre-miRNAs are generated bypri-miRNAs,which is cleaved byDrosha. Later, pre-
miRNAs are transported into the cytoplasm by exportin-5 and further converted into double-stranded mature miRNAs by Dicer. Mature miRNAs are incorporated into the RISC complex,
unwound and annealed to the target mRNAs carrying complementary sequences. miRNAs are able to regulate tens to hundreds ofmRNAs via the imperfect base pairing betweenmiRNAs
and the 3′ or 5′ untranslated region of the target mRNAs. The miRNA-mRNA interaction silences the target genes through mRNA cleavage or translational inhibition.
131Y. Chen et al. / Advanced Drug Delivery Reviews 81 (2015) 128–141
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metastasis, and immunosuppression33. Two strategies are currently used to regulate the function of 
miRNAs in cancers. miRNAs can be downregulated when they function as tumor suppressors or 
overexpressed when they function as oncogenes34 (Figure 6). 
 
Figure 6. miRNAs targeting the hallmarks of cancer at various progression stages (The up arrows represent oncomiRs 
and the down arrows indicate tumor-suppressive miRNAs). [Reproduced from Wang, H., et al. (2015). Adv. Drug Deliv. 
Rev.34 with permission]  
In case miRNAs are downregulated, replacement therapy with miRNA mimics is used to 
restore miRNA levels and their tumor suppressive functions. For instance, miR-34a, miR-15a, 
miR-16, miR-17, miR-29, miR-126, miR-143/145, and the let-7 family are under-expressed in 
many human cancers. Hence, up-regulation of these tumor-suppressive molecules reprograms 
cancer cells by incorporation into the RISC and silencing their target mRNAs35,36. Additionally, 
the mimics of duplex structures are preferred over single-stranded mimics because the double-
stranded miRNA mimics have been found to facilitate RISC loading and so enhance the gene-
silencing efficacy37. Furthermore, plasmid DNAs, which encode hairpin pre-miRNA can be 
utilized to reactivate cellular pathways and induce therapeutic responses38. Different approaches 
related to restoring of miRNA levels to decrease tumor growing and progression have been 
proposed as novel therapeutic strategies for CRC, for example, miR-200c by targeting ZEB1 
mRNA, miR-4458 by targeting hexokinase2 mRNA, and miR-145 by targeting fascin-1 mRNA39-
41. 
miRNA are widely acknowledged [11]. There is thus dramatically grow-
ing interest in miRNA-based medicine.
2.1. Brief overview of miRNA therapeutics
miRNAs are biologically functional RNAs that cause gene silencing by
targetingmRNA.Many pathological processes involve abnormalmiRNA
expression. For example, in rheumatoid arthritis, differential expression
of miR-155, miR-124a, miR-146a, miR-15, and miR-16 has been identi-
fied [12]. In systemic lupus erythematosus, dysregulation of miR-21,
miR-25, andmiR-186 in peripheral bloodmononuclear cellswas report-
ed recently [13]. In Sjögren's syndrome, increasedmiR-4524-b3p and an
unidentified miR-5100 were found [14]. In multiple sclerosis patients,
distinct expression of miR-20a, miR-326, and miR-17-5p was shown
in CD4+ and CD8+ T cells [15].
It is well accepted that cancers often result from genetic mutations.
In early studies comparing miRNA expression in normal tissues and
primary carcinomas, approximately 50% of miRNA genes were located
at fragile sites and genomic regions highly related to cancers [16–19].
Consequently, considering their important roles in tumorigenesis,
miRNAs have been investigated as diagnostic biomarkers, oncogenic
factors, or tumor suppressors with therapeutic potential (Fig. 2) [20].
miRNAs are generally associated with various stages in cancer progres-
sion, such as unlimited proliferation, metastasis and invasion, sustained
angiogenesis, apoptosis and drug/radio-resistance.
Two approaches are used to modulate the function of miRNAs in
cancers. The first approach is directed towards inhibiting the activity
of oncogenicmiRNAs activity usingmiRNA antagonists, such as synthet-
ic anti-miRNAs or locked nucleic acids (LNAs). For example, small anti-
sense oligonucleotides with sequences complementary to endogenous
mature miRNAs can be used as miRNA antagonists. Moreover, mRNAs
involved with various targets can be applied as miRNA sponges (miR-
SP) to sequester the mis-expressed miRNAs [21,22].
OncomiRs (e.g., miR-125b, miR-20, miR-155, and the miR-17-92
family) that down-regulate tumor suppressor genes are over-
expressed in different types of cancers [23,24]. In contrast, miRNAs
(e.g., miR-34a, miR-15a, miR-16, miR-17, miR-29, miR-126, miR-143/
145, and the let-7 family) that can function as tumor suppressors are
under-expressed in many human cancers [25,26]. Up-regulation of
these tumor suppressive miRNAs provides the second approach for
miRNA-based cancer therapy. Specifically, miRNA mimics (functionally
similarly to endogenous miRNAs) are employed to reprogram cancer
cells by incorporation into the RNA-induced silencing complexes. Addi-
tionally, plasmid DNAs that encode hairpin pre-miRNA can be used to
reactivate cellular pathways and induce therapeutic responses [27,28].
Resistance to chemotherapy and radiotherapy is the major barrier
against successful cancer therapy. There is growing evidence that
the expression level of miRNAs is linked to the development of drug
resistance [29]. Indeed, levels of various miRNAs correlate with both
chemo- and radio-resistance through the regulation of drug efflux
transporters, the cell cycle, and DNA repair [30]. For example, simulta-
neous up-regulation of miR-27a and ABCB1 was found in paclitaxel-
resistant ovarian carcinoma cells, while transfectionwithmiR-27 inhib-
itors reduced the expression of P-gp [31]. Up-regulation of miR-485-3p
in human lymphoblastic leukemia CEM cells induced a decrease in
nuclear factor-κB and an increase in the Top2α level, consequently
increasing the sensitivity of these cells to topoisomerase II inhibitors
[32]. In addition, over-expression of miR-9 and let-7g lowered the
NFκB1 level and enha ced the sensitivity f lung tumors o radiation
therapy [33].
2.2. Challenges of miRNA therapy
Delivery of miRNAs for cancer therapy has received much attention
[34]. Although there have been some remarkable advances in using
miRNAs for inhibition and replacement therapies, formidable obstacles
Fig. 2.miRNAs targeting the hallmarks of cancer at various progression stages including unlimitedproliferation,metastasis and invasion, sustained angiogenesis, apoptosis and drug/radio-
resistance. The up arrows represent oncomiRs and the down arrows indicate tumor suppressive miRNAs.
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 On the contrary, oncomiRs (e.g., miR-125b, miR-20, miR-155, and the miR-17-92 family) 
that inhibit the function of miRNAs are overexpressed in different types of cancers. In this case, 
miRNA antagonists such as synthetic anti-miRNAs or locked nucleic acids (LNAs) are used to 
inhibit the activity of oncogenic miRNAs. The usual method is to use the single-stranded 
oligonucleotides with sequences that are partial or complete complementary to endogenous mature 
miRNAs. The complementary binding of the antagonist to the endogenous miRNA prevents its 
processing by RISC. Anti-miRNAs are chemically modified to increase their binding affinity for 
the miRNA42. 
The delivery of nucleic acids requires a protection from serum endonucleases and an 
evasion from immune system detection. These could be accomplished by encapsulating nucleic 
acids inside the non-viral carriers and specific characterization of particles such as chemical 
modifications and adding polyethylene glycol (PEG) or specific ligands. After administration, 
these vectors have to avoid renal clearance, extravasate from the bloodstream to reach tumor sites, 
and mediate cell entry and endosomal escape. Different delivery approaches based on 
nanotechnology are described in section 6.  
4. Biomedical imaging 
Nowadays, biomedical imaging has numerous impacts on scientific discoveries and 
technological innovations. Advances in X-ray computed tomography (CT), magnetic resonance 
imaging (MRI), positron emission tomography (PET), single-photon emission computed 
tomography (SPECT), ultrasound, and optical-imaging techniques, play a crucial role in non-
invasive experiments to obtain uniquely valuable information about tissue composition, 
morphology, and function (Figure 7). In research area, they are widely used for imaging small 
animals, being this understood as translational tools between animal models and human clinical 
applications. Furthermore, a variety of molecular devices and contrast agents have been created to 
drive cellular and molecular imaging for new inventions in biological research43,44. The capability 
to detect, diagnose, and monitor pathological, physiological, and molecular changes utilizing these 




Figure 7. Various types of currently commercially available in vivo molecular multimodal imaging systems and 
applications. [Reproduced from De Jong, M., et al. (2014). Nat. Rev. Cancer37 with permission]  
Nevertheless, each imaging modality has its own advantages and disadvantages, and a 
single technique does not possess all the requirements for comprehensive imaging45. For instance, 
the major merits of radionuclide-based molecular imaging techniques (SPECT and PET) over other 
modalities are that they are quantitative and highly sensitive, and can detect tracer concentrations 
in the picomolar or nanomolar range. In addition, there is no tissue penetration limit. However, one 
disadvantage is that the resolution (typically >1 mm) of either SPECT or PET is not as high as for 
other imaging modalities such as MRI. On the contrary, the spatial resolution of MRI and CT is 
notably higher than that of SPECT, but they have the limitation in sensitivity. For optical imaging, 
they offer higher sensitivity and temporal resolution than PET at the same spatial resolution in 
small animals; however, it is limited to a few centimeters of tissue depth (Table 3).  
 
 











tracers, such as 18fluoro-2-deoxy-d-glucose (FDG), 
18fluoro-thymidine or 18fluoro-choline, are good options 
for PET and SPECT69 but may not det ct slow-growing 
tumour types or micrometastatic lesions with low meta-
bolic rates70. Given the generic use of this echnology, 
we expect an exponential growth of the use of PET 
and/or SPECT.
For MRI, iron-binding proteins and iron-storage 
proteins that lead to iron accumulation — thereby pro-
viding a contrast agent — have been shown to be useful 
reporters of cell-specific gene expression71–73. Imaging 
probes that are directed towards the microenvironment 
of the tumour (such as tumour vasculature, the stromal 
compartment or the immune system) rather than to the 
tumour itself, are interesting alternatives, particularly in 
syngeneic mouse models and GEMMs74–76.
Imaging probes are being applied for diagnostic use, 
as well as to predict and monitor therapy responses 
(FIG. 3). Besides their se in visualization, imaging probe  
with high target specificity may also be used as a thera-
peutic agent to inhibit the disease process. Probes that 
combine imaging and therapy are known as therano stics 
or ther nostic pairs25,77; they represent a cutting-edge 
integration of diagnostics and therapeutics and comprise 
companion diagnostic tests to make the right therapeutic 
decision for each patient.
The use of receptor targeting with small radio labelled 
peptides for tumour imaging by PET or SPECT, as well as 
for radionuclide therapy28,77–79, is a good example of the 
theranostic potential in nuclear oncology. Theranostic 
nanoparticles enable different imaging probes, thera-
peutics and contrast agents to be used in one system 
Figure 2 | Overview of various types of currently commercially available in vivo molecular multimodal imaging 
systems and applications. Text in blue boxes shows some of the currently commercially available multimodal 
modalities indicated with overlapping techniques. a | A positron emission tomography (PET) image of the distribution of 
the metabolic tracer 18fluoro-2-deoxy-d-glucose (FDG) in mic . b | Combined single photon emission computed 
tomography (SPECT) and computed tomography (CT) detection of metastases using 111In-DTPA-octreotide in mice.  
c | Whole-body contrast-enhanced microCT angiogram (image courtesy of R. Ridwan, Department of Genetics, 
ras s  o er a  he e her an s  d | Fluorescence-mediated tomography (FMT)-derived matrix 
metalloproteinase activity in a mouse aorta (image courtesy of S. Belenkov, Perkin Elmer Inc., Waltham, Massachusetts, 
USA). e | Bioluminescence detection of an orthotopic hypopharynx tumour model using a luciferase-expressing tumour 
cell line (image courtesy of J. A. M. Braks, Department of Oral and Maxillofacial Surgery, Erasmus University Medical 
en er o er a  he e her an s  f | High-resolution whole-body magnetic resonance angiogram using gadolinium 
liposomes as an intravascular contrast agent (image courtesy of P. Wielopolski, Department of Radiology, Erasmus MC, 
o er a  he e her an s  g | Cathepsin B activity quantified by FMT and co-registered with anatomical CT data 
(image courtesy of R. Weissleder, Harvard Medical School, Center for Systems Biology, Boston, USA). h | A multiphoton 
laser scanning microscope image by intravital microscopy of a melanoma-bearing mouse expressing vascular green 
fluorescent protei  (GFP), using second harmonic  generat on to detect ollagen (image courtesy of T. L. M. ten H gen, 
e ar en  o  rg a  n o og  ras s  o er a  he e her an s  i | B-mode ultrasound image of a mouse left 
en r e age o r es  o   ee an  o e a  ng neer ng  ras s  o er a  he e her an s  
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Table 3.  Advantages and disadvantages of each image modality.45-47 
 
Medical imaging enables rapid, longitudinal, and noninvasive visualization of the interior 
of living subjects. This technique is categorized into two main approaches. First is an anatomical 
imaging, which offers information on gross structure. Second is a molecular or functional imaging 
that provides data on physiology and cellular processes48-50. For instance, metabolism, protein 
expression, and DNA synthesis. While exogenous imaging agents are optional for anatomic 
imaging (e.g., MRI or CT contrast medium agents, which help improving tissue contrast), there is 
a requirement for molecular imaging, especially within the realm of nuclear medicine (SPECT or 
PET)51-53. Nanoparticles are a new and exciting class of imaging agents that can be used for both 
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anatomic and molecular imaging. An overview regarding the potential of nanotechnology for 
diagnostic applications is provided in section 6. 
For CRC, imaging tests are examined to illustrate the site of tumor. They provide 
information for the doctor to evaluate the stage of cancer and plan treatment. Some imaging 
examinations use contrast agents to display tumor area, which are administered by injection into 
bloodstream54. Generally, this procedure is performed by the radiologist, who conveys imaging 
results to the oncologist. The common image modalities for CRC diagnosis are CT, MRI, and 
PET55. CT is usually advised when the cancer has spread beyond the second layer of the colon wall. 
Moreover, CT colonography has emerged as a potentially comfortable alternative for patients 
undergoing full structural screening of the colon and rectum56,57. Several studies suggest that CT 
colonography is able to depict colorectal neoplasms larger than 1 cm in diameter58,59. In certain 
cases that the CT scan are unclear, MRI can be required such as the evaluation of liver metastases60. 
The combination of PET/CT renders some benefits such as ability to find metastases and 
demonstrate the size of metastases tumor61. In addition, PET is a good option when the patients are 
not able to receive contrast agents of CT or MRI. It is administrated with glucose analog. Due to 
the high demand of sugar in cancer cells, it can have a high uptake, resulting in brighter image in 
tumor compared to normal cells62.  
4.1. Anatomical imaging  
4.1.1 X-ray computed tomography (CT)  
Anatomic imaging by CT can be performed without administration of any contrast agent; 
however, contrast administration can increase the sensitivity and specificity of lesion 
detection63. CT image contrast is dependent on tissue density, which determines the amount of x-
ray beams that will be attenuated as they pass through the object of interest.  Iodinated contrast 
agents are routinely used to visualize blood flow and washout, often delineating areas that can be 
used as a surrogate for neoplasm, infection, and inflammation64,65.  
The CT detectors measure the attenuation coefficient (µ) between the x-ray tube and 
detectors, which is a measure of how much x-rays are absorbed. The gray levels in a CT image 
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represent attenuation as Hounsfield units (HU). Bones or areas of calcification are the most 
attenuating (+1,000HU); whereas air is the least attenuating (−1,000 HU). Clinical CT scanners 
allows acquisition of whole-body images within a few seconds. Nevertheless, CT scans expose 
patients to ionizing radiation, which limits pediatric applications. For adults, short-time procedure 
is recommended66,67. 
4.1.2 Magnetic resonance imaging (MRI) 
MRI is a noninvasive and nonionizing medical imaging for visualizing anatomical, 
physiological, and molecular information for internal structures of living subjects. Depending on 
the magnetic field strength, MRI can illustrate data with spatial resolutions down to 10 µm. 
Generally, clinical magnets provide ∼1 mm in resolution. Its penetration depth is adequate to image 
throughout the whole body of humans. Currently it is beneficial for image in brain, muscles, heart, 
and cancers because of its good contrast between the different soft tissues of the body68,69.  
The sensitivity of standard MRI is associated with the mechanism of signal detection, which 
measures the relaxation rates of water protons. It can also detect other nuclei with nonzero spins. 
However, the most common use is with protons. The precession of water hydrogen nuclei in an 
applied magnetic field changes after applying radiofrequency pulses. This causes changing in the 
alignment of the magnetization of atoms. The proton spin flips from being parallel to the external 
field to being transverse. After the removal of the pulse, the nuclei start to produce a rotating 
magnetic field and revert back to equilibrium. This is detectable by the scanner, which is recorded 
to construct an image. Strong magnetic field gradients affect nuclei at different locations to rotate 
at different speeds, hence giving 3D spatial information70. The different T1 (spin–
lattice/longitudinal relaxation) and T2 (spin–spin/transverse) proton relaxation times in different 
tissues produce the endogenous contrast. To improve the differentiation between tissues, 
exogenous contrast agents are usually utilized to shorten the relaxation parameters (T1 and T2) of 
water resulting in a bright (positive) or dark (negative) contrast enhancement. Thus, contrast agents 
enhance the signal-noise ratio and provide the better detection sensitivity71. Paramagnetic 
molecules such as gadolinium (Gd) and manganese (Mn) can be chelated with small molecules or 
macromolecules creating T1 contrast agents. While gadolinium-based contrast agents shorten the 
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longitudinal relaxation times (T1) of tissues and increase signal strength, iron oxide shortens 
transverse relaxation times (T2) and darkens the contrast72. Currently, several Gd3+ contrast agents 
are FDA approved. Dextran-coated iron formulations are clinically approved for T2 contrast 
agents73. 
Although, conventional high resolution anatomic imaging modalities such as computed 
tomography (CT) and magnetic resonance imaging (MRI) can provide details regarding lesion 
location, size, morphology, and structural changes to adjacent tissues, these modalities offer little 
insight into tumor physiology. According to the increasing focus on molecularly targeted therapies, 
imaging radiolabelled agents are usually used to acquire information of tumor's biologic functions 
and its surrounding microenvironment.  
4.2. Functional imaging  
At the other end of the electromagnetic spectrum lied γ-ray emissions, which are the 
fundamental for PET and SPECT. Both modalities are based on administered radiopharmaceuticals 
and the detection by a camera. As the gamma rays have the megavolt energies, they require little 
signal amplification and are acquired over a nominally low background signal. Unlike MRI, they 
are quantitative techniques74. Biological molecules with labelling radionuclide can be tracked using 
PET or SPECT to obtain their biodistribution75. It is usually assumed that the labelling technique 
does not disturb the characteristics of those molecules regarding metabolism, specific binding or 
non-specific interactions.  
4.2.1 Single-photon emission computed tomography (SPECT)  
SPECT is a nuclear medicine tomographic imaging technique. It can create 3D information 
allowing accurate localization of organs76. It relies on the detection of gamma rays from 
radioisotopes, for example 99mTc, 111In, 123I, and 131I. Several radionuclides can be multiplexed for 
use in SPECT because different isotopes emit different energies of gamma rays, while various 
isotopes for PET all emit the same energy in the form of positrons77. However, SPECT is an order 
of magnitude less sensitive than PET.  
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After in vivo administration, the isotope from the radiolabelled molecules emits gamma 
rays detected by a gamma camera. Normally, a marker radioisotope could be attached to an 
antibody or nanoparticles. As an example, one study was successfully accomplished in the liver to 
study the correlation between tumor accumulation of In-111-bevacizumab and VEGF-A 
expression in patients with colorectal liver metastases78.  
 
4.2.2. Positron emission tomography (PET)  
The principle of PET relies on the administration of radiolabelled tracers to monitor their 
biodistribution, physiological processes, biochemical pathways, etc.79. This modality in clinical 
molecular imaging has a resolution of 1–2 mm. Although it suffers from low anatomical resolution 
compared to MRI, it perhaps has the highest sensitivity of the imaging techniques which is usually 
in a concentration of nanomolar. This enables quantification of the local concentration of 
radionuclide tracer and provides the possibility to detect a single abnormal cell labelled with only 
a few amount of trace isotopes. PET has no limit of the penetration depth. Thereby, it allows image, 
regardless of the location of the target. The advantage of PET is strengthened in cancer research 
for detection of molecular changes, which are occurring in the body before the macroscopic disease 
is shown. It is also helping in monitoring disease progression after treatment such as tumor response 
to therapy80,81.  
 




 PET image is based on the emission of radioisotopes in the form of positrons without the 
need for external excitation. PET scans are acquired after the injection of the radiotracer, a molecule 
incorporated radionuclides during the radiosynthesis step. The radiotracer accumulates in tissues, 
and then its radionuclide decays by emission of a positron (anti-electron) contributing to in vivo 
tracking with a camera. Normally, after a positron travels a few millimeters, it will collide with an 
electron and simultaneously release two photons (gamma-rays) with energy of 511 keV into 
opposite directions (Figure 8). This annihilation is detected by the PET camera82. By collecting a 
statistically significant number of radioactive events and mathematical algorithms, the distribution 
of the positron-emitting molecules in the tissues is reconstructed in three-dimensional image83. 
Radioisotopes for PET include both short-lived or long-lived positron-emitting 
radionuclides. These are examples of positron emitters and their half-lives: 11C (20 minutes), 15O 
(2 minutes), 18F (2 hours), 68Ga (68 minutes), 64Cu (13 hours), and 76Br (16 hours). Among those 
radioisotopes, 18F could be an interesting choice for labelled-molecules to track tumor in whole-
body and provide an efficient diagnosis. Its advantages are ease of production in large quantities 
with high specific activity, appropriated half-life (109.7 min), and high PET resolution84. 
[18F]fluorodeoxyglucose (FDG) is a glucose analog approved for staging several cancers such as 
breast, colorectal, esophageal, head and neck cancers, melanomas and lymphomas85. In most of the 
malignancies that are rapidly metabolizing cells, it is selectively taken up. Nevertheless, in certain 
cases, imaging with FDG can be counter-productive as glucose metabolism is not only specific to 
tumors. Radiotracer with short half-life is also a double-edged sword. While this can reduce toxicity, 
it may be difficult to reach ample amounts at the target areas. Consequently, all pitfalls have driven 
researchers to develop more specific imaging molecules; for instance, antibodies, small proteins, 
peptides, and other targeted biological moieties.  
Nonetheless, the benefits of using PET come with a relatively high price because the only 
approach to generate the positron-emitting isotopes is from a cyclotron. Thus, the laboratory 
operating PET image must be located near such a source in order to rapidly receive the 
radionuclides. Besides, preparing of appropriate storage and handling of these radioactive materials 
should be properly manipulated86. Lastly, the exposure to the ionizing radiation should be limited 
for both patients and clinicians. 
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5. Nanotechnology for treatment and diagnosis of cancer  
 
 Nanotechnology has been utilized in a wide spectrum of biomedical applications including 
imaging, bio-sensoring, and drug delivery, and have attracted a great deal of attention in cancer87-




Figure 9. Nanotechnology-based carrier systems. [Reproduced from Richards, D. A., et al. (2016). Chem. Sci. Polym.90 
with permission]. 
5.1 Marketed nanoformulations in cancer therapy 
  Several nanomedicines have been approved for specific clinical indications related to 
cancer therapy (Table 4).  Doxil/Caelyx® was the first FDA-approved anticancer nanomedicine. 
This liposomal doxorubicin rendered a distinct pharmacokinetic and biodistribution of the drug 
resulting in improvement of safety and effectiveness compared to the free doxorubicin. Currently, 
it has been approved for various indications including Kaposi's sarcoma, ovarian cancer, breast 
cancer, and multiple myeloma91,92. Similar improvements over the current treatments contributed 
to the approvals of other nanomedicines such as Abraxane®, DaunoXome®, Depocyt®, Genexol-
PM®, and Myocet®93. Another advantage is the opportunity to develop a formulation without 
using dose-limiting toxic excipients. For example, patients using Abraxane® and Genexol-PM® 
can receive higher doses of paclitaxel because these formulations avoid the use of cremophor. As 
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a result, the maximum tolerated dose of the active ingredient can be augmented. Commonly, 
approved anti-cancer nanomedicines have been designed exploiting the concept of the EPR effect. 
Further development can be achieved via ligand-mediated targeting. Two targeted formulations are 
now in clinical trials such as BIND-014 (BIND Therapeutics) and MM-302 (Merrimack 
Pharmaceutical)94-96. 
Table 4. Anti-cancer nanomedicine clinically approved91-94.  
 
 
With respect to nanoformulations undergoing clinical trials, there is an increased number over the 
time, metallic and protein-based particles being the predominant types of studied nanomaterials 
(Figure 10a and 10b)97. In general, the whole clinical phase can last approximately 10–15 years 
with $1 billion per new drug. Nanoparticles have to be tested in animal to confirm efficacy, safety, 
and to identify suitable dose ranges in the preclinical phase. Subsequent human trials are composed 
of Phase I to Phase III including dosing, toxicity, excretion, safety, and efficacy. Further post-
marketing (Phase IV) studies are regularly conducted on a request of the FDA according to 
particular questions raised during the Phase III trials. Hence, successfully translating anti-cancer 
nanomedicines from clinical study to the real market is a real challenge.  
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Figure 10. Trends in the development of nanomedicines. Clinical trials identified with arrow indicating approximate 
start date of US law (FDAAA 801) (a). Nanomedicines under clinical trial stratified by category overall (b). 
[Reproduced from Bobo, D., et al. (2016). Pharm. Res.97 with permission]  
 
5.2. Targeting nanoformulations to the tumor 
The access of chemotherapeutic or diagnostic agents at tumor tissues is a critical step for 
achieving therapeutic and diagnostic efficacy98. Problems related to a poor access are mainly 
related to poor pharmacokinetics of low molecular weight anti-cancer drugs and medical diagnostic 
agents. They usually not only distribute to tumor areas but also go through healthy tissues after 
systemic administration. Therefore, improving biodistribution and reducing side effects is one of 
the big challenges relying in the application of nanotechnology to design improved anticancer 
therapies and diagnosis agents. Figure 11 represent key steps in tumor delivery that can be 
improved making use of nanotechnology.  
 78 
 
Figure 11. Three stages in the biodistribution of drugs. Tissue accumulation, tissue penetration, and intracellular 
trafficking. [Reproduced from Miyata, K., et al. (2011). React. Funct. Polym.98 with permission]  
To increase tissue accumulation, nanocarriers are designed to tackle fast renal excretion, 
and escape from the reticuloendothelial system (RES). For this problem, two of the most important 
criteria are size (or molecular weight) and the surface characteristics of the carrier. A molecular 
weight of approximately 45 kDa or between 4 and 9 nm in hydrodynamic diameter99 is known to 
be the threshold of renal clearance; whereas, the RES usually captures highly-charged or large 
molecule (>several-hundred nanometer). Typically, and according to several reviews100-102, <200 
nm nanoparticles can efficiently penetrate and accumulate in tumor tissues owing to enhanced 
permeability and retention (EPR) effect (Figure 12). Finally, the drugs must be released at their 
targeted sites. The payload must be stably retained within the drug carrier until reaching the tumor 
to maximize efficacy and minimize off-target effects.  
5.2.1 Enhanced permeability and retention (EPR) and stealth effect 
The enhanced permeability and retention (EPR) effect is a unique phenomenon of solid 
tumors related to their anatomical and pathophysiological differences from normal tissues103-105. 
The neovasculature of tumors differs greatly from that of normal tissues due to their angiogenesis 
resulting in high vascular density in solid tumors with large gaps existing between endothelial cells 
in tumor blood vessels. Hence, macromolecules (nanometer-scale) can penetrate extensively into 
the tumor tissue. Furthermore, slow venous return in the tumor tissue and poor lymphatic drainage 
system cause macromolecules to be retained in the tumor. On the other hand, this concept does not 
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apply to low-molecular-weight agents because of their diffusion into the entire body with rapid 
renal clearance. Thus, EPR effect served as a basic concept for the delivery of anticancer nanodrugs.  
Surface modification can modulate the fate of nanoparticles. The procedure of non-specific 
protein adsorption occurs when nanoparticles are exposed to the biological environment leading to 
a protein layer around the materials. It is practically impossible to completely avoid the formation 
of this protein corona. The major concern related to protein adsorption is the aggregation of 
nanoparticles and/or activation of macrophages though phagocytosis. This phenomenon leads to 
non-ideal biodistribution and unpredictable pharmacokinetics of nanocarriers. Coating with 
polyethylene glycol (PEG) derivatives can provide hydration shells at the solid-liquid interface106. 
Such coatings cause protein repulsion, hindering opsonization, and providing long circulation 
properties, what is called stealth effect107-109. This steric stabilization can prolong the half-life from 
less than a few minutes to several hours. Additionally, PEGylated nanocarriers are suitable to be 
further modified with targeted ligands110. 
 
Figure 12. Schematic representation of the enhanced permeability and retention (EPR) effect. [Reproduced from 
Cabral, H., et al. (2011). Acc. Chem. Res.103 with permission]   
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5.2.2. Targeted delivery 
The conjugation of targeting ligands to nanocarriers, such as antibodies, peptides, aptamers, 
and proteins, has led to the development of targeted delivery strategies to tumors111-114. Active 
targeting nanocarriers enable specific binding to a receptor or antigen overexpressed on the cell 
surface of a malignant cell. Targeted receptors that are usually expressed on tumor and utilized in 
active targeting are folate receptor (folic acid)115,116, CD-44 receptor (hyaluronic acid)117,118, 
transferrin receptor (transferrin)119, biotin receptor (biotin)120, and integrin receptor (peptide)121,122.  
Peptides are short amino acid chains with the length of approximately 50 amino acids123. 
Their advantages as ligands relate to cost, ease of production, and high stability in a wide range of 
biological conditions. In general, selected peptides have high affinities at concentration down to 
nanomolar level for their receptors. Thereby, they offer a distinctive tool with desirable target-to-
non-target ratios in the development of drug and gene delivery approaches124. As an example, the 
tripeptide Arg-Gly-Asp (RGD), which binds specifically to integrin receptors (integrin αVβ3) 
related to tumor angiogenesis and metastasis125,126, has been conjugated to radiolabelled iron oxide 
nanoparticles (RGD-64Cu-DOTA-IO) showing and improved tumor uptake127. Modification of 
single-walled carbon nanotubes (SWNTs) with PEGylated phospholipids and RGD similarly 
demonstrated higher tumor uptake than those without RGD modification128.  
For colorectal cancer, CPIEDRPMC (RPM) peptide, first discovered in 2003 derived from 
a peptide library via phage display selection, specifically targets invasive colorectal cancer129,130. 
Enhanced cellular internalization of RPM-conjugated bioreducible gene carrier was confirmed by 
using targeted (IR820-SS-bPEI- PEG-RPM) and non-targeted (IR820-SS-bPEI- PEG) polyplexes. 
In vivo images at different time points after intravenously treatment of mice bearing HT-29 with 
the RPM-conjugated polyplex displayed a good targeting efficiency compared with the non-
targeted polyplex (Figure 13)131. 
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Figure 13. In vivo real-time images of mice bearing HT-29 tumor at 30 minutes, 4 hours, and the 1 day after injection 
with the RPM-conjugated or non-targeted polyplex. [Reproduced from Lee, Y., et al. (2015). J. Control. Release.131 
with permission]  
 
5.3 Nanoemulsions 
The development of lipid-based carriers has gained interest in research over the years, as 
they are versatile systems that typically show a good biocompatibility, safety, and efficacy132-134. 
They can be adapted to meet the requirements of the different routes of administration (e.g. topical, 
oral, pulmonary, or parenteral). Various kinds of lipid-based nanocarriers have been developed to 
date,  including microemulsions, nanoemulsions, lipid nanocapsules, lipid nanoparticles, and 
liposome, in most cases with the purpose of  enhancing the solubility of anti-cancer drugs,. Among 
them, nanoemulsions provide outstanding properties to encapsulate active compounds due to their 
flexible design, high kinetic stability, and good reproducibility135,136.  
5.3.1 Composition  
The lipid selection is typically a compromise between its ability to solubilize the drug and 
its capacity to formulate nanoemulsions with desired characteristics. Nanoemulsions can be 
prepared from one lipid or a combination of lipids. The lipid in the formulations can be natural, 
semi-synthetic, or synthetic, and may also be biodegradable, such as based on triglycerides (tri-
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stearic acid, tri-palmitic acid, tri-lauric acid and long-chain fatty acid), steroids, waxes (e.g. 
beeswax and carnauba wax), and phospholipids.  
Phospholipids are one of the essential constituents of the cell membrane, and are widely 
used in the preparation of lipid-based nanosystems and nanoemulsions, as well as cholesterol 137. 
They have solubilizing and polarity properties useful for engineering drug delivery 
nanosystems138,139. Other lipids of interest are non-bilayer lipids, such as triglycerides, waxes, 
vitamin E, and fixed oils (soybean oil and castor oil). Depending on their melting points, 
crystallinity, and polymorphic characteristics, their uses vary in the formulations. Usually long-
chain triglycerides are difficult to nanoemulsify, while medium-chain triglycerides and fatty acid 
esters (e.g., ethyl oleate) are easy to nanoemulsify140. Additionally, the combination of lipids 
between long chain triglycerides and medium chain (mono- and diglycerides) can have a valuable 
benefit on self-emulsifying properties in comparison with a single lipid phase. Mixed lipid 
formulations can be created with lower levels of surfactants and no addition of co-solvents141,142. 
Vitamin E (D-a-tocopherol) has gained huge interest as an oily phase due to its ability to solubilize 
drugs such as paclitaxel, itraconazole, and saquinavir143. Thus, currently there is a great attempt to 
develop nanoemulsions based on Vitamin E144-147.  
Surfactants are necessary to stabilize lipid nanoparticle dispersions and prevent particle 
agglomeration. Based on their properties, for instance charge, molecular weight, chemical structure, 
and hydrophilic-lipophilic balance (HLB), surfactants can be selected for specific preparations. 
The HLB of an emulsifier is specified by the balance between the size and strength of the 
hydrophilic and lipophilic groups. The choice of the surfactant is based largely on the route of 
administration. For parenteral formulations, there are limits on the emulsifiers that can be used148. 
For topical routes, the concern of skin sensitization has to be considered, whereas for oral routes, 
the concentration of emulsifier used in the preparation should not create any physiological effects. 
Emulsifiers could as well be used in combination to produce synergistic effects and better stabilize 
the formulation. Examples of surfactants used in the production of nanoemulsions are Poloxamer 
188 and 407, Polysorbate 20, 65, and 80, Cremophor EL, and Solutol HS 15. Non-ionic surfactants 
(HLB values between 12-16) are commonly utilized in the formulation of self-emulsifying systems. 
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Surfactants with a high HLB have a high hydrophilicity, which can promote the formation of O/W 
droplets and the rapid spreading of the formulation in the aqueous media. The usual surfactant 
strength ranges between 30-60% by weight of the formulation149. As a consequence, a major pitfall 
of these systems is the use of high concentrations of surfactants, leading to possible toxic effects. 
Nonetheless, in the case of ionic surfactants, toxicity problems are relatively more challenging 
compared with non-ionic surfactants. Thus, the selection of appropriate surfactants must be 
considered during the development of nanoemulsions. 
The use of a single surfactant is usually not sufficient to lower the oil–water interfacial 
tension to yield a formulation. The addition of amphiphilic short chain molecules as co-surfactants 
aids in reducing surface tension nearly to zero. Moreover, incorporating co-surfactants in 
nanoemulsions aims to increase drug loading and modulate self-nanoemulsification in terms of 
time and droplet size. Co-surfactants penetrate into the surfactant monolayer giving additional 
fluidity to the interfacial film and disrupting the liquid crystalline phases150. Medium chain length 
alcohols (8 to 12 carbon atoms) and derivatives of ethylene- glycol, glycerol and propylene glycol 
are examples of co-surfactants. 
5.3.2 Manufacturing 
The methods used for fabrication of the nanoemulsionsare divided into high- and low-
energy emulsification proceses  (Figure 14).  
5.3.2.1 High-energy emulsification methods  
Typically, high-energy emulsification methods utilize mechanical devices to create 
nanoemulsions with high kinetic energy. These methods comprise high-pressure homogenization, 
microfluidization, and ultrasonic emulsification. High-pressure homogenization and 
microfluidization can be used for fabrication of nanoemulsions at both laboratory and industrial 
scale, whereas ultrasonic emulsification is predominantly used at laboratory scale.  
High-pressure homogenization is most widely used to produce nanoemulsions of extremely 
low particle size (up to 1 nm). A high-pressure homogenizer passes the coarse macroemulsions 
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through a small orifice at an operating pressure in the range of 500 to 5000 psi. During this process, 
numerous forces, including hydraulic shear, intense turbulence and cavitation, perform together to 
generate nanoemulsions with extremely small droplet size. Recirculation of the emulsions through 
the region of high shear is important in order to obtain nanoemulsions with the desired droplet size 
and relatively low polydispersibility151-153. Owing to the higher shear rates, they are heated above 
room temperature during the process. Subsequently, they are cooled by a heat exchanger without 
affecting the size distribution or stability. The production rate of this strategy is several liters per 
hour.  
The microfluidization process uses a high-pressure positive displacement pump operating 
at very high pressures, up to 20,000 psi. This pump forces macroemulsion droplets with high 
velocity through an interaction chamber, consisting of small channels called “microchannels”, 
resulting in very fine particle nanoemulsions. Nanoemulsions with the desired size range and 
dispersity can be acquired by varying the operating pressure and the number of passes through 
interaction chambers, as in high-pressure homogenization154,155. The development of water-soluble 
nanoemulsions for the highly lipid-soluble drug tamoxifen using microfluidization was reported 
by Tagne and coworkers156. Nanoemulsions with tamoxifen had mean particle sizes of 47 nm and 
could inhibit cell proliferation 20-fold greater and increase cell apoptosis 4-fold higher in the HTB-
20 breast cancer cell line than the suspension of tamoxifen. 
Ultrasonic emulsification uses a probe that produces ultrasonic waves to break up 
microscale droplets to nanoscale by means of cavitation forces. By varying the ultrasonic energy 
input and time, the nanoemulsions with desired properties can be gained. High-energy 
emulsification techniques can be employed to formulate both O/W and W/O nanoemulsions.  
Although high-energy emulsification methods generate nanoemulsions with desired 
properties, and have industrial scalability, they are not suitable for thermolabile drugs and 
macromolecules such as proteins, enzymes, and nucleic acids157,158. In addition, high-energy 
methods involve sophisticated instruments and significant energy input, which affects the cost of 
the procedure. Therefore, researchers are now focusing in low-energy emulsification methods.  
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Figure 14. Nanoemulsions fabrication method 
5.3.2.2 Low-energy emulsification methods  
Low-energy emulsification methods are principally dependent on the modulation of 
interfacial phenomenon/phase transitions and intrinsic physicochemical properties of the oil, 
surfactants, and co-surfactants, to yield nanoemulsions.  
The Phase Inversion Temperature (PIT) method employs the temperature-dependent 
solubility of nonionic surfactants to modify their affinities for water and oil159. For instance, the 
polyoxyethylene surfactants become lipophilic with rising temperature because of dehydration of 
the poly-oxyethylene chains. At low temperature, the surfactant monolayer has a large positive 
spontaneous curvature, thus forming emulsions of o/w type. When the temperature rises, the 
surfactant gets completely solubilized in the oily phase. The curvature becomes negative and 
initiates a phase inversion to w/o microemulsions. Nonetheless, this method involves heating the 
components, which may impact the stability of thermolabile molecules.  
The Phase Inversion Composition (PIC) method, also known as the self-nanoemulsification 
method, can formulate nanoemulsions at room temperature without using any organic solvent or 
heat. Kinetically stable nanoemulsions with small droplet sizes (~50 nm) can be produced by the 
stepwise addition of water into a solution of surfactant in oil, with gentle stirring and at constant 
temperature160. Nanoemulsions obtained from the spontaneous nanoemulsification process can 
have high kinetic energy and long-term colloidal stability161. 
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The solvent displacement method is an approach where the oily phase is dissolved in water-
miscible organic solvents, such as acetone, ethanol and methyl ethyl ketone162,163. The organic 
phase is poured into an aqueous phase containing surfactant to produce spontaneous nanoemulsions 
owing to the rapid diffusion of organic solvent. The organic solvent can be removed from the 
nanoemulsions by a suitable means, such as vacuum evaporation. Spontaneous nanoemulsification 
can occur when a solution of organic solvents consisting of a small percentage of oil is poured into 
aqueous phase without any surfactant. Although this strategy can yield nanoemulsions at room 
temperature with simple stirring, the use of organic solvents such as acetone requires a removal 
process164 that may hamper scale-up. 
The solvent injection method is similar in principle to the solvent displacement method. 
Lipids are dissolved in a water miscible solvent. This system is then injected in an aqueous phase 
containing surfactants, which is carried out under continuous stirring. At the site of injection, 
nanoemulsions are formed by solvent diffusion. Typically, particle sizes prepared from the method 
range between 100–250 nm. Their sizes can be varied depending on the rate at which the organic 
solvent diffuses through the lipid-solvent barrier165. Lipid nanoformulations prepared by the 
ethanol injection method have been reported166-168. 
5.3.3 Sphingomyelin nanoemulsions  
In most of mammalian cells, sphingomyelin (SM) is preferentially concentrated in the outer 
leaflet of the plasma membrane. It contains a long chain sphingoid base backbone (predominantly 
sphingosine), a fatty acid, and a phosphocholine head group. Hydrolysis of the phosphodiester 
bond by a sphingomyelinase yields ceramide and phosphocholine169. Various studies have 
proposed that the ability of ceramide to self-associate and mediate lipid raft reorganization is 
required for receptor capping and other signaling events leading to apoptosis170,171. The 
sphingomyelin metabolic pathway may play an essential role in cell growth, survival, and death. 
The number of aberrant crypts was significantly lower in 1,2-dimethylhydrazine-treated mice fed 
with sphingomyelin relative to controls reported by Dellehay and his groups172. These results 
demonstrate that consumption of sphingomyelin can affect the behavior of colon cells. Another 
study supported that SM cycle may play a role in growth inhibition of HT-29 cells173.  
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SM has an inverted-cone shape due to its large headgroup and preferentially forms 
bilayers174,175. Liposomal nanoparticles (LN) from SM derivatives substantially improved drug 
retention properties both in vitro and in vivo176. Formulations based on SM have been prepared as 
lipid vesicles for delivery of anticancer drugs such as irinotecan, paclitaxel, and vinorelbine177-179. 
Antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models were 
reported by Cheng and colleagues180. This finding indicated that the combination treatment 
revealed synergistic suppression in tumor progression in CT26 cells. Moreover, some of lipid-
based formulations in clinic, as Marqibo®, are based on cholesterol and egg sphingomyelin (45:55 
molar ratio)181,182. 
Considering these properties, SM could be an interesting candidate for the preparation of 
nanoemulsions since this lipid is essential for formation of specific lipid domains, such as lipid 
rafts in artificial lipid membranes or biological membranes183. Moreover, several SM-based 
formulations have supported its potential use as a drug carrier. SM nanoemulsions could serve as 
a suitable lipid structures in drug delivery systems. 
6. Nanoemulsions for gene therapy applications. 
Normally, oligonucleotides have a half-life of a couple of minutes in the bloodstream.  In 
addition to their instability, their hydrophilic property with negative charge and high molecular 
weight hinders them from reaching tumor sites184,185. These problems can be overcomed by using 
non-viral vectors. Ideally, nanocarriers should be able to condense anionic oligonucleotides via 
charge interactions. In general, they have to reach tumor cells and escape endosomal degradation. 
The intracelullar targets depend on each type of molecule (Figure 15) 24,186. 
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Figure 15. Diagram for nanoparticle-based gene delivery from IV administration to their own destinations. 
[Reproduced from Yin, H., et al. (2014). Nature reviews. Genetics24 with permission]  
 
Nanoparticles developed for gene delivery applications include both inorganic 
nanomaterials (gold/silver and calcium phosphate particles)189,190 and organic nanocarriers (lipid-
based, polymer-based, dendrimer).  
 
In vivo DNA delivery
According to the American Society of Gene & Cell 
Therapy, DNA therapy remains a strictly experimen-
tal approach in the United States, and no gene thera-
peutics have so far been approved by the US Food and 
Drug Administration (FDA) despite many clinical 
trials worldwide. Nevertheless, recent clinical progress, 
including the approval of the AAV-based gene thera-
peutic Glybera for use in Europe, has marked a resur-
gence of optimism for a biomedical field burdened by a 
tumultuous history. Many non-viral systems have been 
developed for therapeutic DNA delivery, including the 
injection of naked DNA alone or in combination with 
physical methods22–26 such as gene gun, electroporation, 
hydrodynamic delivery, sonoporation and magnetofec-
tion. These techniques are generally less applicable to 
systemic gene delivery in humans than in small ani-
mals such as mice; hence, a range of synthetic delivery 
vectors has also been developed, including lipids and 
liposomes10,27, polymers (linear and branched polymers, 
dendrimers and polysaccharides)9,28,29, polymersomes30, 
cell-penetrating peptides31 and inorganic nanoparticles32.
Barriers to non-viral DNA delivery. One of the chal-
lenges to systemic delivery of DNA therapeutics is the 
potential degradation of the therapeutic gene by endo-
nucleases in physiological fluids and the extracellular 
space (FIG. 1). The half-life of plasmid DNA has been esti-
mated to be ten minutes following intravenous injection 
in mice33. For this reason, entrapment of the DNA in a 
nanoparticulate carrier is desirable both to provide pro-
tection from endonuclease degradation and to improve 
circulation time. For example, zwitterionic lipids have 
been shown to form a stable structure that envelops DNA 
and can be used in combination with other formulations 
to enhance gene delivery in vivo27,34,35. In addition, poly-
plexes are spherical or doughnut-shaped nanoparticulate 
complexes formed from the condensation of negatively 
charged plasmid DNA by cationic polymers9. Similarly, 
mixtures of cationic lipids, neutral lipids and DNA can 
spontaneously assemble into lipoplexes or liposomes, 
in which DNA is entrapped within lamellar or inverted 
hexagonal arrangements of lipid bilayers36. However, at 
high salt concentrations, electrostatic repulsion between 
the positively charged complexes is reduced, and they 
are therefore prone to colloidal instability and aggrega-
tion in physiological fluids37. In particular, aggregation of 
nanoparticles in the blood as a result of either colloidal 
instability or interaction with blood components (such 
as serum proteins and erythrocytes) can inhibit locali-
zation to the desired tissues, induce rapid clearance by 
circulating macrophages and even cause embolism in 
lung capillaries38.
The challenges of selective accumulation at the tissue 
of interest, cellular internalization and endosomal escape 
are common to the delivery of all nucleic acid therapeu-
tics. However, DNA delivery must also provide transport 
into the nucleus to allow access to the transcriptional 
machinery (FIG. 1). It was reported nearly 30 years ago 
that direct microinjection of plasmid DNA that encoded 
thymidine kinase into the nuclei of thymidine kinase-
deficient cells resulted in expression of the kinase in 
50–100% of the nuclei, as detected by the incorporation 
of 3H-thymidine into DNA following autoradiographic 
analyses39. H wever, in >1,000 cells that received cyto-
plasmic injections of the same plasmid DNA, no thymi-
dine kinase activity was detected. The importance of the 
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Figure 1 | Barriers to successful in vivo delivery of nucleic acids using non-viral 
vectors. Various non-viral vectors can be used to deliver DNA, mRNA and short 
double-stranded RNA, including small interfering RNA (siRNA) and microRNA (miRNA) 
mimics. These vectors need to prevent degradation by serum endonucleases and 
evade immune detection (which could be achieved by chemical modifications of 
nucleic acids and encapsulation of vectors). They also need to avoid renal clearance 
from the blood and prevent nonspecific interactions (using polyethylene glycol (PEG) 
or through specific characteristics of particles). Moreover, these vectors need to 
extravasate from the bloodstream to reach target tissues (which requires certain 
characteristics of particles and specific ligands), and mediate cell entry and endosomal 
escape (by specific ligands and key components of carriers). siRNA and miRNA mimics 
must be loaded into the RNA-induced silencing complex (RISC), whereas mRNA must 
bind to the translational machinery. DNA has to be further transported to the nucleus 
to ex t its activity.
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6.1 Organic nanoparticles 
In the past decade, lipid-based and polymer-based nanoparticles have been intensively 
developed for gene delivery. They have showed promising results in clinical studies191.  
6.1.1 Polymeric nanoparticles 
Normally, cationic polymers used in gene delivery are classified into natural polymers and 
synthetic forms. Natural polymers are proteins, peptides and polysaccharides, whereas synthetic 
polymers comprise poly(l-lysine) (PLL), polyethylenimines (PEIs), polyphosphoesters, and 
dendrimers, among others. The amine groups in cationic polymers interact with the phosphate 
groups in the nucleic acids192-197. The ratio between the amine groups (N) in the polymer and 
phosphate (P) group in the nucleotide (N/P ratio) is calculated to determine the complexation such 
as size and morphology of the polyplexes198.  
PEGylated chitosan nanoparticles encapsulated anti-b-catenin siRNA could successfully 
enter colon cancer cells and decrease the level of a protein that promotes tumor progression193. 
Polyethyleneimine (PEI) are cationic synthetic polymers with protonatable amine groups, 
rendering a proton sponge effect195. PEG–PEI–cholesterol lipopolymer is under clinical 
investigation for immunotherapy of ovarian and colorectal cancers through forced expression of 
the cytokine interleukin-12 (IL-12)196. Similar to PEI, dendrimers can act as a proton sponge, 
thereby enabling endosomal escape into the cytoplasm. The development of combined EGFR and 
c-Src antisense oligodeoxynucleotides encapsulated with poly-amidoamine (PAMAM) dendrimers 
inhibited cell proliferation in HT-29 colon cancer197. 
6.1.2 Lipid-based nanoparticles 
Lipid-based vectors are widely used as non-viral gene carriers. Cationic lipids consist of a 
cationic head group and a hydrophobic moiety attached by a linker. The positively charged head 
group interacts with nucleic acid at the phosphate groups. Monovalent lipids contain a single 
functional amine in their head group such as 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) and 1,2-di- O-octadecenyl-3-trimethylammonium propane (DOTMA). On the other 
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hand, multivalent aliphatic lipids have more than one amine group at the surface; for instance, di-
ioctadecyl-amido-glycyl-spermine (DOGS). The lipoplexes synthesized from these lipids have 
high cationic surface charge and stability199,200. Neutral lipids, such as the fusogenic phospholipid 
DOPE or the membrane component cholesterol, have been incorporated in lipid-based 
formulations as ‘helper lipids’ to enhance transfection activity and nanoparticles stability201,202. 
Pitfalls of cationic lipids are poor stability, rapid clearance, inflammatory effects203,204. Besides, 
several lipid-based nanoparticles continue to be developed clinically, including DOTAP–
cholesterol, GAP-DMORIE–DPyPE and GL67A–DOPE–DMPE–polyethylene glycol (PEG)24. 
Cationic liposomes (DOTAP:cholesterol) for a treatment of non-small-cell lung cancer (NSCLC) 
or small-cell lung cancer (SCLC) have completed phase I trials (DOTAP:Chol-fus1, 
NCT00059605). Currently, DOTAP: Chol-fus1 and erlotinib hydrochloride to control NSCLC, are 
undergoing phase I/II clinical trials205. 
Commercial available transfection agents from Invitrogen are composed of cationic lipids. 
LipofectinTM is a 1:1 (w/w) mixture of DOTMA and di-oleoyl-phosphatidylethanolamine (DOPE).  
LipofectAMINETM is a 3:1 (w/w) mixture of the polycationic lipid (2,3-Dioleyloxy-N-
[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l- propanaminium trifluoroacetate) (DOSPA), and 
DOPE. Both of them are normally used as transfection reagents for research206,207. Figure 16 
demonstrated common-used materials in lipid-based gene carriers. 
Gene therapy has been defined as an interesting application for cationic nanoemulsions 
owing to the capability to complex with nucleic acids208,209. The cationic property of the lipid 
nanoemulsions is imposed by the cationic lipids. Common cationic lipids contain cholesteryl 
carboxyamidoethylenedimethylamine (DC-Chol), stearylamine, DOTAP, and DOTMA. Cationic 
emulsions were shown to successfully improve electrostatic-induced stability and enhance in vivo 
absorption, probably due to increased interactions with biological membranes. Recently, cationic 
nanoemulsions, composed of oil, surfactants, and cationic lipids, have been investigated as lipid 
carriers for gene delivery and DNA vaccines in vivo210-212. For example, (i) cationic nanoemulsions 
contained medium-chain triglycerides, sorbitan monooleate, and stearylamine and (ii) cationic 
nanoemulsions composed of medium chain triglycerides, DOTAP, DOPE, and DSPE-PEG have 
been studied for pDNA delivery213,214. 
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Figure 16. Common-used materials in lipid-based gene carriers. Abbreviation: DOTMA (1,2-di- O-octadecenyl-3-
trimethylammonium propane), DOPE (di-oleoyl-phosphatidylethanolamine), DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane), and DOSPA (2,3-Dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-
propanaminium trifluoroacetate).  
 
6.2 miRNA-based nanoparticles 
As stated in Section 3, the delivery of onco-suppressor miRNAs is a promising strategy for 
the development of innovative anticancer therapies. Systemic delivery of miR-34a mimics to 
orthotopic lung tumors was achieved with neutral lipid emulsion and showed inhibition of tumors 
in mice215. Indeed, MRX34, a miRNA-34a mimic (tumor suppressor and a component in the p53 
signaling pathway), is currently in a phase I clinical trial (NCT01829971) of patients with primary 
liver cancer or liver metastases216,217. The formulation investigated in the trial is based on an 
ionizable liposome contained amphoteric lipids with a diameter of ~120 nm. However, the detailed 
structure of this liposome has not been revealed yet. Other interesting miRNA, miR-145, has also 
been proposed as a potential anticancer therapy, since loss of miR-145 function in several cancers 
lessened apoptosis and promoted proliferation. Successful examples of miRNA145-based 
nanoparticles are compiled in Table 5. 
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7. Nanoparticles for nuclear imaging 
Nanoparticle-based contrast agents are becoming valuable and potentially transformative 
tools for medical diagnostics in a wide range of in vivo imaging modalities. In comparison to 
conventional molecular-scale contrast agents, nanoparticles improve detection abilities and 
targeting efficiencies through longer engineered circulation times, designed clearance pathways, 
and multimeric binding capacities226.  
From a clinical perspective, nuclear imaging is feasible from cell culture to small animals 
in clinical systems, due to its tremendous sensitivity. Several attempts have been reported referring 
to the incorporation of radionuclides into nanoparticles227,228. Nanoparticles with surface-modified 
radioligands have also gained much attention229. The most common way to achieve radiolabelled 
nanoparticles is to attach a radioactive-metal via a metal chelator, such as 1,4,7-triazacyclononane-
1,4,7- triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid (DOTA), 
p-isothiocyanatobenzyl-desferrioxamine (Df- Bz-NCS), diethylene triamine pentaacetic acid 
(DTPA)230-232. 
Currently, there are several SPECT-based nanocarriers developed for cancer diagnosis. For 
example, Zhang and coworkers developed an 111In-labelled nanoplatform, which allowed 
visualization of cancer cells overexpressing EphB4, a member of the largest family of receptor 
tyrosine kinases, in prostate cancer xenografts233. Deng et al. reported 125I-radiolabelled cRGD-
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USPIO (iron oxide nanoparticles) that had a long circulation half-life and high tumor uptake for 
breast cancer234. Other example refers to 99mTc-conjugated manganese-based mesoporous silica 
nanoparticles that could show tumor information in a breast tumor model as described by Gao and 
colleagues235.  
For PET, common isotopes that can be chelated on to, or incorporated within nanoparticles 
include 18F, 11C, 15O, 13N, 64Cu, 124I, 68Ga, 82Rb, and 86Y. 18F-labelling strategies are of high interest, 
due to its ideal imaging characteristics and good availability.18F has become a well-known clinical 
instrument to monitor and quantify changes in receptor and enzyme levels in vivo. However, due 
to the short half-life of 18F, fast conjugation with a high reaction yield between 18F and its probe 
are required to improve the efficiency of the nuclide and to decrease cost. Unfortunately, most of 
the 18F-labelled protocols suffer from harsh coupling conditions, such as high temperature and 
organic solvents, long reaction times, multistep procedures, complicated separation and 
purification methods, and poor overall yields236. Consequently, an efficient conjugation method of 
18F is urgently needed.  
Radiolabelling with 18F has been recently achieved via direct labelling by electrophilic, as 
well as nucleophilic, substitution by nucleophilic attack of activated 18F. Nevertheless, direct 
radiolabelling frequently requires sophisticated and costly equipment with particularly suitable for 
metal oxide nanoparticles237. Therefore, the indirect labelling approach has to be considered by 
using prosthetic groups that are able to react with the target molecule.  Numerous efforts have also 
been investigated on the mechanisms of the organic reactions for 18F labelling. However, due to its 
complexity, the success rate is variable. Undoubtedly, the short half-life of 18F has limited the 
number of labelling reports. 18F-labelled nanoparticles have demonstrated their potential from 
biodistribution studies238. From a recent review, three main labelling strategies for 18F can be 
described, (i) direct radiation method, (ii) ion exchange method (lanthanide-doped upconversion 
nanoparticles), and (iii) indirect labelling method (via a prosthetic group) (Table 6).  
A direct way of labelling Al2O3 nanoparticles (Al2O3-NPs) with 18F was developed by 
Pérez-Campaña and his groups239. Al2O3-NPs were directly activated in a cyclotron via the nuclear 
reaction 18O (p,n)18F. PET scans were performed and showed a renal excretion pathway. The long 
 94 
retention of radioactivity in the heart implied a long blood circulation half-life. Insignificant uptake 
in bones suggested the slow leak of 18F from the nanoparticles.  
Another method was presented by Liu and his colleagues240. They used NaYF4 to develop 
18F -labelled rare earth nanoparticles. The particles were surface-modified with Gd3+ by cation 
exchange with Y3+ for MRI and different rare earth elements (Yb, Er) for luminescence studies. 
18F was incorporated into the nanoparticles through interactions with the rare earth ions in an 
aqueous solution. In vivo studies showed a high uptake almost exclusively in the liver (80.9% ID/g) 
and spleen (36.6% ID/g) after 10 min. However, bone uptake of ~13% ID/g revealed the loss of 
18F from the nanoparticles.  
The study by Guerrero and his groups exhibited 18F-labelled gold nanoparticles using a 
prosthetic group named N-Succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)243. It was observed that 
a considerable level of nanoparticles was trapped by the reticuloendothelial system (RES) in the 
spleen. The rapid renal clearance resulted in a rapid blood concentration drop during the first 
minutes after injection. Furthermore, [18F]SFB conjugated with Ceria nanoparticles was reported254. 
The surface of the ceria nanoparticles was modified with silylation with 3-
(aminopropyl)triethoxysilane enabling subsequent coupling to [18F]SFB. High uptake values in 
liver, spleen and lungs were immediately observed after administration. Ducongé and his 
colleagues designed F-labelling of core/shell quantum dots (QDs)245. The QDs were encapsulated 
with polyethylene glycol (PEG-phospholipid micelles) and this coating was further functionalized 
with thiol groups. A coupling of these functionalities and a maleimido-based prosthetic group (1-
[3(2-[18F]fluoropyridin-3-xyloxy)propyl]pyrrole-2,5-dione ([18F]FPyME)) was performed. 
Biodistribution indicated a long blood circulation time with a plasma half-life of 2 hours. In 
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1. Nanotechnology has played an important role in the development of improved anticancer 
therapies in the last few decades. The development of engineered nanoparticles has been studied 
to diagnose and treat cancer more effectively1,2. Nanoparticles can enhance the stability of the 
encapsulated molecules against degradation in the biological environment, prolong their circulation 
half-life, improve biodistribution, promote accumulation into the targeted tumor, and reduce 
systemic toxicity3,4. The application of nanoparticles for gene therapy purposes has also been 
explored, through the incorporation of different molecules with different activities such as pDNA, 
mRNA, siRNA, and miRNA5,6.  Nanoparticles can additionally be used for in vivo diagnosis since 
they can incorporate different molecules allowing tracking for multiple image modalities such as 
MRI, PET, and SPECT7,8.  
2. Nanoemulsions have been widely explored in the drug delivery field. They are 
thermodynamically stable isotropic systems in which two immiscible liquids (oil and water) are 
mixed to form a single phase and stabilized by surfactants9. They offer several advantages, (i) 
simple, (ii) suitable for the incorporation of labile molecules, and (iii) easy for scale-up. Their 
compositions can be adjusted according to specific needs10. Cationic lipids can be included to 
improve the association of nucleic acids by electrostatic interaction11. The ethanol injection method 
is a low-energy emulsification technique typically used for the preparation of liposomes, which has 
been adapted for the formulation of nanoemulsions12. 
3. Gene therapy offers a lot of potential for the development of targeted anticancer treatments13,14. 
Mature microRNAs (miRNAs) are naturally small non-coding RNA molecules, 21–25 nucleotides 
in length. MicroRNAs are partially complementary to one or more messenger RNA (mRNA) 
molecules15. Their major utility is to downregulate or upregulate gene expression in various ways. 
However, there remain several challenges in miRNA delivery due to the poor stability of these 
molecules in biological environment, and limited access to the intracellular compartment. 
Association to nanocarriers can offer an opportunity for successful translation16. 
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4. Positron Emission Tomography (PET), a technique that detects gamma rays from positron-
emitting isotopes, is widely use in clinic diagnosis. The high sensitivity and specificity of PET 
result from the high sensitivity of radioisotopes compared with other diagnostic modules17,18. 
Numerous studies have been focused on development of radiolabelled nanoparticles for non-
invasive PET cancer diagnosis, to increase patients’ survival rate. In both clinical and preclinical 
research, 18F is the most frequently used radioisotope for the development of PET 
radiopharmaceuticals. It has high specific activity and ease of large-scale production contributing 
to its widely use in molecular imaging. Generally, introduction of 18F into molecules of interest is 
achieved through 18F-prosthetic group. Currently, there are significant needs required for the 
establishing of simple and efficient methods for 18F-labeling procedures for nanoparticles19. 
Tracking of radiolabelled nanoparticles provides valuable information that can pave the way for 





On the basis of general knowledge in clinical use and pharmaceutical science, we set out the 
following hypotheses (H) for this work.  
 
- It is possible to optimize the composition of sphingomyelin nanoemulsions (SNs) for the 
development of miRNA replacement therapies to interfere cancer progression. 
 
H1. SNs can be prepared by a mild method without the use of heat or high-energy input, being 
suitable for the association of labile biomolecules. 
H2. The composition of SNs can be conveniently modulated to mediate an efficient association of 
oncosuppressor miRNA mimics. 
H3. SNs can efficiently interact with colorectal cancer cells to deliver their miRNA cargo. 
H4. Delivery of oncosuppressor miRNA can interfere tumor progression. 
 
- It is possible to radiolabel SNs with Fluorine-18 for in vivo imaging by PET. 
 
H5. SNs and surface decorated SNs (targeted SNs) can be radiolabelled with Fluorine-18 (18F) 
following a simple methodology using a prosthetic group, [18F]FBEM.  
H6. Radiolabelled SNs can be tracked after intravenous injection to provide biodistribution 











Considering the previous background information and the established hypothesis, the main 
goal of this thesis was to develop innovative nanosystems, of application in the treatment and 
molecular diagnosis of colorectal cancer. We aim to explore the full potential of sphingomyelin 
nanoemulsions (SNs) for association and delivery of oncosuppressor miRNAs, and additionally 
optimize a procedure for radiolabelling of SNs with 18F for imaging and diagnosis purposes. This 
goal has been pursued after setting up specific objectives (O) that are disclosed next:  
 
- Development of SNs for miRNA replacement therapies to interfere cancer progression  
 
O1. To optimize the composition of SNs to favor the association of miRNAs. 
O2. To fully characterize the resultant miRNA-loaded SNs. 
O3. To perform in vitro studies which allow studying the transfection efficiency of the developed 
miRNA-loaded SNs and prove the potential of the proposed anticancer therapy.  
Corresponding results are presented in Chapter 2.  
 
- Radiolabelling strategy of SNs with 8F for in vivo imaging by PET  
 
O4. To radiolabel SNs and peptide-decorated SNs (targeted SNs) with 18F-prosthetic group, 
[18F]FBEM.  
O5. To characterize the resultant products and the efficiency of the radiolabelling process.  
O6. To evaluate the biodistribution of the 18F-radiolabelled SNs ex vivo. 
O7. To determine the potential of 18F-radiolabelled SNs for the development of innovative 
diagnosis proofs for PET scan.  
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 Gene replacement therapies with oncosuppressor miRNA mimics have been described as 
promising alternatives to stop cancer progression. However, miRNA mimics are highly unstable in 
a biological environment hampering a successful translation to clinics. Naked RNA requires a 
protection from serum endonucleases and renal excretion. Furthermore, RNA administration may 
induce innate immune responses, resulting in unwanted toxicities. These constraints can be 
overcome upon association to biocompatible delivery systems able to transport intact RNAs to the 
targeted cancer cells. The main objective of this work has been the development of a new 
nanotechnology adapted for the intracellular delivery of miRNA. In this study, self-assembled 
sphingomyelin nanoemulsions (SNs) were adapted to achieve a good association efficiency of 
miRNA mimics and favour their interaction with colorectal cancer cells. Two different approaches 
were pursued. On the one hand, the cationic lipid stearylamine was included as an additional 
component to favour the association of the miRNA by establishment of electrostatic interactions 
(SNs-ST-miRNA). On the other hand, freeze-dried DOTAP-miRNA, lipid complexes were 
encapsulated into SNs (SNs-DOTAP-miRNA). Both approaches were successful for promoting the 
access of oncosuppressor miRNA145 to colorectal cancer cells, SNs-DOTAP-miRNA showing 
superior transfection efficiencies and an improved ability to interfere tumor progression. Our 
results suggest that SNs have the potential for miRNA delivery to develop innovative-targeted 
anticancer therapies.  





Nowadays, cancer is one of the leading causes of death1. Cancer treatments can still be 
improved making use of novel technologies and biotechnological drugs. Advances in 
nanotechnology have shown a prompt impact in numerous applications in cancer, as nano-scaled 
carriers have the potential for incorporating various kinds of molecules into their architecture, 
including anticancer drugs and contrast agents, as well as macromolecules such as proteins, 
peptides, or oligonucleotides2-4. Indeed, several nanoformulations are already routine use in 
clinics5-8.  
RNA-based therapeutics such as small interfering RNA (siRNA) and microRNA mimics 
(miRNA) provide a promising approach to treat cancer by targeting specific proteins involved in 
the mechanism of proliferation, invasion, antiapoptosis, drug resistance, and metastasis9,10. 
MicroRNAs (miRNA) are small (17 to 25 nucleotides) non-coding RNA molecules, which 
specifically interact with target messenger RNA (mRNAs), resulting in inhibiting translation or 
mRNA cleavage and degradation11,12. It is well-known that various miRNAs, for instance miR145, 
miR143, miR137, miR10a, and miR34b/c, are downregulated in colorectal cancer cells compared 
to healthy tissues, and modulation of the corresponding gene expressions is gaining interest in 
cancer therapy13-19. However, the major barriers of miRNA delivery are their poor systemic 
stability, rapid clearance, degradation by nucleases, risk of systemic toxicity, elimination by 
phagocytic immune cells, and lack of efficient delivery to targeted cells to achieve the desired 
therapeutic outcome. Those obstructed phenomena can be avoided by using non-viral vectors. 
MRX34 (NCT01829971) is first-in-class miRNA mimic therapy for cancer, was tested in phase I 
clinical trial for patients with refractory advanced solid tumors. Besides this liposomal miR-34a 
mimic formulation showed evidence of antitumor activity, unfortunately it was halted because of 
immune responses20,21. Different types of nanoplatforms have also been evaluated in the last years 
with promising results, such as PLGA/PEI/miRNA/HA nanoparticles and miRNA-145-based 
magnetic nanoparticles22,23. Therefore, delivery of safe miRNA-nanotherapeutics might represent 
a promising alternative for the development of cancer therapeutics.   
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For the design of nanostructures, it is possible to use organic biodegradable materials that 
do not accumulate in the body and do not cause toxicity. Lipidic sphingomyelin nanoemulsions 
(SNs), which main components are sphingomyelin (SM), present in cell membranes, vitamin E, 
widely used in different formulations that are of clinical use, and a lipid derivative of polyethylene 
glycol (PEG), to modulate the surface properties of SNs and prolong half-life in the blood 
circulation24-27. We aim to develop novel nanosystems, based on SNs, for the efficient association 
of miRNA145 mimics and delivery to colorectal cancer cells to interefere cancer progression. We 
pursue two different strategies. Firstly, the cationic lipid sterylamine was incorporated to the 
nanoemulsions, in order to obtian cationic SNs and favour the association of miRNA mimics (SNs-
ST-miRNA)28-30. Secondly, we propose the encapsulation of preformed DOTAP-miRNA 
complexes into SNs (SNs-DOTAP-miRNA) to provide additional protection for the associated 
miRNA mimics31,32. Transfection experiments and functional in vitro assays will be performed to 
determine the potential of the proposed formulations to developed innovative oncosuppressor 
therapies to colorectal cancer. 
 
2. Materials and methods  
 
2.1 Materials  
 Vitamin E (DL-α-tocopherol) was obtained from Merck (Darmstadt, Germany). 
Sphingomyelin and N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate 
(DOTAP) were acquired from Lipoid (Ludwigshafen, Germany). Stearylamine (ST), agarose, 3-
(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), Triton-X, heparin, 
Mowiol® 4-88, Minimum Essential Media (MEM), Dulbecco’s Modified Eagle’s Medium 
(DMEM), and Dulbecco’s Phosphate Buffered Saline (PBS) were purchased from Sigma Aldrich 
(St.Louis, MO, United States). SH-PEG12-C18 was supplied by Creative PEGworks (North Carolina, 
United States). N-[11-(dipyrrometheneboron difluoride)undecanoyl]-D-erythro 
sphingosylphosphoryl choline (C11 TopFluor® Sphingomyelin) was purchased from Avanti Polar 
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Lipids (Alabama, United States). miRNA145, miRNA145 scramble, and Cy5-modified 
miRNA145 were bought from Eurofins Scientific (Luxembourg) (Table 1).  
Table 1. Sequence of the different RNAs used in this study 
RNAs  Sequence 
miRNA 145 5’GUCCAGUUUUCCCAGGAAUCCCU 3’ 
miRNA scrambled 5’UUCUCCGAACGUGUCACGUUU 3’ 
Cy5-modified miRNA145 5’Cy5-GUCCAGUUUUCCCAGGAAUCCCU 3’ 
 
SYBR® Gold Nucleic Acid Gel Stain, RNAse free water, DNA ladder, penicillin and streptomycin 
were obtained from Invitrogen (Madrid, Spain). microRNA Purification Kit was acquired from 
Norgen Biotek Corporation (Zaragoza, Spain). qScriptTM microRNA cDNA Synthesis kit, 
PerfeCta® Universal PCR Primer and PerfeCta® SYBR® Green SuperMix, Low RoxTM were bought 
from Quantabio, VWR International Eurolab (Barcelona, Spain). Primers, has-miR145-5p 
(5’GUCCAGUUUUCCCAGGAAUCCCU 3’) and the house keeping small RNA control primer 
RNU6 (5’CTCGCTTCGGCAGCACA3’, 5’AACGCTTCACGAATTTGCGT3’) was purchased 
from IDT, (A Coruna, Spain) and Fisher Scientific (Madrid, Spain) respectively. Ultrapure Mili-Q 
water was used all throughout the experiments. Ethanol was of analytical grade and supplied from 
Thermo Fisher Scientific (Madrid, Spain). All other chemicals used were of reagent grade.  
 
2.2 Preparation and characterization of SNs 
SNs were formulated from vitamin E (VitE), sphingomyelin (SM), and SH-PEG12-C18 
(PEG) in a ratio VitE:SM:PEG of 10:1:0.1 w/w, by ethanol injection. In brief, the components were 
dissolved in a final volume of 110 µL in ethanol (organic phase, total lipid concentration 5.05 
mg/mL) and injected with a syringe (0.5 mL) into 1 mL of ultrapure water under magnetic stirring. 
SNs were isolated from non-interacted compounds by ultracentrifugation (Beckman, California, 
United state) at 35000 rpm for 1 h at 15ºC in a 70.1 Ti rotor.  
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2.2.1 Size and zeta-potential measurements  
Nanoemulsions were analyzed for their hydrodynamic size and polydispersity index (PDI) 
by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK) equipped with a standard λ = 633 nm laser as the incident beam. 
Nanoemulsions were diluted in ultrapure water and loaded into a disposable solvent resistant 
microcuvette (ZEN0040). The obtained data were analyzed based on cumulative analysis method 
for determination of mean hydrodynamic diameter and PDI. ζ–potential, a parameter indicative of 
the surface charge of the nanoemulsions, was measured by Lasser Doppler Anemometry (LDA) in 
the same equipment, using a dip-cell (DTS 1060). Each analysis was performed in triplicate.  
 
2.2.2 Transmission electron microscopic (TEM)  
The morphology of SNs was investigated using Transmission electron microscopy, TEM 
(JEOL JEM-2010) high-resolution microscope (Peabody, MA, USA). 10 µL of diluted 
nanoemulsions (1/10 in Mili-Q water) were placed on 400-mesh copper grids, incubated for 3 
minutes at room temperature, and stained with 10 µL of 2% phosphotungstic acid solution for 1 
minute. Excessing of phosphotungstic solution was removed with filter paper. The grids were 
washed five times in water droplets for 1 minute (each time) and dried overnight.  
 
2.2.3 Nanoparticle tracking analysis (NTA)  
NTA measurements were achieved with a NanoSight NS300 (Malvern Instruments, 
Worcestershire, UK), equipped with a sample chamber with a 488-nm laser. Samples were diluted 
1/1000 in Mili-Q water. Samples were then injected in the sample chamber with sterile syringes 
(Omnifix®-F 1ml, Melsungen, Germany) until the liquid reached the tip of the nozzle. All 
measurements were performed at room temperature. The software used for capturing and analyzing 
the data was the NTA 3.3 Build 3.3.104. The samples were measured for 60 seconds. Three 
measurements of the same sample were performed for all of the formulations 3 times. The error 
bars displayed on the NTA graphs were obtained by the standard deviation of the different 
measurements of each sample. The mean particle size and SD values obtained by the NTA software 
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correspond to the arithmetic values calculated with the sizes of all the particles analyzed by the 
software. 
 
2.3 Preparation and characterization of cationic stearylamine SNs and association of miRNA 
(SNs-ST-miRNA)  
Cationic SNs were prepared upon addition of the cationic lipid, stearylamine (ST) to the 
organic phase at a ratio VitE:SM:PEG:ST 10:1:0.1:1 (w/w). Cationic SNs-ST were fully 
characterized as described in the previous section (2.2). miRNA was subsequently associated to 
SNs-ST by the establishment of electrostatic interactions by simple incubation. 10 µg of miRNA 
were incubated with SNs-ST at different miRNA:ST mass ratios (1:1, 1:2.5, 1:5, 1:7.5, and 
1:10) in 100 µL of H2O. The association of miRNA was analyzed by agarose gel electrophoresis 
(1% w/v in Tris-Acetate-EDTA (TAE) Buffer). Briefly, 0.5 µg of nucleic acids labeled with 
SYBR® Gold from solution, associated to the nanoemulsions, and the displacement with an 
excess of heparin were loaded into each well.  Gel electrophoresis was run at 100V, 40 minutes 
in an electrophoresis cell, Ecogen (Barcelona, Spain). Gel images were obtained with a Molecular 
Imager® Gel DocTM XR System (UV light 302 nm; Bio-Rad, Madrid, Spain). To ensure a correct 
association, displacement experiments were addiationlly peformed upon incubation of the 
formulations with a 25-fold heparin (with respect to the amount of miRNA) for 2 h at 37 °C.  
 
2.4 Preparation and characterization of miRNA complexes with cationic lipids  
Preparation of lipid complexes was attempted with miRNA and cationic lipids (ST or 
DOTAP). 10 µg of miRNA were incubated with cationic lipid at different miRNA: cationic 
lipid mass ratios (1:1, 1:5, 1:10, 1:15, and 1:20) in a total solution of 500 µL (H2O 450 µL and 
EtOH 50 µL). They were characterized for their physicochemical properties as described in 




2.5 Loading of lipid complexes into SNs (SNs-DOTAP-miRNA) 
miRNA:DOTAP complexes in a ratio of 1:15 were lyophilized using a VirTis genesis 
Lyophilizer (Warminster, PA, United States). Lyophilization steps contained thermal treatment, 
freezing, primary drying, and secondary drying. During freezing step, it had a condenser 
temperature of −40 °C and vacuum set point 200 mTorr for 60 min. At the end of the cycle, lipid 
complexes were finally obtained. Lyophilized lipid complexes were then suspended in 100 µL the 
organic phase containing VitE, SM, and SH-PEG12-C18, in a ratio of 10:1:0.1 (w/w), and this 
suspension was inmediatly injected to water (1mL) following the same methology reported in 
section 2.2. for the preparation of SNs, finally rendering lipid complex-loaded SNs (SNs-DOTAP-
miRNA). Characterization was performed as disclosed in section 2.3. DOTAP-miRNA lipid 
complexes and broken SNs-DOTAP-miRNA formulation (upon incubation with a 25-fold heparin 
with respect to the amount of miRNA, for 2 h at 37 °C) were additionally placed as controls 
in the heparin displacement experiment.  
 
2.6 In vitro cell uptake  
Confocal laser-scanning microscope (TCS SP5, Leica Microsystems GmbH, Heidelberg) 
was used to observe cell uptake of fluorescent nanoemulsions. 24 h before the experiment SW480 
cells (1 × 105 cells/well) were seeded onto 12 mm diameter glass coverslips in a 24-well plate in 
0.5 mL of supplemented cell culture medium. SNs-ST-miRNA and SNs-DOTAP-miRNA were 
labelled with C11 TopFluor® Sphingomyelin (0.2 ng/µl), and Cy5-labelled miRNA (0.2 ng/µl) 
was also used to allow direct observation of the molecule of interest. After addition of 20 µl  to the 
cells (500 ul of supplemented cell culture medium), they were incubated for 4 h at 37 oC in the cell 
incubator. After that, cells were exhaustively washed with PBS and then fixed with 
paraformaldehyde (PFA; 4% v/v in PBS) in the dark at room temperature for 15 minutes. Cells 
were rinsed again with PBS, and cell nuclei were then counterstained with Hoechst 33342 (1:1000 
in PBS) for 5 minutes. Then washed again with PBS. Lastly, 8 µL of Mowiol® 4-88 were used for 
mounting samples on coverslips. Preparations were conserved in the dark at -20ºC. The confocal 
laser scanning microscopic images were obtained with a 63×oil immersion objective for Hoechst 
33342 (blue), TopFluor® Sphingomyelin (green), and Cy5 (red) respectively. (scanning speed 600 
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Hz, with an image resolution of 1024x1024 pixels). The colocalization ratio of Cy5 and TopFluor® 
Sphingomyelin was determined by LAS AF software (Barcelona, Spain).  
Studies were also accomplished by Fluorescence-Activated Cell Sorting (FACScan flow 
cytometer, BD biosciences, San Jose, CA, United States). For this experiment, the cells were 
transfected with same amount of fluorescent formulations as mentioned in confocal study. They 
were incubated for 4 h at 37 oC in the cell incubator and washed with PBS. Then, the cells were 
trypsinized and resuspended in 0.5 mL of PFA (approx. 1x105 cells/mL) prior to analysis. The 
results were analysed using Flowjo 8.7 (Ashland, OR, United States).   
 
2.7 Transfection efficiency 
SNs-ST-miRNA and SNs-DOTAP-miRNA were evaluated for their transfection efficacy 
in SW480 human coloreatal cancer cells. Both types of nanoemulsions were formulated with 
miRNA145, and with a scrambled sequence miRNAScr. SW480 cells were seeded in 6-well plates 
(5 × 105 cells/well) and incubated in DMEM for 24 h. Formulations were then added (SNs-ST-
miRNA145, SNs-ST-miRNAScr, SNs-DOTAP-miRNA145, and SNs-DOTAP-miRNAScr), being 
the dose 2 µg of miRNA in a final volume of 2 mL of fresh cell culture medium. The nanoemulsions 
were removed after 4 h of incubation, cells washed, and fresh media added (2 mL). The transfection 
efficiency was determined 72 h post transfection by quantitative real-time PCR (qRT-PCR) 
(Stratagene Mx 3000, Agilent Technologies). According to the manufacturer's protocol of Norgen 
Biotek Corporation, microRNA Purification Kit (ON, Canada), the total miRNA was extracted 
from SW480 cells. miRNA concentration and purity were evaluated with UV spectrophotometry 
(Nanodrop, Spectrophotometer ND-100, Thermo Scientific). Extracted RNA samples were 
measured and diluted to have the same amount of RNA (120 ng). Next, the reverse RNA 
transcription to cDNA was carried out using qScript™ microRNA cDNA Synthesis Kits (Quanta 
Biosciences). The qRT-PCR was performed using PerfeCta® MicroRNA Assays (Quanta 
Biosciences), with a primer for miR 145 (has-miR145-5p, IDT). Small nuclear RNA, RNU-6 was 
employed as an endogenous house-keeping gene to normalize the miRNA amount 
(5’CTCGCTTCGGCAGCACA3’, 5’AACGCTTCACGAATTTGCGT3’). PCR cycle consisted of 
activation at 95ºC (2 min), denaturation at 95ºC (5 sec), and annealing at 60 ºC (30 sec) for 40 
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cycles. Quantitative data were analyzed by utilizing the MxPro software (Agilent Tecgnologies). 
The relative miRNA145 expression level was calculated based on comparative 2−ΔΔCT method in 
relation to RNU6 and normalized to that obtained from non-treated cells. 
 
2.8 Functional assays 
 SW480 cells were seeded in 24-well plates (2.5 × 104 cells/well) and incubated in DMEM 
for 24 h. Then the cells were transfected as described in the previous section. For cell proliferation, 
cells were harvested at 72 h post transfection and then counted manually in neubauer-improved 
cell counting chamber, depth 0.100 mm, 0.0025mm2 (Marienfeld, germany). With respect to the 
cell migration assay, after the transfection, the cells were trypsinized and counted. Then 2 × 105 
cells/well were planted onto 24-well plate, artificail wounds were created on the confluent cell 
monolayer using 200 µL pipette tip. Wounded cells were gently washed PBS for 3 times to remove 
the detached cells and cultures in 5% CO2 at 37 oC. The wound closer was observed and 
photographed at time point 0,24,48,72, and 96 h under microscope (Leica type 090-135.00, 
Germany). For colony forming assay, transfected cells were seeded at a density of 200 cells/well 
in 12-well plates and cultured at 37°C for 2 weeks. Cells were stained with MTT solution (5mg/ml) 
and photographed. The images were analyzed using ImageJ software. 
 
2.8 Statistic analysis 
Differences were statistically determined by two-way ANOVA. All statistical analysis was 
perfomed using GraphPad Prism (Version 6.0 software). A p value < 0.05 was considered to be 







3. Results and discussion 
 
3.1 Development and characterizations of sphingomyelin nanoemulsions loaded with miRNA 
mimics 
Nanoemulsions are thermodynamically stable isotropic systems in which two immiscible 
liquids, usually oil and water, are mixed to form a single phase with the help of suitable 
surfactants33,34. They have been extensively applied throughout the pharmaceutical industry for 
delivery of poorly water-soluble drugs. For cationic nanoemulsions, they were widely used for 
gene delivery by utilizing cationic lipids such as DOTMA, DOTAP, linear polyethylenimine 
grafted with cholesterols, and stearylamine, allowing association of nucleic acids on the surface of 
nanoemulsions35-39. In this work, we aim to study the potential of SNs for the delivery of 
oncosuppressor miRNAs to cancer cells. SNs are very simple biocompatible and biodegradable 
formulations produced by ethanol injection in a simple step, which main components are the oil 
vitamin E (VitE) and the sphingolipid sphingomyelin (SM) acting as a surfactant. Lipid PEG 
derivatives (SH-PEG12-C18) were also included in a smaller proportion to improve the stability of 
the formulation after intravenous injection40,41. In this particular work, we additionally incorporated 
small amounts of cationic lipids to increase the association efficiency of miRNA mimics and the 
capacity of the resulting formulation to efficiently transfect colorectal cancer cells42-44. Our first 
strategy for association of miRNA mimics was to incubate the nucleic acids onto the surface of 
preformed cationic SNs. The second approach was to prepare lipid complexes (DOTAP and 
miRNA) for subsequent encapsulation into SNs. A schematic representation of both approaches is 
shown in Figure 1.  
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Figure 1. Preparation and Scheme illustrated components of SNs-ST-miRNA (A) and SNs-DOTAP-miRNA (B). 
 
3.2. Adsorption of miRNA to preformed cationic SNs 
Blank SNs were prepared upon injection of lipids VitE:SM:PEG dissolved in ethanol (in a 
proportion 10:1:0.1 w/w), into ultrapure water. This is a green and simple procedure that renders 
reproducible formulations. SNs have a mean average size of   131 ± 8 nm, a PDI of 0.2, and a 
slightly negative surface charge of -13 ± 7. NTA analysis correlates with DLS analysis, confirming 
the size and the relatively mono-disperse size distribution (Figure 2), and giving a concentration 






Figure 2. Size distribution graph of SNs measured from nanoparticle tracking analysis (NTA) and dynamic light 





Next step consisted in the addition of a cationic lipid to get cationic SNs. Because the 
interaction between cationic lipids and nucleic acids is intensely influenced by charge-charge 
interaction, lipid pKa is expected to play a significant role affecting the association efficiency of 
nucleic acids in lipidic nanosystems45. We selected stearylamine (pKa=10.6) to formulate cationic 
SNs, since it presents a positively charged primary ammonium group over a wide range of pH46,. 
Additionally, steraylamine has already been reported for the preparation of cationic nanoemulsions 
for delivery of nucleic acids47,48.  As shown in Table 2, nanoemulsions with VitE:SM:PEG:ST 
ratios from 10:1:0.1:0.1 to 10:1:0.1:1 rendered monodispersed populations with a mean size of 
around 100 nm. However, SNs-ST with a ratio VitE:SM:PEG:ST above 10:1:0.1:1.5 had a higher 
dispersion. As expected, SNs-ST were positively charged, and the zeta potential increased as the 
amount of ST does. Based on this physicochemical properties, VitE:SM:PEG:ST 10:1:0.1:1 (SNs-
ST) were selected for further studies 
Table 2. Hydrodynamic size, polydispersity index (PDI), and zeta potential (ζ-potential) of SNs-ST  
Formulations Ratio (w/w) 
VitE:SM:PEG:Cationic lipid 






104 ± 10 
115 ± 11 
0.2 
0.2 
  +40 ± 12 
+44 ± 4 
10:1:0.1:1 109 ± 11 0.2 +46 ± 6 
10:1:0.1:1.5 99 ± 12 0.3   +48 ± 11 
10:1:0.1:2 104 ± 22 0.3 +51 ± 3 
 
Association of miRNA mimics was attempted next. Increasing amounts of SNs-ST were 
added over a solution of miRNA (10 µg) (miRNA:ST ratios from 1:1 to 1:10) and incubated under 
magnetic stirring. The characteristics of the resulting formulations are shown in Table 3. Increasing 
the proportion of SNs-ST, and therefore of cationic groups, mainly affect the surface properties of 
the nanosystems. While proportions of miRNA:ST 1:1 and 1:2.5 rendered negative nanosystems, 
there is an inversion on the zeta potential for formulations prepared with the highest proportion of 
ST (miRNA:ST 1:10). These variations in the surface properties are an evidence of the efficient 
adsorption of the oligonucleotides to SNs-ST, in agreement with other reports in the field49. Sizes 
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are around 150-170nm, with low polidispersity indexes, in all cases except for the ratios 
miRNA:ST 1:5 and 1:7.5, for which a massive aggregation is observed. This can be related to the 
neutralization of the surface charge, as reported for other cationic lipid-based nanopaticles50-52. Liu 
et al., demonstrated that when the ζ-potential values was closed to zero, the size of solid lipid 
nanoparticles/miRNAcomplexes became larger. This was probably because the nanoparticles with 
this weight ratio were in an unstable state and easily aggregated. This also supported by Martini et 
al., that the highest size of nanoemulsions was observed when the ζ-potential values were closer to 
neutrality. Teixeira et al., explained about the electrostatic interaction between positively charged 
stearylamine and negatively charged nucleotides that as long as the positive amine groups from the 
stearylamine are not neutralized by ion pairing with DNA phosphate groups, the overall droplet 
zeta potential will remain positive, preventing flocculation.  
The efficient association of the miRNA to the surface of SNs-ST-miRNA was confirmed 
by a gel electrophoresis assay (data not shown). SNs-ST-miRNA with a miRNA:ST mass ratio 
1:10 were selected for the transfection experiments. Analysis by transmission electron microscopy 
(TEM) show a spherical morphology, comparable to plain SNs-ST, and analystis by NTA 
corroborated the data obtained by DLS (Figure 3).  
Table 3. Hydrodynamic size, polydispersity index (PDI), and zeta potential (ζ-potential) of SNs-ST-miRNA. 
Formulations Mass ratio (w/w)* 
 miRNA:ST 




1:1       155 ± 2 0.2  -30 ± 3 
1:2.5 172 ± 4 0.2 -15 ± 2 
1:5 Aggregate 
1:7.5 Aggregate 
1:10 148 ± 8 0.2 +26± 3 
*miRNA was maintained constant (10 ug per formulation). 
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Figure 3. Characterization of SNs-ST and SNs-ST-miRNA. Transmission electron microscopy (TEM) images (A). Size 
distribution graph measured from nanoparticle tracking analysis (NTA) and dynamic light scattering (DLS) (B), and  
video frame acquired by NTA (C).  
 
3.3 Development and characterizations of of lipid complexes and encapsulation into SNs 
Lipid complexes of miRNA-ST and miRNA-DOTAP, prepared at different 
miRNA:cationic lipid mass ratios were characterized with respect to their size, PDI, and surface 
charge (Table 4). In general, most of the complexes had a broad PDI, and were therefore 
disregarded. Complexes with a PDI of 0.3 were obtained for complexes with a miRNA:cationic 
lipid ratio 1:15. Due to the smallest size of the miRNA:DOTAP complexes 1:15, around 80 nm, 
these were selected for futher association to SNs. The incorporation of DOTAP into cationic 
nanocarriers is commonly described. It is available as GMP material for clinical studies and able 
to hold a positive charge at a pharmaceutically relevant pH. Due to the anionic electrostatic charge 





A B C 
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effective carriers for the anionic nucleotides RNA and DNA. They mediate high encapsulation 
efficiencies for nucleotides and high cellular uptakes and transfection efficiencies53.  
Table 4. Hydrodynamic size, polydispersity index (PDI), and zeta potential (ζ-potential) of lipid complexes  
Lipid 
complexes 
Mass ratio (w/w)* 
miRNA:Cationic lipid 







76 ± 86 
0.4 
0.7 
-9 ± 4 
+17 ± 4 
1:10 158 ± 96 0.6 +28 ± 6 
1:15 189 ± 54 0.3          +29± 4 






15 ± 18 
68 ± 73 
0.7 
0.7 
-10 ± 4 
+6 ± 7 
1:10 46 ± 34 0.4 +20 ± 7 
1:15 83 ± 16 0.3 +32 ± 3 
 1:20 123 ± 80 0.5 +32 ± 3 
*miRNA was maintained constant (10 ug per formulation) 
The pre-condensation of DNA with polycations has been described to be a favorable 
method to increase in vitro and in vivo transfection efficiency of lipid emulsions. This enhancement 
is due to the formation of compacted complexes supporting encapsulation of nucleic acid and 
additional protection against enzymatic degradation54-56. For example, the complexation of a model 
plasmid with different cationic lipids via hydrophobic ion pairing (HIP), reduced hydrophilicity 
and enabled its incorporation into a lipophilic carrier, which provided additional protection in 
biological environment57. A similar strategy has also been described for encapsulation of other 
hydrophilic biomolecules to be uploaded into lipid nanosystems.  The modification by HIP has 
been described to increase the lipohilicity of peptides, allowing further association to lipid 
nanosystems and improving protection against enzymatic degradation as well as bioavailability58. 
In our case, we follow a similar approach for complexation of miRNA mimics and further 
association to SNs. Within this study, HIP was established among the amino group of the cationic 
lipid DOTAP and the negatively charged phosphate group of the RNA backbone. Resulting 
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complexes were freezed-dried and subsequently resuspended in the ethanol phase containing the 
lipid mixture (VitE:SM:PEG 10:1:0.1), prior injection onto ultrapure water (see Figure 1B). SNs-
DOTAP-miRNA nanosystems exhibited a mean particle size of 124 ± 9 nm, a PDI of 0.2, and a 
postivie ζ-potential of +37 ± 3. We performed a gel electrophoresis assay to prove that miRNA was 
efficiently complexed by the cationic DOTAP, and that association to SNs actually provide an 
additional protection. As it can be observed in Figure 4, no free RNA was shown in both 
formulations. Free miRNA was only observed in broken SNs-DOTAP-miRNA with heparin, not 
in SNs-DOTAP-miRNA, indicating the dissociation was prevented due to the association of the 
complexes to SNs. Transmission electron microscopy (TEM) reveal the spherical morphology of 
SNs-DOTAP-miRNA (Figure 5). DLS and NTA data prove that SNs-DOTAP-miRNA 








Figure 4. Electrophoresis of lipid complexes and SNs-DOTAP-miRNA. A displacement experiment upon incubation 
with a 25-fold excess of heparin (w/w) for 2 hours at 37 °C allowed the migration of the associated miRNA. 




Figure 5. Characterization of lipid complexes and SNs-DOTAP-miRNA. Transmission electron microscopy (TEM) images 
(A). Size distribution measured from nanoparticle tracking analysis (NTA) and dynamic light scattering (DLS) (B), and 
video frame acquired by NTA (C). 
 
3.4 In vitro cell uptake and transfection efficiency  
It is recognized that the physicochemical properties of nanoparticles impact their cellular 
uptake mechanism. The surface charge of nanocarriers plays an important role in their cellular 
uptake and internalization pathway. Cationic nanocarriers can bind to sulfated proteoglycan of cell 
surfaces through electrostatic interactions and subsequently be internalized by pinocytosis and 
endocytosis59. We wanted to investigate if the developed nanosystems were able to efficiently 
interact with cancer cells and deliver their payload with a similar efficiency. Main differences are 
related to the location of the miRNA (disposed at the nanoparticle surface for SNs-ST-miRNA 
nanosystems and complexed with cationic lipids and further entrapped into SNs for SNs-DOTAP-
miRNA nanosystems) and to their negative or positive surface charge, for SNs-ST-miRNA and 
SNs-DOTAP-miRNA nanosystems, respectively.  
SNs-DOTAP-miRNA 
Lipid complexes 
A B C 
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Cell uptake studies with double fluorescent SNs-ST-miRNA and SNs-DOTAP-miRNA 
(miRNA was labelled with Cy5, Cy5-miRNA, and SM with green TopFluor®, TopFluor®-SM) in 
SW480 (human colon cancer cells; cell nuclei counterstained with Hoechst) were performed by 
confocal laser-scanning microscopy. As it can be obsvered (Figure 6A), both formulations were 
efficiently internalized by the cells (green signal), and the associated Cy5-miRNA was transported 
to the cell cytoplams (red signal). Importantly, merged images illustrated that SNs-ST-miRNA and 
SNs-DOTAP-miRNA were uptaken in assembled form of stable nanoemulsions, as we can see a 
good co-localization of the green and red signals in both cases. 
Complementary FACS analysis was used to verify the results and provide quantitative data 
(Figure 6B-C). Three controls were established in the FACS experiment to observe the signal of 
fluorescent dyes on nanoemulsion and distinguish from double-negative control cells (Cy5 -, 
TopFluor®  -) located in quadrant 4 (Q4) (cells without treatment), cells positive for Cy5 (Cy5 +, 
TopFluor® -) localized in quadrant 1 (Q1) (cells incubated with SNs-ST-miRNA prepared only 
with miRNA-Cy5), and cells cells positive for TopFluor® (Cy5 -, TopFluor® +) localized in 
quadrant 3 (Q3) (cells incubated with SNs-ST-miRNA prepared only with TopFluor®-SM). 
Double positive cells (Cy5 +, TopFluor® +), were observed in the double-positive quadrant 2 (Q2). 
Importantly, cells treated with double labeled nanoemulsions (either SNs-ST-miRNA and SNs-
DOTAP-miRNA), were indeed observed in Q2, indicating that the nanoemulsions labeled with 
TopFluor® effectively delivered miRNA-Cy5 into the cells, both molecules travelling together. 
SNs-DOTAP-miRNA showed higher co-localization of Cy5-miRNA and TopFluor®-SM signals 
compared to SNs-ST-miRNA, related to a higher population in Q2 (92.8% compared with 57.7% 
respectively). The signal of TopFluor®-SM showed almost the same intensity for both 
formulations stating the ability of the SNs-based formulation to penetrate the tumor cells. On the 
contrary, SNs-DOTAP-miRNA showed higher intensity of Cy5-miRNA compared to SNs-ST-
miRNA (Figure 6B-C). This suggest that our second approach, preparation of miRNA-lipid 
complexes prior to the synthesis of SNs-DOTAP-miRNA, is more efficient for the intracellular 
delivery of miRNA, than having it adsoverd onto the surface of SNs (SNs-ST-miRNA), which may 










Figure 6. Internalization of SNs-ST-miRNA and SNs-DOTAP-miRNA in SW480. Maximal projection of confocal images 
upon incubation of nanoemulsions labeled with TopFluor® Sphingomyelin (green), and Cy5-miRNA (red) (4 h at 37 
oC). Cell nuclei were counterstained with Hoechst (blue) (A). FACS results showing controls of untreated control cells 
(Q4, blue), cells positive for Cy5 (treated with SNs-ST-miRNA-Cy5, Q1, red), cells positive for TopFluor® (treated 
SNs-ST-miRNA 
SNs-DOTAP-miRNA 





with SNs-ST-miRNA-TopFluor®, Q3, green), and double positive cells for Cy5 and TopFluor® (treated with either SNs-
ST-miRNA-Cy5-TopFluor®, Q2, orange, or SNs-DOTAP-miRNA-Cy5-TopFluor®, Q2, pink) (B). FACS Histogram of two 
different fluorophores, TopFluor® and Cy5, obtained for cells treated with double labeled nanoemulsions, (SNs-ST-
miRNA-Cy5-TopFluor®, orange, or SNs-DOTAP-miRNA-Cy5-TopFluor®, pink) (C).  
 
 
Figure. 7. Expression of miR145 after transfection with SNs-ST-miRNA145, Lipid complexes145 (LP145), and 
SNs-DOTAP-miRNA145 nanosystems (as well as nanosystems prepared with the scrambled sequence, SNs-ST-miRNAscr, 
LP scr, and SNs-DOTAP-miRNAscr (A). Relative expression of miR145 after transfection with LP145, a physical mixture 
of LP145 and SNs, and SNs-DOTAP-miRNA145 in SW480 cells (B). (2 µg miRNA/well in 6-well plates, 4 h incubation, 
72 h post-transfection, data normalized against RNU6) (**** p<0.0001, *** p<0.001, and ** p<0.01). 
 
To study the transfection efficiency, and ability to incrase the levels of intracellular 
miRNA145, SW480 cells were transfected with SNs-ST-miRNA and SNs-DOTAP-miRNA, lipid 
DOTAP-miRNA145 complexes (LP145) for control, and with the same formulations but with a 
scrambled sequence, and samples analysed by qRT-PCR.  (Figure 7A). Results show that all 
formulations were able to efficiently increase intracellular miRNA 145 levels compared to control 
cells, SNs-DOTAP-miRNA145 showing the higher transfection efficiency (64-fold higher than 
SNs-ST-miRNA). This is because the preformed lipid complexes later encapsulated in SNs-
DOTAP-miRNA, provide a supportive protection for miRNA145 and mediate an improved 
miRNA145 delivery. Moreover, these cationic lipid complexes might be able to destabilize the cell 
membranes by themselves and penetrate into the cells even if dissociated from the nanoemulsions60. 
Despite of this, when we compared the transfection efficiency of the cationic lipid complexes 
(LP145), a physical mixture of LP145 and SNs, and SNs-DOTAP-miRNA, results highlighted the 
B A 
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the benefits of incorporating lipid complexes into SNs (Figure 7B). The results obtained with SNs-
DOTAP-miRNA nanoemulsions are superior to those recently published with cationic microRNA-
loaded nanoparticles in HTC-116 cells (11-fold increase)22, miRNA-145-loaded magnetic 
nanoparticles in AsPC-1cells (19-fold increase) and HPAF-II cells (4-fold increase)23, miRNA145-
loaded cationic liposomes in HepG2 cells (9-fold increase)61, and miRNA145 associated to a 
lentiviral vector in SW620 cells (8.2-fold increase)62. Therefore, SNs-DOTAP-miRNA145 
nanosystems were selected for further anticancer activity experiments. 
 
3.4 Anticancer activity   
 
Finally, to determine whether SNs-DOTAP-miRNA145 can suppress growth in SW480 
colorectal cancer cells, cell proliferation assays were conducted. The cell number of cells 
treansfected with SNs-DOTAP-miRNA145 was significantly reduced with respect to both 
untreated control cells and cells treated with their scramble formulations (Figure 8A). In addition, 
a colony formation assay was subsequently performed. Our data indicated a significant reduction 
in colony formation in SNs-DOTAP-miRNA145 cells as compared to control cells (Figure 8B). 
Wound-healing studies finally confirmed that our proposed treatment also affects cell migration. 
Indeed, the artificially created wound of SW480 treated with SNs-DOTAP-miRNA145 remained 
almost inalterable at the end of the study, opposibtel to what observed in the case of untreated cells 
and cells treated with the scrambled sequence SNs-DOTAP-miRNAscr (the wound closure was 
superior to 50%) (Figure 8C). These results are in agreement with previously published work with 
biodegradable PLGA and magnetic nanoparticles22, 23, and clearly indicated that SNs-DOTAP-
miRNA145 inhibited cell growth and migration in colorectal cancer cells and is a potential 
treatment for avoiding tumor progression in colorectal cancer. 
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Figure. 8. Anticancer activity of SNs-DOTAP-miRNA145 in SW480 transfected cells. Proliferation of SW480 cells 72 h 
post-transfection (**** p<0.0001) (A). Quantitative analysis of colony numbers, 2 weeks after transfection is shown 
(*** p<0.001 and ** p<0.01) (B). Representative images showing cell migration in wound healing assay, of untreated 
control cells and cells treated with SNs-DOTAP-miRNA145 and the same formulation with the scrambled sequence 
(SNs-DOTAP-miRNAscr). Images were taken 0,24,48,72, and 96 h after treatment. The dark lines designated the rough 













 We have successfully proved the potential of SNs for the efficient association of 
miRNA145 mimics to interfere cancer progression in colorectal cancer. We pursue two different 
strategies to associate miRNA (adsorption to the surface of SNs, SNs-ST-miRNA, and 
preformation of lipid complexes for further encapsulation, SNs-DOTAP-miRNA). Both 
formulations showed capacity to deliver miRNA145 intracellularly and thereafter efficiently 
restore its expression. Restitution of miRNA145 from the delivery of SNs-DOTAP-miRNA 
demonstrated to be related to a decreasing tumor proliferation, colony forming, and migration 
capacity. Further investigation of this SNs-DOTAP-miRNA in an animal models of colorectal 
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A radiolabelling strategy with Fluorine-18 for in vivo imaging of lipid-based 
nanosystems by PET  
 
Abstract 
Organic nanoparticles made out of biodegradable and biocompatible materials have 
attracted increased attention in the diagnostic and therapeutic fields.  In this study, we attempted to 
explore the potential of biocompatible sphingomyelin nanoemulsions (SNs) for clinical positron 
emission tomography (PET) imaging after radiolabelling with Fluorine-18 (18F), a radioisotope 
regularly used in clinic. [18F] fluoride was produced by the cyclotron and was incorporated into 4-
[18F]fluorobenzamido-N-ethylmaleimide ([18F]FBEM), which was coupled next to SNs previously 
functionalized with a thiol group, via inclusion either of a lipid-PEG-thiol derivative (SNs), or a 
lipid-PEG-peptide (SNs-RPM). Radiolabelling of SNs and SNs-RPM was obtained through facile-
conjugated chemistry with simple purification and without the use of organic solvents, providing 
a simple platform for rapid and efficient nanoparticle labelling.  PET imaging and biodistribution 
studies in BALB/c mice allowed obtaining the pharmacokinetics of both formulations and 
determining the clearance pathways. Altogether, we confirmed the potential of this new technique 













































	 	 	 	 	The	engineering	of	nanotheranosGcs	show	a	prompt	impact	in	numerous	applicaGons	in	cancer,	since	
they	 allow	 simultaneous	 diagnosis,	 treatment,	 and	 follow-up	 of	 the	 disease.	 NanotheranosGcs	 are	 the	




	 	 This	 project	 aims	 to	 develop	 biodegradable	 nanoemulsions	 for	 applicaGon	 as	 tumor-targeted	
mulGfuncGonal	 nanotheranosGcs.	 Nanostructures	 are	 composed	 by	 biocompaGble	 lipids	 and	 incorporate	




	 	 	 	 	 	 	 	We	have	successfully	developed	two	different	types	of	lipidic	nanoemulsions	that	incorporate	miRNA	(miR	NE	and	DOTAP:miR	NE)	and	can	be	decorated	with	a	














	Formula.ons	 Size	(nm)	 PDI	 ZP	
	DOTAP:miR	NE	 155±	4	 0.2	 		+45	±	1	

























































	Formula.ons	 Size	(nm)	 PDI	 ZP	
miR	NE		 172	±	4	 0.2	 	-15	±	2	
















































Nanotechnology offers promising standpoints for diagnosis of a number of diseases such 
as cancer, atherosclerosis, leukemia, and tuberculosis, by providing innovative non-invasive 
methodologies1-3. Most typically, nanoparticles designed for in vivo whole-body imaging purposes 
are inorganic, such as quantum dots (fluorescent nanocrystals) for optical image, iron oxide and 
manganese oxide nanoparticles (magnetic nanoparticles) for Magnetic Resonance 
Imaging (MRI), and gold nanorods (plasmonic nanoparticles) for photonics4-6. In the case of 
molecular imaging, apart from inorganic nanoparticles, polymeric micelles, liposomes, and 
dendrimers are generally used as basic materials labeled with radionuclides for Positron Emission 
Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT)7-11. The use of 
biodegradable organic nanoparticles has several advantages with respect to inorganic materials. 
For example, no toxicity is observed, oppositely to other materials such as heavy metal ions 
(CdSe/CdTe) present in quantum dots (QDs). More importantly, since QDs are efficient energy 
donors, they could transfer energy to nearby oxygen molecules, resulting in the generation of 
reactive oxygen species (ROS), causing cell damage or death12,13. While many iron oxide 
nanoparticles have shown excellent results in vitro, many of them had failed in vivo due to toxicity 
via plentiful mechanisms including the disruption of cytoskeletons, inducement of oxidative stress, 
generation of free radicals, impairment of mitochondrial function, damage of DNA, and altering of 
cell signaling pathways among others14. On the other hand, organic nanoparticles can provide an 
upper edge in terms of biocompatibility and biodegradability over inorganic nanoparticles. 
Among all various imaging modalities currently used in clinical applications, one of the 
prevalent techniques at the hospital is PET due to its own merits, such as high sensitivity, feasible 
functional image, and precise quantification of signals from radionuclides15,16. 18F-
fluorodeoxyglucose (FDG) is broadly used clinically for tumor imaging based on increased glucose 
metabolism in most types of tumors. This clinical approved agent by the Food and Drug 
Administration (FDA) helps improving diagnosis and treatment of cancers17,18. Nonetheless, in 
certain cases, imaging with FDG can be counter-productive as glucose metabolism is not only 
specific to tumors. It may be difficult to reach sufficient amounts at the target area. Consequently, 
this drawback has driven researchers to develop more specific delivery systems for imaging19,20. 
 159 
Radiolabelled nanocarriers can increase the signal, sensitivity, and resolution of the 
acquired image compared to the current standard radiotracer e.g. FDG21. Additionally, radiolabeled 
nanoparticles can be tailored to have long blood circulation times and be stable in plasma, therefore 
holding a great potential for clinical applications22-24. Harrington et al. demonstrated that 111In-
DTPA-labeled pegylated liposomes were able to accumulate in solid tumors at high concentrations 
and remained there for prolonged periods in patients with locally advanced cancers particularly in 
head and neck cancer25. 64Cu-DOTA-loaded pegylated liposomes, reported by A.L. Petersen et al., 
showed a high retention stability and a high degree of tumor accumulation in HT29 (colon 
adenocarcinoma) xenografts26. In another study by Zhang et al., 99mTc-labeled dendrimers 
conjugated with folic acid improved the tumor targeting in human oral epidermoid carcinoma27. 
Therefore, developments of targeted-radiolabeled nanocarriers can lead to imaging tools with high 
potential in cancer diagnosis.  
To date, the development of radiolabeled nanoparticles is widely based on chelation 
principles by means of a bifunctional chelator (BFC)28-30. However, the attachment of a 
radionuclide using BFCs has some disadvantages. The coordination chemistry of common 
radiometals and their chelators may be hampered due to steric hindrance of nanoparticles. Along 
the production, the presence of non-radioactive metals may interfere the chelation, leading to less 
radiochemical yield. One alternative for the use of radiometals is labelling nanoparticles with 
fluorine-18 (18F).  18F can be considered as promising positron emitter for PET, resulting from its 
half-life of 110 min allowing performing scans over several hours, together with a low positron 
energy allowing for images of high resolution, and a large-scale production with high specific 
activity31-33. Therefore, 18F seems to be an interesting choice for radiolabelling of nanoparticles. 
There have been several attempts for radiolabeling biologically active compounds with 18F, such 
as peptides, neuro-transmitter ligands, and enzyme targets34,35. So far, labeling methods are often 
described and characterized by multi-step synthetic pathways. First of all, 18F-labeled molecule 
(18F-prosthetic group) have to be synthesized in advance by intricate techniques. Then the 
conjugation of the 18F-prosthetic group with the biomarker is achieved for the last step36-38. Such a 
conjugation usually targets primary amino groups either at the N-terminus of peptides (α-NH2) or 
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at internal lysine residues (α-NH2). Nevertheless, this process still has pitfalls related to non-
selective radio-labeling because of the relative abundance of lysine in proteins. 
Thus, the peptide labelling at thiol groups has emerged as a method offering the opportunity 
to accomplish efficient and site-specific radiolabeling. Since a free thiol group is only present in 
cysteine residues, radiolabeling of thiol functional groups definitively renders a regio-specific 
modification of peptides. In addition, under physiological conditions, the thiol group is more 
nucleophilic than amines. The common approaches for synthesis thiol labeling precursors are 
counted on a maleimide group via Michael addition reaction. Consequently, numerous labeling 
precursors containing a maleimide functional group have been developed, as for example 4-
[18F]fluorobenzamido-N-ethylmaleimide ([18F]FBEM)39, and N-[4-[(4-[18F] 
fluorobenzylidene)aminooxy]butyl]-maleimide40.  
We describe here a new methodology for radiolabelling organic lipid-based nanosystems 
with 18F, and provide an example with biocompatible and biodegradable SNs and SNs-RPM. We 
started by the synthesis of a 18F-labeled prosthetic group, [18F]FBEM, which was later conjugated 
to thiol groups located at the surface of SNs, or to the cysteine residue of the SNs-RPM via Michael 
addition reaction. Both radiolabelled nanoemulsions (SNs-[18F]FBEM and SNs-RPM-[18F]FBEM) 
were then purified at room temperature without organic solvents, and fully characterized for their 
physicochemical properties. The labeling was confirmed by ultra-performance liquid 
chromatography (UPLC) in both UV and gamma detectors. SNs-[18F]FBEM and SNs-RPM-
[18F]FBEM were eventually injected to healthy mice, to determine their potential for future PET 
imaging studies. This strategy could represent a step-forward towards the development of 









2. Materials and methods  
 
2.1 Materials  
Vitamin E (DL-α-tocopherol), stearylamine, potassium carbonate (K2CO3), N,N-
diisopropylethylamine (DIPEA), diethyl cyanophosphonate (DECP), and N-(2-
Aminoethyl)maleimide trifluoroacetate salt were purchased from Sigma Aldrich (St.Louis, MO, 
United States). Sphingomyelin was acquired from Lipoid (Ludwigshafen, Germany). SH-PEG12-
C18 was supplied by Creative PEGworks (North Carolina, United States). Cys-Pro-Ile-Glu-Asp-
Arg-Pro-Met-Cys-PEG8-C18 (RPMpeptide-PEG8-C18) was obtained from ChinaPeptides (Shanghai, 
China). Both of SH-PEG12-C18 and RPMpeptide-PEG8-C18 were used as references for UPLC 
analysis, Ref-SH-PEG12-C18 (Ref-lipid), and Ref-RPMpeptide-PEG8-C18 (Ref-peptide). Tris (2-
carboxyethyl) phosphine hydrochloride (TCEP.HCl) was purchased from Pierce Biotechnology. 
Kryptofix® 222 was supplied by Merck KGaA (Darmstadt, Germany).  2,5-Dioxopyrrolidin-1-yl 
4-fluorobenzoate (N-succinimidyl 4-fluorobenzoate) was provided from AK Scientific (California, 
United States). PD-10 desalting column was obtained from GE healthcare (Chicago, IL, United 
States).   Water used in all experiments was deionized from Milli-Q Integral Water Purification 
System.  
 
2.2 Nanoemulsions preparation by ethanol injection method  
SNs functionalized with a thiol group (SNs) were formulated from vitamin E, 
sphingomyelin, stearylamine, and SH-PEG12-C18 in a ratio of 10:1:1:0.06 w/w. In the case of 
peptide-decorated SNs (SNs-RPM) they were formulated from vitamin E, sphingomyelin, 
stearylamine, and RPMpeptide-PEG8-C18 in a ratio of 10:1:1:0.1 w/w.  
All components were dissolved in a final volume of 110 µL of ethanol (organic phase, 
sphingomyelin concentration 0.45 mg/mL) and injected with syringe pump (0.5 mL) into 1 mL of 
ultrapure water under magnetic stirring. SNs and SNs-RPM were spontaneously formed and 
maintained in agitation for 10 minutes at room temperature. Both formulations were isolated from 
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non-interacted compounds by ultracentrifugation (Beckman, California, United states) at 35000 
rpm for 1 hour at 15ºC in a 70.1 Ti rotor.   
 
2.3 Size and zeta-potential measurements  
 Nanoemulsions were analyzed for their hydrodynamic size by dynamic laser scattering 
(DLS) (Zetasizer Nano ZS, Malvern Instruments, Worcestershire, UK). Measurements were 
performed at 25 ºC with a detection angle of 173º.The obtained data were analyzed based on 
cumulative analysis method for determination of mean hydrodynamic diameter and polydispersity 
index (PDI).  ζ–potential was measured by Lasser Doppler Anemometry (LDA). Nanoemulsions 
were diluted with filtered ultrapure water and loaded into a Disposable Solvent Resistant Micro 
Cuvette (ZEN0040) and a dip-cell (DTS 1060) for size and ζ-potential analysis, respectively.  
 
2.4 Synthesis of [18F]FBEM 
The automated radiosynthesis of [18F]FBEM was conducted on a GE Healthcare FastLab® 
in three-steps, and then purified by the semipreparative HPLC on a SymmetryPrep C18 column 
(Figure 1A and 1B)41. In brief, the [18F]fluoride obtained from the cyclotron (23 ± 0.8 GBq) was 
recovered and trapped on an ion exchange resin QMA Carbonate Cartridge. The activity was eluted 
with the solution of a Kryptofix® (K2.2.2., 37.5 mg in 630 µL of ACN) and K2CO3 (7.5 mg in 70 
µL of water) into the reactor. Water was azeotropically evaporated by heating at 105 °C and 120 °C 
under vacuum and nitrogen flow. Precurrsor 1 (Figure 1A) was prepared according to a previously 
described methodology42. 10 mg of Precurrsor 1 in anhydrous DMF 1.0 mL was then added to the 
reactor. The labeling was performed for 10 min at 130 °C. After that NaOH (1 mL, 2 M) was added 
to the bulk reaction to hydrolyze the ester for 10 min. HCl (2 mL, 4 M) was added to quench the 
reaction. After dilution with water (6 mL), the bulk solution is trapped on an HLB cartridge. The 
cartridge was washed afterwards with water (6 mL) and dry with hexane (5 mL). The reactor was 
washed three times with ACN (4 mL). Then 3 was eluted with N,N-diisopropylethylamine (20 µL) 
in a 1:1 mixture of ACN/Et2O (4 mL) to the reactor. After evaporation the solution at 60 °C under 
N2 flow for 5 min, maleimidetrifluoroacetate salt (10 mg, 16 µmol) and diethyl cyanophosphonate 
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DECP (20 µL, 60 µmol) in a 1:1 mixture of ACN/Et2O (3 mL) was added to the reactor. The 
reaction was heated at 60 °C for 20 min under N2 flow until the volume was reached 1 mL. The 
bulk solution was diluted with water (4 mL) and injected in a semi-preparative HPLC to separate 
[18F]FBEM from by-products that may interfere with the labeling with the nanoemulsions. The 
peak of purified [18F]FBEM was collected in water (15 ml) and transferred back to the FastLab 
module through a second HLB cartridge. Then this cartridge was washed with water (6 mL), dried 
with hexane (5 mL) and then eluted with ACN (4 mL). A fraction (0.74 GBq) of this solution was 
evaporated under N2 to dryness, which was ready for nanoemulsions labeling. 
 
Figure 1. Radiosynthesis of [18F]FBEM (A). Cassette layout for [18F]FBEM preparation on a FastLab module (B). 





2.5 Synthesis of [18F]FBEM-labelled nanoemulsions 
SNs and SNs-RPM were firstly treated with TCEP.HCl (20 eq.) during 20 min at room 
temperature (RT) to reduce the disulfide bond. Nanoemulsions were then purified using a PD-10 
desalting column with Sephadex G-25 resin. 5 fractions of 500 µL. They were collected and 
characterized by DLS. Nanoemulsions were eluted in a total volume of 1 ml, added to the thin film 
of evaporated [18F]FBEM (see section 2.4), mixed for 30 min at RT, and purified by a PD-10 
desalting column. The fractions of [18F]FBEM-labelled nanoemulsions were collected and the 
amount of radioactivity was measured by ionization chamber. Furthermore, [18F]FBEM-labelled 
SNs and SNs-RPM (SNs-[18F]FBEM and SNs-RPM-[18F]FBEM), as well as free [18F]FBEM, Ref-
[19F]FBEM, Ref-SH-PEG12-C18 (Ref-lipid), and Ref-RPMpeptide-PEG8-C18 (Ref-peptide), were 
subsequently analyzed by UPLC (Figure 4). The analysis was implemented on ACQUITY UPLC 
BEH C18 Column, 130Å, 1.7 µm, 2.1 mm X 50 mm with a flow rate of 0.7 mL/min. Eluent A: 
H2O + 0.1%TFA, Eluent B: ACN. The gradient was linear 1.9 min from 90/10 to 40/60, linear 1.2 
min from 60/40 to 0/100 and the washout linear 0.9 min from 0/100 to 90/10.  
2.6 Biodistribution studies and PET imaging 
All animal studies were performed in compliance with the European Ethics Committee. 
The study protocol was approved by the local Animal Experimental Ethical Committee of the 
University of Liège (Belgium). The mice were anesthetized with 1–2% isoflurane, placed in the 
MINERVE animal cell bed (Equipement Veterinaire Minerve, Esternay, France) and continuously 
received anesthesia via a nose cone system. Temperature was controlled at 37 ± 0.5 °C by an air 
warming system (Minerve, France). PET studies were obtained using a Siemens FOCUS 120 
microPET scanner (Siemens, Knoxville, TN, USA). PET data acquisition started with a 10-min 
transmission scan using a 57Co point source with single event acquisition mode. Afterward SNs-
SH-[18F]FBEM and SNs-RPM-[18F]FBEM nanoemulsions, suspended in 0.1 mL of 0.5% Glucose 
(280 mOsm/kg, 6 ± 2.2 MBq), were injected via the lateral tail vein of male BALB/c mice. 
Dynamic microPET scans over 120 minutes were started few seconds before the tracer injection.  
The list-mode data was histogrammed into three-dimentional (3D) sonograms by Fourier rebinning 
(Defrise M, et al. IEEE Trans Med Imag 1997, 16:145-158) and reconstructed by filtered 
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backprojection with all corrections, except for scatter events (Bahri et al. 2009)43. A set of 2D 
images was reconstructed in a 256 x 256 x 95 matrix with a pixel size of 0.433 x 0.433 x 0.796 
mm. the dynamic time framing was as follow 6 x 5 s, 6 x 10s, 3 x 20 s, 5 x 30s, 5 x 60 s, 8 x 150 s, 
6 x 300s, and 6 x 600 s. The obtained images were then analyzed for the kinetic studies.  
For anatomical whole-body imaging, the anesthetized mice were transferred into a 9.4 
Tesla MRI DirectDrive VNMRS horizontal bore system with a shielded gradient system (Agilent 
Technologies, Palo Alto, CA). The used sequence parameters were as follows: 25 contiguous 
coronal slices, slice thickness = 1 mm, TR/TE = 2000/ 23.68 ms, FOV = 80 × 40 mm, matrix = 
256 × 128. By using PMOD software version 3.6 (PMOD Technologies Ltd., Zurich, 
Switzerland), dynamic PET images were co-registered to the corresponding MRI structural image 
(guided by the fiducial markers) in each mouse. Then regions of interest (ROIs) were drawn over 
major organs using PMOD software on the structural MRI image and transferred into the whole-
body dynamic PET images in order to extract their time activity curves (TACs).  
The mice were sacrificed at the end of the imaging experiment. Their blood and organs 
were harvested 3 h after injection. All the collected organs were weighed and the radioactivity 
was measured with a γ-counter (2480 Wizard2 Gamma counter, Perkin Elmer). The output 









3. Results and discussion 
 
3.1 Physiochemical characterizations of nanoemulsions 
 
Figure 2. Components (A). and Scheme of preparation of SNs and SNs-RPM (B). 
 Currently, lipid-based systems have gained greatly interest owing to their ability to allow 
efficient drug delivery system 44,45. Nanoemulsions are thermodynamically stable isotropic systems 
in which two immiscible liquids (oil and water) are mixed to formulate a single phase. They are 
typically composed of an oily core and stabilized by surfactants such as phospholipids and cationic 
lipids. In this report, SNs and SNs-RPM were prepared by a low-energy method, using the ethanol 
injection procedure46.  Nanoemulsions were spontaneously formed after injection of the lipid phase 
(containing all components dissolved in ethanol) into the aqueous phase (in this particular study, 
ultrapure water) (Figure 2A and 2B). SNs and SNs-RPM had a vitamin E core stabilized by 
sphingomyelin and stearylamine. A lipid-PEG-thiol derivative (SH-PEG12-C18), or a lipid-PEG-
peptide (RPMpeptide-PEG8-C18) were incorporated to the formulations, for further labelling with 
[18F]FBEM. RPMpeptide was selected to provide a basic information of radiolabelling of peptides 
that could be incorporated to the formulations for targeting purposes. RPM has been described as 





SNs-RPM are described in Table 1. As it can be observed, nanoemulsions formed monodispersed 
populations with a mean size of 120-140 nm and are positively charged.  
Table 1. Hydrodynamic size, polydispersity index (PDI), and zeta potential (ζ-potential) of SNs and SNs-RPM (n=3). 
 
3.2 Synthesis of [18F]FBEM-labelled nanoemulsions 
Following a previous published methodology41, we proceed to the synthesis of [18F]FBEM. 
All steps and HPLC purification were automated on a FastLab from GE Healthcare. Time of 
radiosynthesis was approximately 85 min. This radiosynthesis was reproducible, reliable and 
rendered sufficient yields for multi-step procedures. The specific radioactivity of [18F]FBEM (830 
GBq/µmol) was analyzed on one batch for quality control. With respect to the labelling of the 
nanoemulsions, after [18F]FBEM was synthesized, it was evaporated as a thin film. Nanoemulsions 
were added onto this film, after reduction of the disulfide bond was performed to reactivate the free 
thiol function41, and subsequent purification to remove the reducing agent. 
Formulation Size (nm) PDI ζ-Potential (mV) 
SNs 125 ± 3 0.2 +37± 2 




Figure 3. Labelling Process of SNs-[18F]FBEM and SNs-RPM-[18F]FBEM. 
Radiolabeling was performed by chemical reaction between a maleimide group of 
[18F]FBEM and the free thiol groups at the surface of SNs and SNs-RPM. Radiolabelled 
nanoemulsiones were purified again rendering SNs-[18F]FBEM and SNs-RPM-[18F]FBEM 
(Figure 3). Radiochemical yields (RCY) (decay corrected) of SNs-[18F]FBEM and SNs-RPM-
[18F]FBEM were 35.1 + 5.7%  (n=4) and 39.4 + 5.5% (n=4) respectively. The radioactivity amounts 
were sufficient for injection and observation in vivo biodistribution in mice during 2 hours. Both 
[18F]FBEM-labelled nanoemulsions had hydrodynamic sizes of 130-150 nm with narrow PDI and 
positive ζ-Potential. No significant changes with respect to the unlabeled nanoemulsions are 
reported, allowing us to conclude that the radiolabeling process is mild and do not compromise the 
structure and stability of the nanosystems. SNs-[18F]FBEM and SNs-RPM-[18F]FBEM also have a 
pH between pH 7-8 and an osmolarity between 280-290 mOsm/kg, characteristics that make them 
suitable for parenteral injection (Table 2).   
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Table 2. Radiochemical yields, hydrodynamic size, polydispersity index (PDI), zeta potential (ζ-potential), pH, and 
osmolality of SNs-[18F]FBEM and SNs-RPM-[18F]FBEM (n=4). 






SNs-[18F]FBEM 35.1 ± 5.7 136 ± 9 0.2 +38 ± 6 7.6 ± 0.2 287 ± 5 
SNs-RPM-[18F]FBEM 39.4 ± 5.5 149 ± 8 0.2 +37 ± 5 7.8 ± 0.3 285 ± 6 
This study reported the successful labelling of lipid-based nanoparticles with [18F]FBEM, 
using indirect labelling method and in absence of organic solvents. The chemical reaction was 
based on thiol-maleimide groups via Michael addition reaction. Generally, radiolabelling of 
nanoparticles could be accomplished either before or after the synthesis of nanoparticles. Labelling 
with different 18F-prosthetic groups after the formation of nanoparticles have already been 
reported50-52. On the other hand, (4-[18F]fluorobenzyl-2-bromoacetamide ([18F]FBBA) conjugated 
to polymers before the preparation of nanoparticles (RCY = 5-14%, decay corrected) has been 
described53. Due to the short half-life of 18F, the method of post-labelling may display an advantage 
allowing high radiochemical yields in relation to the pre-labelling method. In addition, the labelling 
process was performed under controlled pH and osmolarity to prepare the appropriated 
characteristics of radiolabelled nanoemulsions for injection in animal54. 
To confirm the radiolabelling results, the signals of non-labelled products, Ref-[19F]FBEM, 
Ref-SH-PEG12-C18 (Ref-lipid), and Ref-RPMpeptide-PEG8-C18 (Ref-peptide) were analyzed with 
UV detector. Then [18F]FBEM-labelled nanoemulsions were broken in ethanol and evaluated by 
gamma detector to confirm the signal of labelled products with the references mentioned above. 
No free [18F]FBEM peak was detected from both chromatograms of broken labelled nanoemulsions, 
stating that the purification was completely accomplished to separate labelled nanoemulsions and 
free [18F]FBEM  (Figure 4A, 4B, 4D, and 4F). Broken SNs-[18F]FBEM confirmed that they were 
conveniently labeled, as a signal of [18F]FBEM-PEG12-C18 ([18F]FBEM-lipid) was detected at 3.1 
min, in agreement with the chromatograph of the Ref-lipid (Figure 4C and 4D). The corresponding 
of Ref-peptide with conjugated product [18F]FBEM-RPMpeptide-PEG8-C18 ([18F]FBEM-peptide) 
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in the broken of SNs-RPM-[18F]FBEM at 2.5 min was confirmed by UPLC chromatogram (Figure 
4E and 4F). From these results, the labelling position was confirmed at thiol functional groups 
either on lipid or peptide. Non-specific labelling was not observed from both labelled 
nanoemulsions. Lastly, the purification process was successfully performed for obtaining purified 
labelled nanoemulsions. 
 
Figure 4.  Chromatogram UPLC in UV and gamma detector of Ref-[19F]FBEM) (A). [18F]FBEM (B). Ref-lipid(C). 
[18F]FBEM-lipid (D). Ref-peptide (E) and [18F]FBEM-peptide (F). 
 171 
3.3 Biodistribution studies and PET imaging nanoemulsions 
To determine the in vivo behavior of the radiolabelled nanoemulsions, they were 
administered via tail injection to healthy mice. On the one side, the radioactivity was measured in 
dissected organs, to determine the biodistribution ex vivo. On the other side, PET-MRI studies were 
carried out to prove the potential of the developed nanoemulsions as contrast agents for in vivo 




Figure 5. Ex vivo biodistribution profile of SNs-[18F]FBEM and SNs-RPM-[18F]FBEM in organs of male BALB/c mice 3h 
after injection. 
 
The ex vivo biodistribution of SNs-[18F]FBEM (n=4) and SNs-RPM-[18F]FBEM (n=5) in 
organs of male BALB/C 3 h post injection, demonstrated an uptake in liver (46.6 ± 22.6% and 47.4 
± 10.7%ID/g ), kidneys (5.6 ± 2.5 and 16.1 ± 2.9%ID/g), spleen (39.6 ± 9.0 and 26.4 ± 7.6%ID/g) 
and intestine (18.4 ± 5.6% and 11.6 ± 2.2%ID/g) (Figure 5). The presence of radioactivity in the 
intestine might originate from liver excretion via gallbladder within feces. The radioactivity in the 
kidney showed that parts of the radiolabelled nanoemulsions were eliminated via urine.  The low 











































native bone targeting capability, this suggesting that most of the 18F radiolabel remained on 
nanoemulsions55,56. In general, the uptake in different organs depends on the stability of the 
nanostructures, which resulted from the nanomaterial composition, size, and surface 
functionalization57. The ex vivo pattern of both SNs-[18F]FBEM and SNs-RPM-[18F]FBEM 
displayed different pharmacokinetic profiles compared to the free labelled-peptide ([18F]FBEM-
peptide) from preliminary study. The capture of [18F]FBEM-peptide was lower than both 
[18F]FBEM-nanoemulsions in liver, spleen, and intestine demonstrated with the uptake of 
27.73%ID/g, 12.92%ID/g, and 6.39 %ID/g respectively. Form all these results, the radiolabelled 
nanoemulsions were stable in vivo upon intravenous injection. 
According to nanoparticles viewpoints, a possible explanation for the high uptake in liver 
and spleen might be described by the action of mononuclear phagocyte system (MPS). The protein 
adsorption might occur on the surface of nanoemulsions, stimulating the elimination of foreign 
particles58-60. Similar distribution patterns from lipid-based nanoparticles has been reported from 
52Mn-DOTA and 64Cu-DOTA liposomes, 159Gd-DTPA liposomes, and 99mTc-labelled solid lipid 
nanoparticles61-63. One strategy to modulate biodistribution and interaction with MPS could be the 
modification of the surface of nanoparticles64,65. For instance, the decoration of the nanoparticles 
with a PEG layer could prevent opsonization and sequestration by the MPS, resulting in prolonged 
blood circulation as reported from ([18F]FBBA) labelled nanoparticles and  [18F]FPyME (1-[3-(2-
fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione) labelled quantum dot micelles53,66.  Indeed, SNs 
decorated with the hydrophilic peptide RPM (SNs-RPM-[18F]FBEM) had a decreased 
accumulation in spleen and liver.  
In vivo biodistribution studies with PET-MRI were accomplished to evaluate the potential 
of the nanoemulsions to be used for in vivo diagnosis, as well as to determine the pharmacokinetics 
of SNs-[18F]FBEM and SNs-RPM-[18F]FBEM. Figure 6 shows images acquired by PET-MRI, 2h 
after intravenous injection of both types of nanosystems. It is possible to observe a high 
accumulation of nanoemulsions in liver and spleen. Certain amounts of radioactivity appeared in 
urinary bladder indicating that radiolabelled nanoemulsions or their radiolabeled metabolic 
products were excreted through urinary tracts. With respect to the ROI drawn on the heart ventricles 
confirmed the success of the injection in the tail vein since the radioactivity decreased after the 
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administration. Time-activity curves (Figure 7) indeed show a quick uptake in the liver and spleen. 
Two ways of clearance (liver and kidney) can be observed, being the predominant liver excretion. 
The progressive increase in the bladder could indicate that a fraction of the labelled nanoemulsions 
was circulating in the bloodstream being later excreted through the kidney into urine51. Time-
activity curves in the lung, heart, and kidney followed a similar way, and remained lower compared 
to liver and kidney. Overall, these results correlate well with the ex vivo at 2 hours after injection.  
In conclusion, in vivo biodistribution and pharmacokinetic studies proved that our approach 
resulted adequate radiolabelling for SNs and SNs-RPM, paving the way for the future delivery of 
biodegradable and biocompatible organic nanoemulsions for tumor diagnosis. 
 
Figure 6. Whole body in vivo biodistribution of SNs-[18F]FBEM (left) and SNs-RPM-[18F]FBEM (right) in male BALB/c 
mice 2h p.i. using PET and MRI: two different coronal slides showing respectively the kidneys (A,C) and the liver and 






Figure 7. Graphical representation of the whole body in vivo biodistribution of SNs-[18F]FBEM (A) and SNs-RPM-
[18F]FBEM (B) in male BALB/c mice using PET in different organs after single intravenous injection. Data are given in 





































4. Conclusion  
Radiolabeling of lipid-based nanocarriers was successfully developed for both 
biodegradable lipid nanoemulsions (SNs-[18F]FBEM) and peptide-decorated nanoemulsions (SNs-
RPM-[18F]FBEM) by a simple method under mild conditions, without altering their 
physicochemical properties, and rendering acceptable radiolabelling yields. Radiolabelled 
nanoemulsions can be followed by PET-MRI and could be exploited for further development of 
nanoemulsions for molecular imaging diagnosis. Additionally, this strategy could be applied for 









1. Synthesis of [19F]FBEM (Ref-[19F]FBEM)  
Synthesis of [19F]FBEM (also used as Ref-[19F]FBEM) was described in previous report67. 
Briefly, N-(2-Aminoethyl)maleimide (20 µmol) in 800 µL of acetonitrile, N-succinimidyl 4-
fluorobenzoate (18 µmol) in 400 µL of acetonitrile, and 2 mL of 50 mmol/L of K3PO4  buffer (pH 
8.5) were mixed. The reaction was continued at 50°C for 20 minutes. The solution was purified 
with the semipreparative HPLC on C18 column (110Å, 5 µm, 10 mm × 250 mm) at a flow rate of 
4 mL/min (Eluent A: ACN/H2O 5/95+0.1%TFA, Eluent B: ACN. The gradient was linear 25 min 
from 100/0 to 0/100 and the washout linear 10 min from 0/100 to 100/0. After the collection of the 
[19F]FBEM and further lyophilization, the characteristic of [19F]FBEM was confirmed by UPLC-
MS. Analytical UPLC was accomplished on ACQUITY UPLC BEH C18 Column (130Å, 1.7 µm, 
2.1 mm X 50 mm) controlled by Empower® software. They were performed with a flow rate of 
0.5 mL/min (Eluent A: H2O + 0.1%TFA, Eluent B: ACN). The gradient was linear 3.8 min from 
90/10 to 0/100 and the washout linear 1.2 min from 0/100 to 90/10. The synthesis of [19F]FBEM 
was confirmed by Mass spectrum analysis with molecular weight of 262.98 g/mol.  
 
 
S1. MS analysis (electospray, negative ionization mode) of [19F]FBEM. 
 
2. Synthesis of [18F]FBEM-RPMpeptide-PEG8-C18 ([18F]FBEM-peptide) 
RPMpeptide-PEG8-C18 firstly treated with TCEP.HCl (20 eq.) during 20 min at room 
temperature (RT) to reduce the disulfide bond. The solution then purified using semipreparative 
HPLC on C18 column (110Å, 5 µm, 10 mm × 250 mm) at a flow rate of 4 mL/min (Eluent A: 












Ethanol/H2O 5/95+0.1%TFA, Eluent B: Ethanol. The gradient was linear 25 min from 100/0 to 
0/100 and the washout linear 10 min from 0/100 to 100/0. It was collected and added to the thin 
film of evaporated [18F]FBEM (see section 2.4). [18F]FBEM-peptide was analyzed with gamma 
detector in UPLC and injected to observe biodistribution in healthy mice. 
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Chapter 4  
 












Overall Discussion  
Colorectal cancer is one of the most common causes of cancer deaths worldwide. Poor 
patient survival rates result from poor prognosis, drug resistance, tumor invasion and migration, 
and inefficient therapeutic methods. Although survival rates are high at early stages of the disease, 
survival in the metastatic setting continues to be low1,2. Furthermore, due to the broad effect of 
conventional chemotherapeutic drugs, a number of patients are suffering from side-effects3. 
Therefore, improvements are necessary to specifically deliver drugs to tumor cells while avoiding 
systemic toxicity. Delivery based on nanotechnology can tackle this drawback4. Currently, there 
are FDA-approved nanoparticle-based therapies in oncology, and several formulations are under 
clinical investigation5,6. 
The potential of nanotechnology for delivery of innovative therapeutics such as 
polynucleotides has already been stated7-9. Due to its ability to interfere with tumor progression, 
invasion, and dissemination, oncosuppressor miRNAs become one of the choices for designing 
novel nanocarriers in the battle against colorectal cancer. miRNAs are endogenously expressed 
RNAs 18-24 nucleotides that can regulate gene expression through translational repression by 
binding to a target mRNA10,11. As previously reported, nanotechnology-based delivery systems 
have enabled the development of promising miRNAs to clinical trials12. We selected miRNA145 
because it was frequently found to be downregulated in various kinds of neoplasia including colon 
cancer and could act as tumor suppressor13-15.  
Nanoparticles can also be of utility for the association of molecular agents prompting their 
application in molecular diagnosis, either for direct application in clinical diagnosis, for example 
to determine the efficiency of a particular treatment and/or follow-up of the diseas16-18, or for in 
vivo tracking of the nanotherapeutics, rendering what are currently known as nanotheranostics19. 
The use of 18F for radiolabelling has numerous benefits related to specific properties, such as (i) 
half-life of 109.8min, (ii) low b+-energy (0.64 MeV), (iii) ease of production, (iv) availability as 
clinical routine use in the hospital. 18F half-life is long enough to allow synthesis, transportation, 
and imaging procedure to be extended over hours, while limits the amount of radiation doses to 
patients in relation to other PET radionuclides. In addition, 18F has a short positron linear range in 
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tissue because of its low positron energy, leading to particularly high resolution in PET imaging20. 
Unfortunately, direct labelling of peptide/protein with 18F is difficult as the basic conditions of 
nucleophilic introduction of 18F usually cause proton abstraction from the precursor molecules. The 
harsh labelling conditions may denature the sensitive biomolecules21. Hence, most 18F labelling 
techniques utilize the use of 18F-prosthetic groups, which could be activated and coupled to specific 
functional groups within the proteins (such as amino, carboxylate or sulfhydryl groups)22,23. The 
prosthetic group 4-[18F]fluorobenzamido-N-ethylmaleimide ([18F]FBEM) has been widely used for 
labelling peptides24,25. 
In the scope of this work, we have focused on the engineering and evaluation of 
nanoemulsions for gene delivery and radio-imaging purposes. Structurally, nanoemulsions are 
thermodynamically stable isotropic systems in which two immiscible liquids, usually oil and water, 
are mixed to form a single phase with the help of surfactants26,27. Nanoemulsions have already been 
explored for gene therapy applications and have already been decorated with target ligands such as 
peptides and proteins28,29. Adding cationic lipids such as DOTAP, DOTMA, and ST to the 
formulation mediates the association/complexation with nucleic acids, serving as a suitable gene 
carrier system30,31. A variety of targeting ligands can be attached to the surface of nanoemulsions 
to enable recognition by appropriate receptors expressed at the target site. Several articles relate to 
targeting receptors that are overexpressed on cancer cells including epidermal growth factor 
receptor (EGFR), folate, and transferrin32-34. We selected nanoemulsions formulated from natural 
lipid compounds, such as sphingomyelin and vitamin E, which are indeed being used in different 
formulations in clinical research35,36. Sphingomyelin nanoemulsions, SNs, were formulated 
following a very mild methodology, conveniently adapted to associate oncosuppressor miRNA 
mimics, and successfully radiolabeled with 18F for PET. In vitro and in vivo assays were performed 
to determine their potential in the treatment and diagnosis of colorectal cancer.  
SNs can be conveniently modulated to meet specific biomedical applications  
The composition of SNs was conveniently adapted for each specific purpose. In the case of 
the development of SNs for miRNA replacement therapies to interfere cancer progression, cationic 
lipids were included in the formulation, either as part of the composition (stearylamine, (SNs-ST-
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miRNA)), or as condensing agents for miRNAs, to obtain complexes that will eventually be 
encapsulated into SNs (SNs-DOTAP-miRNA) (Figure 1).  
 
Figure 1. Preparation and illustration of SNs-ST-miRNA (A) and SNs-DOTAP-miRNA (B). 
In the case of radiolabelling of SNs with 18F for in vivo imaging by PET, thiol groups had 
to be exposed at the nanoparticle surface. For this, a lipid-PEG-SH derivative was included in the 
preparation of SNs. Other approach was to surface-decorated SNs with a targeted peptide that has 
already been proposed in colorectal cancer, the RPM peptide, with a thiol group in its structure 
(Figure 2). 
  







By adding a cationic lipid (stearylamine) during the formulation of SNs-ST, we were able 
to obtain monodisperse nanoemulsions with cationic charge suitable for miRNA association on 
their surface. The association was achieved by the establishment of electrostatic interactions 
between the positive charge of the cationic lipid and the negative charge of the phosphate groups 
of miRNA37,38. SNs-ST-miRNA with mass ratio of miRNA:ST 1:10 has suitable properties and a 
good association efficiency, being therefore selected for in vitro testing of their antitumor activity 
(Figure 3). Modifications of the preparation methodology allowed the development of a second 
type of formulation. SNs-DOTAP-miRNA were synthesized from the encapsulation of preformed 
lipid complexes into SNs. Lipid complexes were formulated employing hydrophobic ion pairing 
between the positively charged amino-functionalized lipids (DOTAP) and the negatively charged 
phosphate group of the RNA backbone. The complexes formation could increase the lipophilicity 
of the hydrophilic molecule, subsequently favoring its incorporation into lipid-based 
nanoformulations, similar to what reported with other type of hydrophilic molecules39. 
 
Figure 3. Characterization of SNs-ST-miRNA and SNs-DOTAP-miRNA. Transmission electron microscopy (TEM) images 
(A). Size distribution graph measured from nanoparticle tracking analysis (NTA) and dynamic light scattering (DLS) 
(B), and video frame acquired by NTA (C).  
B A C 
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With respect to the radiolabelling, the strategy was to add the required functionalities to 
SNs for further conjugation of 18F-prosthetic group, [18F]FBEM. Thiol functional groups were 
incorporated via the inclusion of a lipid-PEG-thiol derivative into SNs, or upon surface decoration 
with the RPM peptide, which on the other hand has already proved to be an interesting ligand for 
targeted delivery to colorectal cancer cells expressing the integrin α5β1 receptor40-42. Table 1 shows 
the physicochemical properties of SNs with a thiol group and SNs-RPM. They maintained a small 
size and form monodisperse formulations, proving that it is possible to introduce the desired 
functionalities in the formulation without altering the physicochemical properties. 
Table 1. Hydrodynamic size, polydispersity index (PDI), and zeta potential (ζ-potential) of SNs and SNs-RPM (n=3). 
 
Altogether, SNs proved to provide a nanoplatform that can be tailored according to specific 
medical needs, in this particular case to allow the association of oncosuppressor miRNA mimics 
and radiolabelling with 18F, to develop new strategies for treatment and diagnosis of colorectal 
cancer.  
SNs can mediate a therapeutic effect after intracellular delivery of oncosuppressor miRNAs 
to colorectal cancer cells 
The capability of SNs-loaded with miRNA to interact with colorectal cancer cells and 
deliver their cargo was analyzed. SNs-ST-miRNA and SNs-DOTAP-miRNA showed 
colocalization of two fluorescence dyes labelled with miRNA and lipid parts, demonstrating the 
ability to deliver miRNA to tumor. It is worth mentioning that SNs-DOTAP-miRNA exhibited 
higher internalization of miRNA145 compared to SNs-ST-miRNA (Figure 4). This confirmed the 
improvement of greatly compacted complexes to support encapsulation of nucleic acid and to 
protect them against enzymatic digestion43,44. Furthermore, tumor activity was suppressed by 
transfection of SNs-DOTAP-miRNA, in reference to untreated control cells and cells treated with 
Formulation Size (nm) PDI ζ-Potential (mV) 
SNs 125 ± 3 0.2 +37± 2 
SNs-RPM 138 ± 5 0.2  +41 ± 7 
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the scrambled sequence. These results are in agreement with previously published work with 
miRNA145-based biodegradable PLGA and magnetic nanoparticles45, 46, providing potential for 
further development of gene replacement therapies for colorectal cancer. From these results, it can 
be considered that SNs can be conveniently modulated and adapted to the specific requirements of 










Figure 4. Expression of miR145 after transfection with SNs-ST-miRNA145, Lipid complexes145 (LP145), and SNs-
DOTAP-miRNA145 nanosystems (as well as nanosystems prepared with the scrambled sequence, SNs-ST-miRNAscr, 
LPscr, and SNs-DOTAP-miRNAscr (A). Proliferation of SW480 cells 72 h post-transfection (**** p<0.0001) (B). 
Quantitative analysis of colony numbers, 2 weeks after transfection is shown (*** p<0.001 and ** p<0.01) (C). 
Representative images showing cell migration in wound healing assay, of untreated control cells and cells treated 
with SNs-DOTAP-miRNA145 and the same formulation with the scrambled sequence (SNs-DOTAP-miRNAscr). Images 










SNs can be radiolabelled with 18F for PET imaging  
Radiolabelled SNs and SNs-RPM were obtained through facile-conjugated chemistry with 
simple purification and without the use of organic solvents. Moreover, the labelling process was 
performed under controlled pH and osmolarity to obtain a formulation with suitable characteristics 
for further intravenous injection47.  
We started from the synthesis of [18F]FBEM, which was later coupled to the nanoemulsions.  
It is a reproducible and reliable automated synthesis, which renders adequate yields at the end of 
the procedure for further experiments48. The conjugation of [18F]FBEM to SNs and SNs-RPM was 
performed after the reduction of the disulfide bond when free thiol groups were available for 
radiolabelling49,50. Further experiments specifically confirmed that the labelling position occurred 
at thiol functional groups either coming from the lipid-PEG derivative or the peptide. Non-specific 
labelling was not observed in any case. Lastly, the purification process was successfully performed. 
In general, radiolabelling of nanoparticles could be accomplished either before or after the 
synthesis of nanoparticles. Other reports of post-labelled nanoparticles using different 18F-
prosthetic groups have been reported51-53. Due to the short half-life of 18F, the method of post-
labelling may display an advantage allowing high radiochemical yields in relation to the pre-
labelling method.  
Both SNs-[18F]FBEM and SNs-RPM-[18F]FBEM were characterized and injected to 
healthy mice to determine their biodistribution by PET scan. Generally, the uptake in different 
organs depends on the stability of the nanostructures resulted from the nanomaterial composition, 
size, and surface functionalization54. The ex vivo pattern of both radiolabelled nanoemulsions 
exhibited different pharmacokinetic profiles compared with the free labelled-peptide ([18F]FBEM-
peptide) from preliminary study. The capture of [18F]FBEM-peptide was lower than both 
[18F]FBEM-nanoemulsions in liver, spleen, and intestine, stating that the radiolabelled 
nanoemulsions were stable after injection. 
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A possible explanation for the high uptake in liver and spleen might be due to the interaction 
of mononuclear phagocyte system (MPS), stimulating the elimination of foreign particles55,56. 
Other reports from lipid-based nanoparticles have displayed similar distribution patterns57-59. 
Hence, further optimizations such as surface modification with PEG layer may be required to 
prolong blood circulation time60,61. In vivo biodistribution studies with PET-MRI exhibited that 
other than liver, radiolabelled nanoemulsions or their radiolabeled metabolic products were also 
excreted through urinary tracts (Figure 5). Overall, these results were in agreement with the results 
of the ex vivo study. Biodistribution and pharmacokinetic of this labelled nanoemulsions could 
pave the way for promising tumor diagnosis. 
 
Figure 5. Whole body in vivo biodistribution of SNs-[18F]FBEM (left) and SNs-RPM-[18F]FBEM (right) in male BALB/c 
mice 2h p.i. using PET and MRI: two different coronal slides showing respectively the kidneys (A,C) and the liver and 






The experimental work described in this thesis was aimed to develop nanoemulsions as 
multifunctional platforms for treatment and molecular diagnosis of colorectal. Overall, the results 
allowed us to withdraw the following conclusions:  
1. SNs can be conveniently tailored to incorporate molecules of interest for their application 
in cancer therapy and diagnosis. They can be produced by low energy methods, and their 
composition can be adjusted to mediate an efficient association of biomolecules and 
radionuclides. 
2. Association of oncosuppressor miRNAs was successfully achieved by incorporation of 
cationic lipids in the nanostructure. Stearylamine was included as an additional lipid in the 
original formulation, and DOTAP was used for previous complexation of miRNA previous 
addition to SNs. Both strategies successfully mediated the internalization of the associated 
miRNA by the targeted cancer cells, being the second strategy more efficient.  
3. The increase in the intracellular levels of oncosuppressor miRNAs translated into 
demonstrated anticancer activity. miRNA-loaded SNs are efficient nanosystems for the 
development of innovative gene therapy strategies to treat colorectal cancer.  
4. Radiolabelling of SNs was successfully accomplish after incorporation of a thiol group at 
the nanoparticle surface, either by the inclusion of a PEG surfactant functionalized with 
thiol, or a targeted peptide with thiol residues.  
5. A Michael addition reaction was set among the –SH groups of SNs and a 18F-prosthetic 
group, [18F]FBEM. The properties of SNs were maintained after the radiolabelling process. 
6. 18F-radiolabelled SNs proved to render an adequate signal for PET scan and allowed 
studying their biodistribution both ex vivo and in vivo. 
7. Radiolabeling SNs opens an entire new horizon towards the development of biocompatible 
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18F  Fluorine-18 
[18F]FBEM  4-[18F]fluorobenzamido-N-ethylmaleimide 
[18F]SFB N-Succinimidyl-4-[18F]fluorobenzoate  
AuNPs  Gold nanoparticles  
BFC  Bifunctional chelator 
CaP  Calcium phosphate  
CRC  Colorectal cancer  
CT  Computed tomography 
DDS  Drug delivery system 
DLS  Dynamic laser scattering 
DOGS  di-ioctadecyl-amido-glycyl-spermine 
DOPE   di-oleoyl-phosphatidyl ethanolamine 
DOSPA  2,3-Dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l- 
propanaminium trifluoroacetate);  
DOTA  1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid 
DOTAP  1,2-dioleoyl-3-trimethylammonium-propane  
DOTMA  1,2-di- O-octadecenyl-3-trimethylammonium propane 
DTPA  Diethylene triamine pentaacetic acid 
EGFR  Epidermal growth factor receptor  
EPR   Enhance permeability and retention  
FACS  Fluorescence-Activated Cell Sorting  
FDG  18F-fluorodeoxyglucose 
Gd  Gadolinium  
miRNA  MicroRNA  
MPS  Mononuclear phagocyte system  
MRI  Magnetic resonance imaging  
mRNA  Messenger RNA 
NOTA  1,4,7-triazacyclononane-1,4,7- triacetic acid  
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NTA  Nanoparticle tracking analysis 
pDNA  Plasmid DNA  
PDI  Polydispersity index 
PEG  Polyethylene glycol  
PEI  Polyethyleneimine 
PET  Positron emission tomography  
PLGA   Poly(D,L-lactide-co-glycolide acid 
PLL  Poly(l-lysine)  
QDs   Quantum dots  
ROS  Reactive oxygen species 
siRNA  Small interfering RNA 
SM  Sphingomyelin 
SNs  Sphingomyelin nanoemulsions 
SPECT Single-photon emission computed tomography  
ST  Stearylamine 
SWNTs single-walled carbon nanotubes  
TEM  Transmission electron microscopy 
UPLC  Ultra-performance liquid chromatography 
Vit E  Vitamin E (DL-α-tocopherol) 
VEGF  Vascular endothelial growth factor 
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